HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF

Abstract

 The present invention relates to a heteroaryl derivative compound and a use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against HER2 and EGFR, and thus can be effectively used as a therapeutic agent for HER2- and/or EGFR-associated diseases.

Description

[Technical Field]

[0001] The present disclosure relates to a heteroaryl derivative compound and medicinal uses thereof. Specifically, the present disclosure relates to a heteroaryl derivative compound having HER2 and/or EGFR inhibitory activity.

[Background Art]

[0002] Protein kinases act as molecular switches to participate in signal transduction pathways, and the transition between active and inactive states of target proteins by kinases in cells should be smoothly controlled. If the transition between the active and inactive states is abnormally controlled, intracellular signal transduction is excessively activated or deactivated to induce uncontrollable cell division and proliferation. In particular, abnormal activation by mutation, amplification and/or overexpression of protein kinase genes causes the development and progression of various tumors or plays a crucial role in the development of various diseases such as inflammatory diseases, degenerative brain diseases, and autoimmune diseases.

[0003] In particular, HER2 (ErbB2), which is a receptor tyrosine kinase of the ErbB family, forms homodimers or heterodimers with other EGFR receptors such as HER1 (EGFR, ErbB1), HER3 (ErbB3), or HER4 (ErbB4) and is activated by autophosphorylation at intracellular tyrosine residues to play an important role in cell proliferation, differentiation and survival in normal cells and cancer cells (Di Fore PP, et al., Science. 1987; 237: 178-182). HER2 is known to be overexpressed in various carcinomas such as breast cancer, gastric cancer and ovarian cancer (Hardwick R, et al., Eur. J Surg Oncol. 1997 (23):30-35; Korkaya H, et al., Oncogene. 2008;27(47):6120-6130;).

[0004] In addition, it is known that epidermal growth factor receptor (EGFR), which is another ErbB family, is abnormally active in many epithelial cell tumors, including non-small cell lung carcinoma (NSCLC), breast cancer, glioma, squamous cell carcinoma of the head and neck, colorectal cancer, rectal adenocarcinoma, head and neck cancer, stomach cancer and prostate cancer, and the activation of the EGFR-tyrosine kinase causes continuous cell proliferation, invasion of surrounding tissues, distant metastasis, and angiogenesis, and increases cell survival.

[0005] There are afatinib (GILOTRIF) and trastuzumab (HERCEPTIN), etc., as anticancer drugs that target HER2 and EGFR, but these anticancer drugs have problems in that cancer recurs after treatment or only some patient groups show reactivity. For example, in the case of trastuzumab, the following cases have been reported that about 11.6% of patients with HER2-overexpressing breast cancer who received conventional anticancer treatment are responsive to trastuzumab, and the remaining 88.4% of patients have no or weak response to trastuzumab (Baselga et al., J. Clin. Oncol. 14:737-744 (1996)).

[0006] As described above, there is an increasing unmet need for novel compounds capable of being usefully utilized in the treatment of HER2- and EGFR-related diseases by modulating HER2 and EGFR activities.

[Disclosure]

[Technical Problem]

[0007] An object of the present disclosure is to provide a heteroaryl derivative having a novel structure, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.

[0008] Another object of the present disclosure is to provide a method for preparing the heteroaryl derivative compound.

[0009] Still another object of the present disclosure is to provide a pharmaceutical use of the heteroaryl derivative compound, and specifically, to a pharmaceutical composition for the treatment or prevention of HER2- and/or EGFR-related diseases comprising the heteroaryl derivative compound as an active ingredient, use of the compound for the treatment or prevention of HER2- and/or EGFR-related diseases, or a method for treating or preventing HER2- and/or EGFR-related diseases comprising administering the compound.

[Technical Solution]

[0010] In order to achieve the above object, the present inventors have made research efforts, and as a result, completed the present invention by confirming that a heteroaryl derivative compound represented by the following Chemical Formula 1 inhibited the proliferation of HER2- and/or EGFR-activated cells.

Heteroaryl Derivative Compound

[0011] The present invention provides a compound represented by the following Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof:

in Chemical Formula 1 above,

X is N or CR_X1;

R₁ is -H, -OR_X2, or -NR_X3R_X4;

R_X1 is -H, -C_1-6alkyl, -C_1-6haloalkyl, -CN, or -halo;

R_X2 is -H, -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -C_1-6alkyl-O(C_1-6alkyl) -C_1-6aminoalkyl, -(CH₂)n-cycloalkyl, or -(CH₂)n-heterocycloalkyl {wherein at least one H of the -(CH₂)n-cycloalkyl or -(CH₂)n-heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, -halo, or heterocycloalkyl};

n is 0, 1, 2, 3, or 4;

R_X3 and R_X4 are each independently -H or -C_1-6alkyl, or R_X3 and R_X4 are linked to each other to form

or

ring together with an N atom, and the W₁ and W₂ are each independently CH₂, NH, O, or S {wherein at least one H of the

heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl) (C_1-6alkyl), -NO₂, -OH, -halo, or heterocycloalkyl};

a to d are each independently 1, 2, or 3;

R₂ is -H, -C_1-6alkyl, -C_1-6haloalkyl, -CN, or -halo;

L is -NH-,

or

{wherein the ring B is a single ring or multiple rings containing an N atom in the ring, and at least one H of the ring B may be substituted with -C_1-6alkyl, -C₁-₆hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -CN, -NH₂, - NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, =O, or - halo};

R₃ is -CZ₁=Z₂Z₃, -C_1-6alkyl, -C_1-6haloalkyl, or cycloalkyl;

Z₁ is -H, -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6hydroxyalkyl, -C_1-6haloalkyl, -CN, or -halo;

Z₂ and Z₃ are each independently -H, -C_1-6alkyl, -C₁-₆hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -halo, cycloalkyl, heterocycloalkyl, -C_1-6alkylcycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein at least one H of the cycloalkyl, heterocycloalkyl, -C_1-6alkylcycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, =O, or heterocycloalkyl};

Y₁ to Y₃ are each independently N or CR_Y;

R_Y is -H, -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6hydroxyalkyl, -C_1-6haloalkyl, -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, or -halo;

R₄ is -C_1-6alkyl, -C_1-6alkyl-O-C_1-6alkyl, -C_1-6haloalkyl, cycloalkyl, heterocycloalkyl, -C_1-6alkyl-cycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein at least one H of the cycloalkyl, heterocycloalkyl, -C_1-6alkyl-cycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl};

ring A is aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl {wherein at least one H of the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring may be substituted with -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6hydroxyalkyl, -C_1-6haloalkyl, -C_1-6alkenyl, -CN, -C(=O)-R_A1, -NO₂, -NR_A2R_A3, - OR_A4, -S-C_1-6alkyl, -halo, or heterocycloalkyl [here, at least one H of the heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -halo, or heterocycloalkyl], and substituents on the aryl or heteroaryl ring may be linked to each other to form a 5-6 membered cycloalkyl or a 5-6 membered heterocycloalkyl};

R_A1 is -H, -C_1-6alkyl, -NH₂, -NH-C_1-6alkyl, -N(C₁-₆alkyl) (C_1-6alkyl), -NH-(CH₂)m-aryl, -OH, or -O-C_1-6alkyl {wherein at least one H of the -NH-(CH₂)m-aryl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, or -halo};

m is 0, 1, 2, 3, or 4;

R_A2 and R_A3 are each independently -H, -C_1-6alkyl, - C(=O)-C_1-6alkyl, -C(=O)-C_1-6alkenyl, -C(=O)-cycloalkyl,-C(=O)-heterocycloalkyl, or -C(=O)-aryl {wherein at least one H of the -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or - C(=O)-aryl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, -halo, or aryl}; and

R_A4 is -H, -C_1-6alkyl, or -C_1-6haloalkyl.

[0012] According to an embodiment of the present invention, the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be in the following ranges:

X is N or CR_X1;

R₁ is -H, -OR_X2, or -NR_X3R_X4;

R_X1 is -H or -CN;

R_X2 is -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -C_1-6alkyl-O(C_1-6alkyl)-C_1-6aminoalkyl, or -(CH₂)n-heterocycloalkyl {wherein at least one H of the - (CH₂)n-heterocycloalkyl ring may be substituted with -C₁-₆alkyl, -C_1-6alkyl-O(C_1-6alkyl), or heterocycloalkyl};

n is 0, 1, 2, 3, or 4;

R_X3 and R_X4 are each independently -H or -C_1-6alkyl, or R_X3 and R_X4 are linked to each other to form

or

ring together with an N atom, and W₁ and W₂ are each independently CH₂, NH, or O {wherein at least one H of the

ring may be substituted with - halo, or heterocycloalkyl};

a to d are each independently 1 or 2;

R₂ is -H or -halo;

L is -NH-,

or

{wherein the ring B is a single ring or multiple rings containing an N atom in the ring, and at least one H of the ring B may be substituted with -C_1-6alkyl, -C₁-₆haloalkyl, =O, or -halo};

R₃ is -CZ₁=Z₂Z₃, -C_1-6haloalkyl, or cycloalkyl;

Z₁ is -H, -C_1-6aminoalkyl, -CN, or -halo;

Z₂ and Z₃ are each independently -H, -C_1-6alkyl, -C₁-₆aminoalkyl, -C_1-6alkyl-O(C_1-6alkyl), -halo, -heterocycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein at least one H of the -heterocycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl or -heterocycloalkyl};

Y₁ to Y₃ are each independently N or CR_Y;

Ry is -H, -C_1-6alkyl, or -halo; and

R₄ is -C_1-6alkyl, -C_1-6alkyl-O-C_1-6alkyl, -C_1-6haloalkyl, cycloalkyl, or heterocycloalkyl {wherein at least one H of the cycloalkyl or heterocycloalkyl may be substituted with -C_1-6alkyl};

ring A is aryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl {wherein at least one H of the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -C_1-6alkenyl, -CN, -C(=O)-R_A1, -NO₂, -NR_A2R_A3, - OR_A4, -S-C_1-6alkyl, -halo, or heterocycloalkyl [here, at least one H of the heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -halo, or heterocycloalkyl], and substituents on the aryl or heteroaryl ring may be linked with each other to form a 5-6 membered cycloalkyl or a 5-6 membered heterocycloalkyl};

R_A1 is -H, -NH-(CH₂)m-aryl, -OH, or -O-C_1-6alkyl {wherein at least one H of the -NH-(CH₂)m-aryl ring may be substituted with -halo};

m is 0, 1, 2, 3, or 4;

R_A2 and R_A3 are each independently -H, -C_1-6alkyl, - C(=O)-C_1-6alkyl, -C(=O)-C_1-6alkenyl, -C(=O)-cycloalkyl, - C(=O)-heterocycloalkyl, or -C(=O)-aryl {wherein at least one H of the -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or - C(=O)-aryl ring may be substituted with =O, -halo, or aryl}; and

R_A4 is -H, -C_1-6alkyl, or -C_1-6haloalkyl.

[0013] According to an embodiment of the present invention, the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be in the following ranges:

X is N or CR_X1;

R₁ is -H, -OR_X2, or -NR_X3R_X4;

R_X1 is -H or -CN;

R_X2 is -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -C_1-6alkyl-O(C_1-6alkyl)-C_1-6aminoalkyl, or - (CH₂)n-heterocycloalkyl {wherein the -(CH₂)n-heterocycloalkyl ring is 4-6 membered, and at least one H of the -(CH₂)n-heterocycloalkyl ring may be substituted with - C_1-6alkyl, -C_1-6alkyl-O(C_1-6alkyl), or 4-6 membered heterocycloalkyl};

n is 0, 1, 2, or 3;

R_X3 and R_X4 are each independently -H or -C_1-6alkyl, or R_X3 and R_X4 are linked to each other to form

or

together with an N atom, and W₁ and W₂ are each independently CH₂ or O {wherein at least one H of the

or

ring may be substituted with -halo, or 4-6 membered heterocycloalkyl};

a to d are each independently 1 or 2; and

R₂ is -H or -halo.

[0014] According to an embodiment of the present invention, the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be in the following ranges:

L is -NH-,



{wherein at least one H of the



ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, or -halo};

V₁ and V₂ are linked together by a single bond, C₁alkyl, C₂alkyl, or C₃alkyl to form a bridged double ring or nothing (null); and

e to h are each independently 1, 2, or 3.

[0015] According to an embodiment of the present invention, the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be in the following ranges:

R₃ is -CZ₁=Z₂Z₃, -C_1-6haloalkyl, or cycloalkyl {wherein the cycloalkyl ring is a single ring or multiple rings};

Z₁ is -H, -C_1-6aminoalkyl, -CN, or -halo; and

Z₂ and Z₃ are each independently -H, -C_1-6alkyl, -C₁-₆aminoalkyl, -C_1-6alkyl-O(C_1-6alkyl), -halo, -heterocycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein the heterocycloalkyl or -C_1-6alkyl-heterocycloalkyl ring is 4-6 membered, and at least one H of the heterocycloalkyl, -C_1-6alkyl-cycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C₁-₆alkyl, or 4-6 membered heterocycloalkyl}.

[0016] According to an embodiment of the present invention, the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be in the following ranges:

Y₁ to Y₃ are each independently N or CR_Y;

R_Y is -H, -C_1-6alkyl, or -halo; and

R₄ is -C_1-6alkyl, -C_1-6alkyl-O-C_1-6alkyl, -C_1-6haloalkyl, 3-7 membered cycloalkyl, or 4-6 membered heterocycloalkyl {wherein at least one H of the 3-7 membered cycloalkyl or 4-6 membered heterocycloalkyl may be substituted with -C₁-₆alkyl}.

[0017] According to an embodiment of the present invention, the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be in the following ranges:

ring A is phenyl, 5-10 membered heteroaryl, 4-6 membered heterocycloalkyl, or 4-6 membered heterocycloalkenyl {wherein at least one H of the phenyl, 5-10 membered heteroaryl, 4-6 membered heterocycloalkyl, or 4-6 membered heterocycloalkenyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -C_1-6alkenyl, -CN, -C(=O)-R_A1, -NO₂, -NR_A2R_A3, -OR_A4, -S-C_1-6alkyl, -halo, or 4-6 membered heterocycloalkyl [here, at least one H of the 4-6 membered heterocycloalkyl ring may be substituted with -C_1-6alkyl, - C_1-6haloalkyl, -halo, or heterocycloalkyl], and substituents on the phenyl or 5-10 membered heteroaryl ring may be linked to each other to form a 5-6 membered cycloalkyl or a 5-6 membered heterocycloalkyl};

R_A1 is -H, -NH-(CH₂)m-phenyl, -OH, or -O-C_1-6alkyl {wherein at least one H of the -NH-(CH₂)m-phenyl ring may be substituted with -halo};

m is 0, 1, or 2;

R_A2 and R_A3 are each independently -H, -C_1-6alkyl, - C(=O)-C_1-6alkyl, -C(=O)-C_1-6alkenyl, -C(=O)-cycloalkyl,-C(=O)-heterocycloalkyl, or -C(=O)-phenyl {wherein at least one H of the -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or -C(=O)-phenyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, -halo, or phenyl}; and

R_A4 is -H, -C_1-6alkyl, or -C_1-6haloalkyl.

[0018] According to another embodiment of the present invention, the compound represented by Chemical Formula 1 may be selected from the group consisting of compounds listed in Table 1 described below.

[0019] In the present disclosure, unless otherwise specified, the term "alkyl" may refer to a straight or branched chain acyclic, cyclic, or saturated hydrocarbon to which they are bonded. For example, "C_1-6alkyl" may indicate an alkyl containing 1 to 6 carbon atoms. As an example, acyclic alkyl may include, but is not limited to, methyl, ethyl, n-propyl, n-butyl, isopropyl, sec-butyl, isobutyl, tert-butyl, or the like. Cyclic alkyl may be used interchangeably with "cycloalkyl" as used herein, and as an example, may include, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or the like.

[0020] In the present disclosure, "alkoxy" may indicate -(O-alkyl) as an alkyl ether group, wherein alkyl is the same as defined above. For example, "C_1-6alkoxy" may mean alkoxy containing C_1-6alkyl, that is, - (O-C_1-6alkyl), and as an example, may include, but is not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, or the like.

[0021] In the present disclosure, "halo" may be F, Cl, Br, or I.

[0022] As used herein, "haloalkyl" may mean a straight or branched chain alkyl (hydrocarbon) having one or more halo-substituted carbon atoms as defined herein. Examples of the haloalkyl may include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl or n-butyl independently substituted with one or more halogens, such as F, Cl, Br, or I.

[0023] In the present disclosure, "hydroxyalkyl" may indicate a straight or branched chain alkyl (hydrocarbon) having a carbon atom substituted with -hydroxy (-OH). Examples of the haloalkyl may include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl or n-butyl independently substituted with one or more halogens, for example, -OH.

[0024] As used herein, "aminoalkyl" may mean a straight or branched chain alkyl (hydrocarbon) having a carbon atom substituted with amino (NR'R"). Here, R' and R" may be each independently selected from the group consisting of hydrogen and C_1-6alkyl, and the selected R' and R" may be each independently substituted or unsubstituted.

[0025] In the present disclosure, "heterocycloalkyl" may mean a ring containing 1 to 5 heteroatoms selected from N, O, and S, which atoms form the ring, and may be saturated or partially unsaturated. Here, when unsaturated, it may be referred to as a heterocycloalkene. Unless otherwise stated, heterocycloalkyl may be a single ring or a multiple ring such as a spiro ring, a bridged ring or a fused ring. In addition, "3- to 12-membered heterocycloalkyl" may indicate a heterocycloalkyl containing 3 to 12 atoms forming a ring. As an example, the heterocycloalkyl may include, but is not limited to, pyrrolidine, piperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidin-2,4(1H,3H)-dione, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane, (1R,5S)-3-azabicyclo[3.2.1]octane, (1s,4s)-2-azabicyclo[2.2.2]octane, or (1R,4R)-2-oxa-5-azabicyclo[2.2.2]octane, and the like.

[0026] In the present disclosure, "arene" may mean an aromatic hydrocarbon ring. The arene may be a monocyclic arene or a polycyclic arene. The number of ring-forming carbons in the arene may be 5 or more and 30 or less, 5 or more and 20 or less, or 5 or more and 15 or less. Examples of the arene may include, but are not limited to, benzene, naphthalene, fluorene, anthracene, phenanthrene, bibenzene, terbenzene, quaterbenzene, quinquebenzene, sexibenzene, triphenylene, pyrene, benzofluoranthene, chrysene, and the like. In the present specification, the residue obtained by removing one hydrogen atom from "arene" is referred to as "aryl".

[0027] In the present disclosure, "heteroarene" may be a ring containing at least one of O, N, P, Si, and S as a heterogeneous element. The number of ring-forming carbons in the heteroarene may be 2 or more and 30 or less, or 2 or more and 20 or less. The heteroarene may be a monocyclic heteroarene or a polycyclic heteroarene. The polycyclic heteroarene may have, for example, a bicyclic or tricyclic structure. Examples of the heteroarene may include thiophene, purine, pyrrole, pyrazole, imidazole, thiazole, oxazole, isothiazole, oxadiazole, triazole, pyridine, bipyridyl, triazine, acridyl, pyridazine, pyrazine, quinoline, quinazoline, quinoxaline, phenoxazine, phthalazine, pyrimidine, pyridopyrimidine, pyridopyrazine, pyrazinopyrazine, isoquinoline, indole, carbazole, imidazopyridazine, imidazopyridine, imidazopyrimidine, pyrazolopyrimidine, imidazopyrazine or pyrazolopyridine, triazolopyridine, triazolopyrimidine, N-arylcarbazole, N-heteroarylcarbazole, N-alkylcarbazole, benzoxazole, benzoimidazole, benzothiazole, benzocarbazole, benzothiophene, dibenzothiophene, thienothiophene, benzofuran, phenanthroline, isoxazole, oxadiazole, thiadiazole, benzothiazole, tetrazole, phenothiazine, dibenzosilole, dibenzofuran, and the like, but are not limited thereto. In an embodiment of the present disclosure, heteroarene may also include bicyclic heterocyclo-arene containing heteroarene fused to an arene ring or a cycloalkyl ring fused to heterocycloalkyl rings. In the present specification, the residue obtained by removing one hydrogen atom from the "heteroarene" is referred to as "heteroaryl".

[0028] In the present disclosure, "ring" may be a single ring or a multiple ring, and the multiple ring may be in the form of a spiro ring, a bridged ring, a fused ring, or the like.

[0029] In the present disclosure, the term "optical isomer (enantiomer)" means compounds of the present disclosure or salts thereof that have the same chemical formula or molecular formula but are different in stereostructure. Each of these enantiomers and mixtures thereof are also included within the scope of the present disclosure. Unless otherwise specified, the straight solid-line bond (-) connecting an asymmetric carbon atom may include a wedge-shaped solid-line bond (

) or a wedge-shaped dashed-line bond (

) indicating the absolute configuration of the stereocenter.

[0030] In the present disclosure, the term "cis" refers to a case in which the binding directions of two substituents in a ring are the same, and the term "trans" refers to a case in which the binding directions of two substituents in the ring are different.

[0031] The compound of Chemical Formula 1 of the present disclosure may exist in the form of a "pharmaceutically acceptable salt". As the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. The term "pharmaceutically acceptable salt" as used herein means any and all organic or inorganic acid addition salts of the compound represented by Chemical Formula 1 of which side effects caused by the salt do not reduce the beneficial efficacy of the compound at concentrations having an effective action that is relatively non-toxic and harmless to a patient.

[0032] Acid addition salts are prepared by conventional methods, for example by dissolving the compound in an excess of aqueous acid solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. An acid or alcohol in an equimolar amount of the compound and water may be heated, and the mixture may then be evaporated to dryness, or the precipitated salt may be filtered off with suction.

[0033] Here, an organic acid and an inorganic acid may be used as the free acid, wherein the inorganic acid may be hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like, and the organic acid may be methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, or the like. However, the present disclosure is not limited thereto.

[0034] In addition, it is possible to prepare a pharmaceutically acceptable metal salt using a base. The alkali metal salt or alkaline earth metal salt is obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. Here, it is pharmaceutically suitable to prepare a sodium, potassium, or calcium salt as the metal salt, but the present disclosure is not limited thereto. Further, the corresponding silver salt may be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).

[0035] Unless otherwise indicated, the pharmaceutically acceptable salt of the present disclosure includes salts of acidic or basic groups that may be present in the compound of Chemical Formula 1. For example, the pharmaceutically acceptable salt may include sodium, calcium and potassium salts of hydroxyl groups, and the like, and as other pharmaceutically acceptable salts of amino groups, may include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, and the like, and may be prepared by a method for preparing a salt known in the art.

Use of heteroaryl derivative compound

[0036] The present invention provides use of a compound represented by the following Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof:



wherein the Chemical Formula 1 is the same as defined above.

[0037] The compound represented by Chemical Formula 1 of the present invention, the optical isomer thereof, or the pharmaceutically acceptable salt thereof exhibits inhibitory activity against various kinases.

[0038] According to an embodiment of the present invention, the heteroaryl derivative represented by Chemical Formula 1 may exhibit excellent inhibitory activity against HER2 and EGFR kinases, thereby being usefully employed for treatment or prevention of HER2- and/or EGFR-related diseases, in particular, cancer. In particular, the heteroaryl derivative compound of the present invention may exhibit excellent inhibitory activity against HER2 mutations (for example, HER2 L869R, HER2 L755S, HER2 T798I, HER2 T862A, and the like) and EGFR mutations (for example, EGFR G719A, EGFR L861Q, EGFR S768I, EGFR G719A/S768I, EGFR Del19/T790M, and the like), which may be usefully employed for the treatment or prevention of carcinomas induced by HER2 and/or EGFR.

[0039] In the present disclosure, the cancer includes any cancer capable of exhibiting therapeutic or prophylactic efficacy due to inhibition of HER2 and/or EGFR kinase activity, and may be a solid cancer or a hematologic cancer. For example, the cancer may be one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell tumor, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, sinonasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small bowel cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, renal cancer, heart cancer, duodenal cancer, malignant soft tissue tumor, malignant bone tumor, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid tumor, gastrointestinal stromal tumor, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid tumor, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleura cancer, hematological cancer, and thymic carcinoma, but are not limited thereto. The cancer includes not only primary cancer but also metastatic cancer.

[0040] According to an embodiment of the present disclosure, the present disclosure provides a pharmaceutical composition for treatment or prevention of HER2- and/or EGFR-related diseases containing the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof as an active ingredient. Specifically, the HER2- and/or EGFR-related disease may be cancer. The types of cancer are the same as described above.

[0041] The pharmaceutical composition of the present disclosure may further include one or more active ingredients exhibiting the same or similar drug efficacy in addition to the compound represented by Chemical Formula 1 above, the optical isomer thereof, or the pharmaceutically acceptable salt thereof.

[0042] Further, according to an embodiment of the present disclosure, there is provided a method for treating or preventing HER2- and/or EGFR-related diseases, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof. The subject may be a mammal including a human.

[0043] The term "therapeutically effective amount" as used herein refers to an amount of the compound represented by Chemical Formula 1 that is effective for the treatment or prevention of HER2- and/or EGFR-related diseases. Specifically, "therapeutically effective amount" indicates an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level may be determined depending on factors including the subject type and severity, age, sex, type of disease, drug activity, drug sensitivity, administration time, administration route and excretion rate, treatment period, drugs used at the same time, and other factors well-known in medical fields. The pharmaceutical composition of the present disclosure may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with commercially available therapeutic agents. In addition, the pharmaceutical composition of the present disclosure may be administered in a single dose or multiple doses. It is important to administer the minimum amount capable of obtaining the maximum effect without side effects in consideration of all of the above factors, and the amount may be readily determined by those skilled in the art. The dosage of the pharmaceutical composition of the present disclosure may be determined by a medical specialist according to various factors such as the patient's condition, age, sex, complications, and the like. Since the active ingredient of the pharmaceutical composition of the present disclosure has excellent safety, it may be used at a dose higher than the determined dosage.

[0044] Further, according to an embodiment of the present disclosure, the present disclosure provides use of the compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof for use in preparation of a medicament to treat or prevent HER2- and/or EGFR-related diseases. The compound represented by Chemical Formula 1 for preparing the medicament may be mixed with acceptable adjuvants, diluents, carriers, and the like, and may have a synergistic effect of active ingredients by being prepared as a complex formulation with other active agents.

[0045] Matters mentioned in the uses, compositions and treatment methods of the present disclosure are applied equally except to the extent that they are inconsistent with each other.

[Advantageous Effects]

[0046] The heteroaryl derivative compound of the present disclosure exhibits excellent inhibitory activity against HER2 and/or EGFR, and thus may be usefully employed for the treatment or prevention of HER2- and/or EGFR-related diseases.

[Best Mode]

[0047] Hereinafter, the present invention will be described in detail by Examples and Experimental Examples. However, the following Examples and Experimental Examples are only provided to illustrate the present invention, and the scope of the present invention is not limited to these Examples.

<Analysis and purification conditions>

1. HPLC analysis conditions

[0048] 

(a) Instrument: Waters e2695

Column: Xbridge C18, 4.6 x 150 mm, 5 µm, 40 °C

Mobile phase: 20% -> 95% acetonitrile/H₂O + 0.1% TFA

Analysis time: 10 minutes, flow rate: 1 mL/min

UV detector: 254 nm

(b) Instrument: Waters e2695

Column: YMC-Pack ODS-AM, 150 x 4.6 mm, 3 um, 12 nm, 40 °C

Mobile phase: 10% -> 90% acetonitrile/H₂O + 0.1% TFA

Analysis time: 20 minutes, flow rate: 1 mL/min

UV detector: 254 nm

2. LC-MS analysis conditions

[0049] 

Instrument: Waters ACQUITY UPLC

Column: ACQUITY UPLC^® BEH C18, 50 x 2.1 mm, 5 µm, 40 °C

Mobile phase: acetonitrile/H₂O + 0.1% TFA

Flow rate: 0.6 mL/min

UV detector: 254 nm

3. MPLC analysis conditions

[0050] 

Instrument: CombiFlash^® Rf+

UV detector: 254 nm

4. Prep-HPLC purification conditions (A)

[0051] 

Instrument: ACCQPrep HP125

Column: XBridge^® Prep Shield RP18, 250 x 19 mm, 10 um

Mobile phase: acetonitrile/0.1% TFA H₂O

Flow rate: 25 mL/min

UV detector: 254 nm

5. Prep-HPLC purification conditions (B)

[0052] 

Instrument: ACCQPrep HP125

Column: XBridge^® Prep Shield RP18, 250 x 19 mm, 10 um

Mobile phase: acetonitrile/0.1% FA H₂O

Flow rate: 25 mL/min

UV detector: 254 nm

6. ¹H NMR

[0053] Instrument: Bruker Ascend^™ 400 (400 MHz)
Commercial reagents used in the experiments were used without further purification. In the present invention, room temperature means a temperature of 15 ~ 25 °C. Concentration under reduced pressure or solvent distillation removal was performed using a rotary evaporator.

Preparation Example 1. Preparation of N-(2,6-difluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

[0054] 

[0055] In acetic acid (15.4 equiv.), 2,6-difluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0 equiv.) and acetic anhydride (2.81 equiv.) were dissolved, DMAP (0.02 equiv.) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to obtain the target compound as an ivory solid, which was used in the next reaction without further purification (yield: 100%, MS (ESI): m/z 298 [M+1]⁺).

Example 1. Preparation of N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)acetamide

[0056] 

[Step-1] Preparation of tert-butyl 4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate

[0057] In DCM, 4-chloro-7-methoxyquinazolin-6-ol (1.0 equiv.), tert-butyl 4-hydroxypiperidine-1-carboxylate (2.0 equiv.), and triphenylphosphine (1.5 equiv.) were dissolved. Then, DTBAD (1.5 equiv.) was slowly added at 5 °C, followed by stirring at room temperature for 16 hours. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 52%, MS (ESI): m/z 394 [M+1]⁺).

[Step-2] Preparation of tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate

[0058] In sec-BuOH, tert-butyl 4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-1 above and 5-bromo-2-methoxyaniline (1.2 equiv.) were dissolved. To the reaction mixture, 4.0M HCl dissolved in dioxane was added, and stirred at 80 °C for 2 hours. The reaction mixture was cooled to room temperature, and ethyl ether was then added to produce a solid. The solid was filtered through a filter to obtain the target compound as an ivory solid (yield: 96%, MS (ESI): m/z 559 [M+1]⁺).

[Step-3] Preparation of N-(5-bromo-2-methoxyphenyl)-7-methoxy-6-(piperidin-4-yloxy)quinazolin-4-amine

[0059] In DCM, tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-2 above was dissolved, and then trifluoroacetic acid (50 equiv.) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a pale yellow solid (yield: 97%, MS (ESI): m/z 459 [M+1]⁺).

[Step-4] Preparation of 1-(4-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one

[0060] In THF, N-(5-bromo-2-methoxyphenyl)-7-methoxy-6-(piperidin-4-yloxy)quinazolin-4-amine (1.0 equiv.) obtained in Step-3 above and saturated NaHCO₃ aqueous solution (5.0 equiv.) were dissolved, and then acryloyl chloride (1.0 equiv.) was added at 0 °C and stirred for 1 hour. The reaction mixture was concentrated, water was added thereto, and organic materials were extracted with DCM. The collected organic layer was concentrated by removing remaining water using MgSO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 60%, MS (ESI) : m/z 513 [M+1]⁺).

[Step-5] Preparation of N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)acetamide

[0061] In dioxane:water (5:1), 1-(4-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one (1.0 equiv.) obtained in Step-4 above, N-(2,6-difluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (2.3 equiv.) obtained in Preparation Example 1, and K₃PO₄ (3.5 equiv.) were dissolved. The reaction mixture was degassed using nitro gas, and Xphos Pd G2 (0.1 equiv.) was added at 80 °C, followed by stirring at 100 °C for 30 minutes. The reaction product was filtered through a celite filter, and concentrated. The reaction mixture was purified by prep-HPLC to obtain the target compound as a yellow solid (yield: 96%, MS (ESI): m/z 604 [M+1]⁺).

Preparation of Compounds of Examples 2 to 231

[0062] Compounds of Examples 2 to 231 according to the present invention were prepared in a similar manner to Example 1 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 1 below.

[Table 1]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
1		N-(3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)acetamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.56 (d, J = 3.2 Hz, 1H), 8.02 (s, 1H), 7.70 (s, 1H), 7.58 (d, J = 8.6 Hz, 1H), 7.47-7.39 (m, 1H), 7.29 (d, J = 8.7 Hz, 1H), 7.23 (s, 1H), 7.13 (t, J = 8.9 Hz, 1H), 6.82 (dd, J = 16.8, 10.7 Hz, 1H), 6.23 (dd, J = 16.8, 1.9 Hz, 1H), 5.77 (dd, J = 10.7, 1.9 Hz, 1H), 4.90-4.86 (m, 1H), 4.08 (s, 3H), 3.99-3.93 (m, 2H), 3.91 (s, 3H), 3.71-3.61 (m, 2H), 2.19 (s, 3H), 2.17-2.05 (m, 2H), 1.98-1.84 (m, 2H); MS (ESI): m/z=501 [M+1] +	96	8.84 97 (b)
2		N-(3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)- 2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropa ncarboxamide	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.34 (s, 1H), 8.19 (s, 1H), 7.85 (s, 1H), 7.81 (s, 1H), 7.49-7.41 (m, 2H), 7.24-7.20 (t, 2H), 7.13-7.08 (t, 1H), 6.85-6.78 (m, 1H), 6.24-6.19 (dd, J = 16.81 Hz, 1H), 5.77-5.74 (dd, J = 10.66 Hz, 1H), 4.02 (s, 3H), 3.98-3.93 (m, 2H), 3.91 (s, 3H), 3.71-3.61 (m, 2H), 2.13-2.05 (m, 2H), 1.96-1.84 (m, 3H), 0.99-0.96 (m, 2H), 0.92-0.90 (m, 2H); MS (ESI): m/z=630 [M+1] +	88	9.50 99 (b)
3		N-(3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropa ncarboxamide	1H NMR (400MHz, FA salt, Methanol-d4) δ 9.30 (s, 1H), 8.64 (s, 1H), 7.78 (s, 1H), 7.59-7.50 (m, 2H) 7.32-7.27 (m, 2H), 7.09-7.03 (m, 2H), 6.99-6.93 (m, 1H), 6.87 (d, J = 15.2 Hz, 1H), 4.18 (s, 3H), 4.14-4.08 (m, 1H), 3.93 (s, 3H), 3.84-3.78 (m, 1H), 3.28-3.23 (m, 2H), 2.49-2.44 (m, 1H), 2.31-2.07 (m, 3H); MS (ESI): m/z 602 [M+1]+	8	9.19 100 (b)
4		N-(3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-fluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropa ncarboxamide	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.31 (s, 1H), 8.20 (dd, J = 7.4, 2.0 Hz, 1H), 7.88-7.83 (m, 2H), 7.53 (dd, J = 8.6, 2.3 Hz, 1H), 7.41-7.36 (m, 1H), 7.24-7.18 (m, 3H), 6.86-6.78 (m, 1H), 6.24-6.18 (m, 1H), 5.76 (dd, J = 10.6, 1.9 Hz, 1H), 4.86-4.83 (m, 1H), 4.02 (s, 3H), 3.98-3.93 (m, 2H), 3.90 (s, 3H), 3.71-3.61 (m, 2H), 2.14-2.04 (m, 2H), 1. 93-1. 84 (m, 3H), 0.99-0.95 (m, 2H), 0.91-0.86 (m, 2H); MS (ESI): m/z=612 [M+1]+	30	9.91 99 (b)
5		1-(3-((7-methoxy-4-((4-methoxy-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.36 (s, 1H), 8.03 (d, J = 2.0 Hz, 1H), 7.63-7.61 (m, 2H), 7.53 (d, J = 8.8 Hz, 1H), 7.44-7.36 (m, 3H), 7.32-7.28 (m, 1H), 7.18 (s, 1H), 7.16 (s, 1H), 6.41-6.26 (m, 2H), 5.78 (d, J = 7.6 Hz, 1H), 5.22-5.19 (m, 1H), 4.78-4.76 (m, 1H), 4.57-4.55 (m, 1H), 4.41-4.39 (m, 1H). 4.17-3.91 (m, 1H), 4.01 (s, 3H), 3.91 (s, 3H); MS (ESI): m/z 483 [M+1]+	52	5.99 100 (a)
6		1-(3-((7-methoxy-4-((2-methoxy-5-(pyridin-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.84 (d, J = 1.6 Hz, 1H), 8.51 (d, J = 4.8 Hz, 1H), 8.40 (s, 1H), 8.14-8.12 (m, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.65-7.62 (m, 1H), 7.55-7.52 (m, 1H), 7.49 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.25 (s, 1H), 6.43-6.39 (m, 1H), 6.34-6.28 (m 1H), 5.81-5.78 (m, 1H), 5.32-5.27 (m, 1H), 4.86-4.85 (m, 1H), 4.68-4.61 (m, 1H), 4.59-4.53 (m, 1H), 4.23-4.19 (m, 1H), 4.06 (s, 3H), 3.96 (s, 3H); MS (ESI): m/z 484 [M+1]+	37	100*
7		1-(3-((4-((4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.61 (s, 1H), 7.76 (d, J = 2.4 Hz, 1H), 7.69-7.60 (m, 4H), 7.29-7.26 (m, 2H), 7.20-7.14 (m, 2H), 6.43-6.27 (m, 2H), 5.80-5.77 (m, 1H), 5.29 (s, 1H), 4.65-4.60 (m, 1H), 4.47-4.45 (m, 1H), 4.18-4.11 (m, 4H), 3.91 (s, 3H); MS (ESI): m/z=508 [M+1]+	78	6.08 99 (a)
8		1-(3-((4-((3'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.38 (s, 1H), 8.01-8.00 (m, 1H), 7.60-7.57 (m, 1H), 7.48-7.40 (m, 3H), 7.39-7.36 (m, 1H), 7.25-7.24 (m, 2H), 7.06-7.00 (m, 1H), 6.45-6.38 (m, 1H), 6.33-6.28 (m, 1H), 5.81-5.79 (m, 1H), 5.34-5.28 (m, 1H), 4.61-4.60 (m, 2H), 4.49-4.43 (m, 1H), 4.22-4.18 (m, 1H), 4.05 (s, 3H), 3.94 (s, 3H); MS (ESI): m/z 501 [M+1]+	78	6.06 100 (a)
9		1-(3-((7-methoxy-4-((4-methoxy-3'-(trifluoromet hyl)-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.37 (s, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.90 (s, 2H), 7.64-7.58 (m, 3H), 7.44 (s, 1H), 7.26-7.22 (m, 2H), 6.44-6.37 (m, 1H), 6.32-6.27 (m, 1H), 5.80-5.77 (m, 1H), 5.27-5.24 (m, 1H), 4.84-4.81 (m, 1H), 4.63-4.59 (m, 1H), 4.45-4.42 (m, 1H), 4.19-4.15 (m, 1H), 4.04 (s, 3H), 3.95 (s, 3H); MS (ESI): m/z 551 [M+1] +	19	6.69 100 (a)
10		1-(3-((4-((2',5'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.34 (s, 1H), 7.90 (tr, J = 2 Hz, 1H), 7.52-7.49 (m, 1H), 7.46 (s, 1H), 7.30-7.24 (m, 1H), 7.22-7.17 (m, 3H), 7.10-7.04 (m, 1H), 6.44-6.37 (m, 1H), 6.31-6.25 (m, 1H), 5.79-5.76 (m, 1H), 5.29-5.24 (m, 1H), 4.63-4.59 (m, 3H), 4.45-4.41 (m, 1H), 4.18-4.15 (m, 1H), 4.03 (s, 3H), 3.93 (s, 3H); MS (ESI): m/z=519 [M+1] +	47	6.16 98 (a)
11		1-(3-((4-((3',5'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, DMSO-d6) δ 9.60 (br, 1H), 8.41 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.74-7.71 (m, 1H), 7.58 (s, 1H), 7.47-7.41 (m, 2H), 7.27-7.24 (m, 2H), 7.20-7.14 (m, 1H), 6.41-6.34 (m, 1H), 6.16-6.12 (m, 1H), 5.23-5.18 (m, 1H), 4.82-4.78 (m, 1H), 4.59-4.55 (m, 1H), 4.32-4.28 (m, 1H), 3.97-3.94 (m, 4H), 3.85 (s, 3H), 1.23 (s, 2H); MS (ESI): m/z=519 [M+1]+	31	6.37 99 (a)
12		3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile	1H NMR (400MHz, free base, Methanol-d4) δ 9.07-9.06 (m, 1H), 8.78 (s, 1H), 7.94-7.87 (m, 3H), 7.63-7.55 (m, 2H), 7.33 (s, 1H), 7.30-7.26 (m, 1H), 7.08-7.05 (m, 1H), 6.89 (s, 1H), 6.42-6.38 (m, 1H), 6.28-6.21 (m, 1H), 5.76-5.73 (m, 1H), 5.19-5.18 (m, 1H), 4.72-4.50 (m, 3H), 4.34-4.28 (m, 1H), 4.08 (s, 3H), 4.04 (s, 3H); MS (ESI): m/z 508 [M+1]+	21	5.71 100 (a)
13		1-(3-((4-((2'4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, CDCl3) δ 8.88 (s, 1H), 8.72 (s, 1H), 7.89 (s, 1H), 7.49-7.45 (m, 1H), 7.32 (s, 1H), 7.26-7.22 (m, 1H), 7.05-6.88 (m, 4H), 6.41-6.37 (m, 1H), 6.27-6.20 (m, 1H), 5.75-5.72 (m, 1H), 5.17-5.15 (m, 1H), 4.56-4.48 (m, 3H), 4.32-4.30 (m, 1H), 4.05-4.00 (m, 6H); MS (ESI): m/z 519 [M+1]+	23	6.20 100 (a)
14		3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-fluoro-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile	1H NMR (400MHz, free base, Methanol-d4) δ 8.38 (s, 1H), 8.05-7.99 (m, 3H), 7.60-7.57 (m, 1H), 7.49-7.43 (m, 2H), 7.28 (s, 1H), 7.25 (s, 1H), 6.46-6.39 (m, 1H), 6.33-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.29-5.28 (m, 1H), 4.61-4.60 (m, 2H), 4.51-4.49 (m, 1H), 4.25-4.24 (m, 1H), 4.05 (s, 3H), 3.96 (s, 3H); MS (ESI): m/z 526 [M+1]+	35	5.92 91 (a)
15		1-(3-((4-((4'-chloro-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, CDCl3) δ 8.92-8.91 (m, 1H), 8.72 (s, 1H), 8.02-7.88 (m, 1H), 7.48-7.46 (m, 1H), 7.44 (s, 1H), 7.31-7.21 (m, 3H), 7.18-7.03 (m, 1H), 6.88 (s, 1H), 6.42-6.37 (m, 1H), 6.28-6.21 (m, 1H), 5.75-5.73 (m, 1H), 5.17-5.16 (m, 1H), 4.69-4.48 (m, 3H), 4.27-4.33 (m, 1H), 4.06 (s, 3H), 4.04 (s, 3H); MS (ESI): m/z 535 [M+1]+	24	6.73 100 (a)
16		3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-3-fluoro-4'-methoxy-[1,1'-biphenyl]-4-carbonitrile	1H NMR (400 MHz, free base, Methanol-d4) δ 8.62 (s, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.83-7.80 (m, 2H), 7.68-7.65 (m, 3H), 7.34 (d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 6.43-6.36 (m, 1H), 6.32-6.27 (m, 1H), 5.80-5.77 (m, 1H), 5.30-5.28 (m, 1H), 4.65-4.60 (m, 1H), 4.48-4.45 (m, 1H), 4.19-4.11 (m, 4H), 3.94 (s, 3H); MS (ESI): m/z=526 [M+1]+	24	5.92 95 (a)
17		1-(3-((4-((2'-fluoro-4-methoxy-3'-(trifluoromet hyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.36 (s, 1H), 7.94 (s, 1H), 7.83-7.82 (m, 1H), 7.67-7.66 (m, 1H), 7.54-7.51 (m, 1H), 7.48-7.44 (m, 2H), 7.29-7.24 (m, 2H), 6.45-6.39 (m, 1H), 6.33-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.28-5.27 (m, 1H), 4.85-4.83 (m, 1H), 4.62-4.60 (m, 1H), 4.47-4.62 (m, 1H), 4.20-4.19 (m, 1H), 4.09 (s, 3H), 4.01 (s, 3H); MS (ESI): m/z 569 [M+1]+	39	6.71 100 (a)
18		1-(3-((4-((2'-chloro-3'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.35 (s, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.48 (s, 1H), 7.42-7.39 (m, 2H), 7.30-7.22 (m, 4H), 6.45-6.38 (m, 1H), 6.32-6.28 (m, 1H), 5.81-5.77 (m, 1H), 5.30-5.27 (m, 1H), 4.61-4.60 (m, 2H), 4.47-4.43 (m, 1H), 4.20-4.16 (m, 1H), 4.04 (s, 3H), 3.95 (s, 3H), 2.05-2.03 (m, 1H), 1. 70-1. 68 (m, 1H); MS (ESI): m/z 535 [M+1] +	39	6.34 100 (a)
19		1-(3-((4-((2',3'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, CDCl3) δ 8.94 (s, 1H), 8.73 (s, 1H), 7.92 (s, 1H), 7.31-7.26 (m, 3H), 7.16-7.13 (m, 2H), 7.12-7.04 (m, 1H), 6.89 (s, 1H), 6.42-6.37 (m, 1H), 6.28-6.21 (m, 1H), 5.76-5.73 (m, 1H), 5.20-5.17 (m, 1H), 4.62-4.38 (m, 3H), 4.26-4.21 (m, 1H), 4.06 (s, 3H), 4.03 (s, 3H); MS (ESI): m/z 519 [M+1] +	39	6.11 100 (a)
20		1-(3-((4-((3'-chloro-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, Free base, Methanol-d4) δ 8.34 (s, 1H), 7.89 (S, 1H), 7.50-7.41 (m, 4H), 7.25-7.21 (m, 3H), 6.43-6.37 (m, 1H), 6.31-6.26 (m, 1H), 5.79-5.76 (m, 1H), 5.29-5.25 (m, 1H), 4.62-4.58 (m, 2H), 4.45-4.42 (m, 1H), 4.18-4.13 (m, 1H), 4.08-4.03 (m, 3H), 3.93 (s, 3H), 2.03-2.02 (m, 1H), 1.62-160 (m, 1H), 0.92-0.88 (m, 2H); MS (ESI): m/z=535 [M+1] +	3	6.42 96 (a)
21		3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-2-fluoro-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile	1H NMR (400MHz, free base, DMSO-d6) δ 9.26 (s, 1H), 8.32 (s, 1H), 7.93-7.88 (m, 2H), 7.75 (s, 1H), 7.53-7.47 (m, 3H), 7.30 (d, J = 8.4, 1H), 7.23 (s, 1H), 6.39-6.35 (m, 1H), 6.16-6.12 (m, 1H), 5.75-5.69 (m, 1H), 5.23-5.21 (m, 1H), 4.99-4.98 (m, 1H) 4.79-4.78 (m, 1H), 4.57-4.55 (m, 1H), 4.02-4.00 (m, 1H), 3.96 (s, 3H), 3.86 (s, 3H); MS (ESI): m/z 524 [M+1]+	22	5.78 93 (a)
22		1-(3-((4-((5-(6-fluoropyridin -3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, CDCl3) δ 9.01 (s, 1H), 8.74 (s, 1H), 8.47 (s, 1H), 8.05-8.01 (m, 2H), 7.36 (s, 1H), 7.07-7.00 (m, 2H), 6.89 (s, 1H), 6.40 (d, J = 19.2, 1H), 6.27-6.21 (m, 1H), 5.74 (d, J = 10 Hz, 1H), 5.18-5.17 (m, 1H), 4.69-4.65 (m, 1H), 4.59-4.50 (m, 2H), 4.31-4.29 (m, 1H), 4.06 (s, 3H), 4.04 (s, 3H), 3.49 (s, 1H), 2.00 (s, 3H), 1.25 (s, 1H); MS (ESI): m/z=519 [M+1]+	14	5.10 99 (a)
23		1-(3-((4-((3'-fluoro-4-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) 8.36 (s, 1H), 7.71 (s, 1H), 7.27 (s, 1H), 7.26-7.21 (m, 4H), 7.13-7.02 (m, 2H), 6.46-6.41 (m, 1H), 6.39-6.29 (m, 1H), 5.81-5.78 (m, 1H), 5.32-5.31 (m, 1H), 4.85-4.83 (m, 1H), 4.62-4.61 (m, 1H), 4.49-4.48 (m, 1H), 4.25-4.23 (m, 1H), 4.05 (s, 3H), 3.95 (s, 3H), 2.27 (s, 3H); MS (ESI): m/z 515 [M+1]+	33	4.46 100 (a)
24		1-(3-((4-((2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, Free base, CDCl3) δ 8.88 (s, 1H), 8.71 (s, 1H), 7.95 (s, 1H), 7.54-7.49 (m, 1H), 7.33-7.13 (m, 5H), 7.04 (d, J = 8.4 Hz, 1H), 6.90 (s, 1H), 6.41-6.36 (m, 1H), 6.27-6.20 (m, 1H), 5.75-5.72 (m, 1H), 5.19-5.13 (m, 1H), 4.67-4.63 (m, 1H), 4.59-4.54 (m, 1H), 4.50-4.47 (m, 1H), 4.32-4.28 (m, 1H), 2.01-2.00 (m, 1H), 1. 70-1. 60 (m, 4H), 1.43 (s, 1H), 1.22-1.10 (m, 3H), 0.89-0.83 (m, 4H); MS (ESI): m/z=501 [M+1]+	5	6.09 95 (a)
25		1-(3-((4-((4'-fluoro-4-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, CDCl3) δ 8.74 (d, J = 1.6 Hz, 1H), 8.68 (s, 1H), 7.93 (s, 1H), 7.29 (s, 1H), 7.03-6.89 (m, 5H), 6.43-6.38 (m, 1H), 6.28-6.24 (m, 1H), 5.76-5.74 (m, 1H), 5.20-5.18 (m, 1H), 4.58-4.56 (m, 1H), 4.53-4.50 (m, 2H), 4.34-4.30 (m, 1H), 4.06 (s, 3H), 4.03 (s, 3H), 2.36 (s, 3H); MS (ESI): m/z 515 [M+1]+	18	6. 62 100 (a)
26		3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'- methoxy-[1,1'-biphenyl]-4-carbonitrile	1H NMR (400MHz, TFA salt, DMSO-d6) δ 9.30 (s, 1H), 8.33 (s, 1H), 8.16-8.15 (m, 1H), 8.04-8.01 (m, 1H), 7.91-7.90 (m, 1H), 7.78-7.70 (m, 1H), 7.15-7.10 (m, 1H), 7.69-7.62 (m, 1H), 7.55 (s, 1H), 7.28-7.23 (m, 2H), 6.42-6.35 (m, 1H), 6.17-6.12 (m, 1H), 5.72-5.69 (m, 1H), 5.25-5.18 (m, 1H), 4.82-4.76 (m, 1H), 4.58-4.52 (m, 1H), 4.33-4.28 (m, 1H), 4.01-3.99 (m, 1H), 3.96 (s, 3H), 3.85 (s, 3H); MS (ESI): m/z 508 [M+1]+	30	5.64 100 (a)
27		1-(3-((4-((5-(6-chloro-5-fluoropyridin -3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 9.29 (s, 1H), 8.66 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 7.97 (s, 1H), 7.77-7.74 (m, 1H), 7.55 (s, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 6.41-6.35 (m, 1H), 6.16-6.12 (m, 1H), 5.72-5.69 (m, 1H), 5.22-5.20 (m, 1H), 4.86-4.82 (m, 1H), 4.62-4.59 (m, 1H), 4.33-4.32 (m, 1H), 4.01-3.99 (m, 1H), 3.96 (s, 3H), 3.85 (s, 3H); MS (ESI): m/z 536 [M+1]+	15	5. 60 100 (a)
28		1-(3-((4-((4'-chloro-3'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.54 (s, 1H), 7.74-7.73 (m, 1H), 7.65-7.61 (m, 2H), 7.47-7.43 (m, 2H), 7.39-7.38 (m, 1H), 7.36-7.35 (m, 2H), 7.23-7.20 (m, 2H), 6.31-6.28 (m, 1H), 6.24-6.20 (m, 1H), 5.73-5.70 (m, 1H), 5.21-5.20 (m, 1H), 4.58-4.51 (m, 1H), 4.40-4.39 (m, 1H), 4.10-4.01 (m, 2H), 4.00 (s, 3H), 3.84 (s, 3H); MS (ESI): m/z 535 [M+1]+	10	6.75 100 (a)
29		1-(3-((4-((3',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl) oxy) azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.38 (s, 1H), 7.99 (s, 1H), 7.57-7.52 (m, 2H), 7.48 (s, 1H), 7.45-7.43 (m, 1H), 7.37-7.32 (m, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 6.45-6.39 (m, 1H), 6.33-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.29-5.27 (m, 1H), 4.99-4.97 (m, 1H), 4.61-4.60 (m, 1H), 4.46-4.45 (m, 1H), 4.19-4.18 (m, 1H), 4.05 (s, 3H), 3.93 (s, 3H); MS (ESI): m/z 519 [M+1] +	25	6.33 98 (a)
30		1-(3-((4-((5-([1,2,4]triaz olo[1,5-a]pyridin-7-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 9.31 (s, 1H), 8.98 (d, J = 7.2 Hz, 1H), 8.50 (s, 1H), 8.34 (s, 1H), 8.12 (d, J = 1.2 Hz, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.86-7.83 (m, 1H), 7.59-7.56 (m, 2H), 7.31 (d, J = 8.4 Hz, 1H), 7.24 (s, 1H), 6.42-6.35 (m, 1H), 6.17-6.12 (m, 1H), 5.73-5.70 (m, 1H), 5.28-5.22 (m, 1H), 4.84-4.81 (m, 1H), 4.49-4.48 (m, 1H), 4.32-4.30 (m, 1H), 4.08-4.00 (m, 1H), 3.96(s, 3H), 3.87 (s, 3H); MS (ESI): m/z 524 [M+1]+	53	4.04 92 (a)
31		1-(3-((4-((5-([1,2,4]triaz olo[1,5-a] pyridin-6-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.08 (s, 1H), 8.66 (s, 1H), 8.49 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 2.4 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.87-7.81 (m, 1H), 7.73 (s, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 6.44-6.29 (m, 2H), 5.81-5.79 (m, 1H), 5.31-5.30 (m, 1H), 4.67-4.62 (m, 1H), 4.49-4.46 (m, 1H), 4.18-4.13 (m, 4H), 3.96 (s, 3H); MS (ESI): m/z 524 [M+1] +	15	4.05 100 (a)
32		1-(3-((7-methoxy-4-((2-methoxy-5-(pyrazolo[1,5 -a]pyrimidin-6-yl)phenyl) ami no)quinazolin -6-yl) oxy) azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, DMSO-d6) δ 9.41 (s, 1H), 9.33 (s, 1H), 8.95 (s, 1H), 8.33 (s, 1H), 8.24 (d, J = 2.4 Hz, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.79-7.76 (m, 1H), 7.56 (s, 1H), 7.30 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 6.77 (d, J = 1.6 Hz, 1H), 6.38-6.35 (m, 1H), 6.17-6.12 (m, 1H), 5.73-5.70 (m, 1H), 5.28-5.25 (m, 1H), 4.88-4.82 (m, 1H), 4.62-4.57 (m, 1H), 4.35-4.32 (m, 1H), 4.09-4.02 (m, 1H), 4.96 (s, 3H), 3.88 (s, 3H); MS (ESI): m/z 524 [M+1]+	22	4.56 97 (a)
33		1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, CDCl3) δ 9.12-9.11 (m, 1H), 9.10-9.09 (m, 1H), 8.88-8.87 (m, 1H), 8.27-8.26 (m, 1H), 8.07 (s, 1H), 7.34-7.31 (m, 2H), 7.11-7.09 (m, 1H), 6.90 (s, 1H), 6.43-6.42 (m, 1H), 6.39-6.38 (m, 1H), 5.77-5.74 (m, 1H), 5.18-5.17 (m, 1H), 4.68-4.66 (m, 1H), 4.65-4.53 (m, 2H), 4.36-4.34 (m, 1H), 4.33 (s, 3H), 4.08 (s, 3H), 4.04 (s, 3H); MS (ESI): m/z 538 [M+1]+	3	4.86 100 (a)
34		1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-indol-6-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.63 (s, 1H), 7.86 (s, 1H), 7.80-7.72 (m, 1H), 7.70 (s, 1H), 7.62 (s, 1H), 7.60 (s, 1H), 7.35-7.20 (m, 3H), 7.18 (d, J = 2.8 Hz, 1H), 6.46-6.29 (m, 2H), 5.81-5.79 (m, 1H), 5.35-5.28 (m, 1H), 5.11-5.02 (m, 1H), 4.67-4.64 (m, 1H), 4.48-4.46 (m, 1H), 4.18-4.15 (m, 1H), 4.13 (s, 3H), 3.93 (s, 3H), 3.89 (s, 3H); MS (ESI): m/z 536 [M+1]+	10	6.38 100 (a)
35		1-(3-((4-((5-(imidazo[1,2-a]pyridin-8-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.45 (d, J = 6.4 Hz, 1H), 8.34 (s, 1H), 8.25 (d, J = 2.0 Hz, 1H), 7.94 (S, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 1.6 Hz, 1H), 7.50 (s, 1H), 7.45-7.43 (m, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.24 (s, 1H), 7.06 (t, J = 7.2 Hz, 1H), 6.41-6.38 (m, 1H), 6.33-6.32 (m, 1H), 5.81-5.78 (m, 1H), 5.35-5.29 (m, 1H), 4.62-4.61 (m, 2H), 4.45-4.42 (m, 1H), 4.28-4.22 (m, 1H), 4.05 (s, 3H), 3.96 (s, 3H); MS (ESI): m/z 523 [M+1]+		98 52 (a)
36		1-(3-((4-((5-(benzo[d]thia zol-7-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, DMSO-d6) δ 9.43 (s, 1H), 9.28 (s, 1H), 8.34 (s, 1H), 8.23 (d, J = 8.8 Hz, 1H), 7.94-7.93 (m, 1H), 7.82-7.80 (m, 1H), 7.74-7.71 (m, 1H), 7.60 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 6.42-6.35 (m, 1H), 6.17-6.12 (m, 1H), 5.72-5.70 (m, 1H), 5.22-5.21 (m, 1H), 4.58-4.57 (m, 1H), 4.31-4.29 (m, 1H), 4.11-4.10 (m, 1H), 3.96 (s, 3H), 3.86 (s, 3H); MS (ESI): m/z 540 [M+1] +	14	5.48 100 (a)
37		1-(3-((4-((5-(benzofuran-5-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, CDCl3) δ 8.96 (d, J = 2.4 Hz, 1H), 8.74 (s, 1H), 7.82 (s, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.56 (s, 2H), 7.33-7.26 (m, 2H), 7.03 (d, J = 8.4 Hz, 1H), 6.87 (s, 1H), 6.83 (d, J = 2.0 Hz, 1H), 6.40-6.35 (m, 1H), 6.24-6.17 (m, 1H), 5.74-5.71 (m, 1H), 5.13-5.12 (m, 1H), 4.61-4.52 (m, 2H), 4.47-4.464 (m, 1H), 4.30-4.26 (m, 1H), 4.04 (s, 6H); MS (ESI): m/z 523 [M+1] +	69	6.16 100 (a)
38		1-(3-((4-((5-(benzofuran-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.62 (s, 1H), 8.06 (d, J = 2.4 Hz 1H), 7.97-7.94 (m, 1H), 7.67 (s, 1H), 7.59-7.57 (m, 1H), 7.49-7.47 (m, 1H), 7.32-7.20 (m, 4H), 7.11 (d, J = 0.8 Hz, 1H), 6.43-6.36 (m, 1H), 6.31-6.26 (m, 1H), 5.80-5.77 (m, 1H), 5.30-5.27 (m, 1H), 4.65-4.61 (m, 1H), 4.47-4.44 (m, 1H), 4.17-4.13 (m, 1H) 4.11 (s, 3H), 3.93 (s, 3H); MS (ESI): m/z=523 [M+1]+	93	6.58 98 (a)
39		1-(3-((7-methoxy-4-((2-methoxy-5-(pyrazolo[1,5 -a]pyrimidin-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.93-8.91 (m, 1H), 8.60-8.59 (m, 1H), 8.55 (s, 1H), 8.41 (d, J = 2.4 Hz, 1H), 8.34 (s, 1H), 8.07-8.04 (m, 1H), 7.51 (s, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 7.04-7.02 (m, 1H), 6.41-6.38 (m, 1H), 6.32-6.31 (m, 1H), 5.80-5.78 (m, 1H), 5.31-5.28 (m, 1H), 4.72-4.68 (m, 2H), 4.55-4.51 (m, 1H), 4.25-4.19 (m, 1H), 4.06 (s, 3H), 3.92 (s, 3H); MS (ESI): m/z 524 [M+1]+	13	4.62 91 (a)
40		1-(3-((4-((5-(benzofuran-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.41 (s, 1H), 8.13 (d, J = 2.0 Hz, 1H), 8.00 (s, 1H), 7.96-7.94 (m, 1H), 7.65-7.62 (m, 1H), 7.57-7.55 (m, 1H), 7.50 (s, 1H), 7.38-7.34 (m, 2H), 7.29 (s, 1H), 7.27 (d, J = 4.4 Hz, 1H), 6.43-6.33 (m, 1H), 6.32-6.29 (m, 1H), 5.81-5.78 (m, 1H), 5.31-5.29 (m, 1H), 4.91-4.88 (m, 1H), 4.72-4.69 (m, 1H), 4.48-4.45 (m, 1H), 4.21-4.17 (m, 1H), 4.06 (s, 3H), 3.97 (s, 3H); MS (ESI): m/z 523 [M+1]+	45	6.37 100 (a)
41		1-(3-((4-((5-(benzo[b]thio phen-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, DMSO-d6) δ 9.29 (s, 1H), 8.38 (s, 1H), 8.08 (t, J = 8.4 Hz, 2H), 7.82 (d, J = 2.0 Hz, 1H), 7.79 (s, 1H), 7.57 (s, 1H), 7.53-7.44 (m, 3H), 7.31 (d, J = 8.8 Hz, 1H), 7.29 (s, 1H), 6.42-6.35 (m, 1H), 6.17-6.15 (m, 1H), 5.73-5.70 (m, 1H), 5.28-5.24 (m, 1H), 4.82-4.81 (m, 1H), 4.61-4.50 (m, 1H), 4.32-4.29 (m, 1H), 4.01-4.00 (m, 1H), 3.96 (s, 3H), 3.89 (s, 3H); MS (ESI): m/z 539 [M+1] +	37	6. 63 100 (a)
42		1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-5-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.39 (s, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.48 (s, 1H), 7.42-7.40 (m, 1H), 7.28 (s, 1H), 7.26 (d, J = 4.0 Hz, 1H), 6.46-6.39 (m, 2H), 6.33-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.29-5.27 (m, 1H), 4.85-4.83 (m, 1H), 4.62-4.60 (m, 1H), 4.48-4.45 (m, 1H), 4.20-4.19 (m, 1H), 3.97 (s, 3H), 3.34 (s, 3H), 3.32 (s, 3H); MS (ESI): m/z 487 [M+1]+	48	4.28 100 (a)
43		1-(3-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.62 (s, 1H), 7.64-7.61 (m, 1H), 7.35-7.31 (m, 2H), 7.24 (s, 1H), 7.21 (d, J = 8.8 Hz, 1H), 7.09-7.07 (m, 1H), 6.68 (s, 1H), 6.32-6.16 (m, 2H), 5.70 (d, J = 10.0 Hz, 1H), 4.80-4.68 (m, 2H), 4.53-4.46 (m, 1H), 4.38-4.28 (m, 1H), 4.10-4.02 (m, 1H), 3.99 (s, 3H), 3.77 (s, 3H); MS (ESI): m/z 489 [M+1]+	29	5.94 98 (a)
44		1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, DMSO-d6) δ 9.22 (s, 1H), 8.49 (s, 1H, FA), 8.33 (s, 1H), 7.81 (d, J = 2.2 Hz, 1H), 7.72-7.67 (m, 1H), 7.64-7.57 (m, 1H), 7.52 (s, 1H), 7.26-7.15 (m, 2H), 6.86-6.81 (m, 1H), 6.59-6.53 (m, 1H), 6.38 (dd, J = 17.0, 10.3 Hz, 1H), 6.14 (dd, J = 17.0, 2.1 Hz, 1H), 5.70 (dd, J = 10.3, 2.1 Hz, 1H), 5.24-5.16 (m, 1H), 4.84-4.75 (m, 1H), 4.60-4.51 (m, 1H), 4.33-4.25 (m, 1H), 4.02-3.91 (m, 4H), 3.81 (s, 3H); MS (ESI): m/z 473[M+H]+	22	5.54 98 (a)
45		1-(3-((4-((5-(furan-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.45 (s, 1H), 7.75 (s, 1H), 7.62 (s, 1H), 7.52 (s, 1H), 7.49-7.44 (m, 2H), 7.16 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.68 (s, 1H), 6.32-6.16 (m, 2H), 5.70 (d, J = 10.0 Hz, 1H), 4.80-4.68 (m, 2H), 4.53-4.46 (m, 1H), 4.38-4.28 (m, 1H), 4.10-4.02 (m, 1H), 3.99 (s, 3H), 3.77 (s, 3H); MS (ESI): m/z 473 [M+1]+	38	5.37 100 (a)
46		1-(3-((7-methoxy-4-((2-methoxy-5-(thiazol-5-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, CDCl3) δ 9.10 (d, J = 2.4 Hz, 1H), 8.78 (s, 1H), 8.74 (s, 1H), 8.09 (s, 1H), 7.34 (s, 1H), 7.30-7.28 (m, 1H), 7.01-7.00 (m, 1H), 6.88 (s, 1H), 6.42-6.37 (m, 1H), 6.28-6.21 (m, 1H), 5.76-5.74 (m, 1H), 5.19-5.16 (m, 1H), 4.67-4.52 (m, 3H), 4.37-4.36 (m, 1H), 4.06 (s, 3H), 4.04 (s, 3H); MS (ESI): m/z 490 [M+1]+	17	4.32 100 (a)
47		1-(3-((7-methoxy-4-((2-methoxy-5-(thiophen-3-yl)phenyl)ami no)quinazolin -6-yl) oxy) azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.62 (s, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.76-7.70 (m, 2H), 7.60-7.59 (m, 1H), 7.52-7.50 (m, 1H), 7.46-7.44 (m, 1H), 7.29-7.24 (m, 2H), 6.44-6.38 (m, 1H), 6.33-6.29 (m, 1H), 5.82-5.79 (m, 1H), 5.30 (s, 1H), 4.66-4.62 (m, 1H), 4.48-4.46 (m, 1H), 4.18-4.09 (m, 4H), 3.91 (s, 3H); MS (ESI): m/z=489 [M+1]+	17	5.80 98 (a)
48		1-(3-((7-methoxy-4-((2-methoxy-5-(2-methylthiazol -5-yl))amino)qui nazolin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.50 (s, 1H), 8.39 (s, 1H), 8.02-8.01 (m, 1H), 7.82 (s, 1H), 7.54-7.53 (m, 1H), 7.52-7.51 (m, 1H), 7.47 (s, 1H), 7.25-7.19 (m, 1H), 6.46-6.39 (m, 1H), 6.33-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.29-5.28 (m, 1H), 4.88-4.87 (m, 1H), 4.20-4.19 (m, 1H), 4.05 (s, 3H), 3.94 (s, 3H); MS (ESI): m/z 504 [M+1]+	3	4.34 100 (a)
49		1-(3-((7-methoxy-4-((2-methoxy-5-(5-methylthiophe n-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.36 (s, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.56-7.54 (m, 1H), 7.46 (s, 1H), 7.28 (d, J = 1.6 Hz, 1H), 7.24 (s, 1H), 7.16-7.13 (m, 2H), 6.44-6.32 (m, 1H), 6.31-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.31-5.26 (m, 1H), 4.92-4.85 (m, 1H), 4.75-4.60 (m, 1H), 4.46-4.42 (m, 1H), 4.21-4.17 (m, 1H), 4.05 (s, 3H), 3.90 (s, 3H), 2.51 (s, 3H); MS (ESI): m/z 503 [M+1]+	54	6.24 98 (a)
50		1-(3-((7-methoxy-4-((2-methoxy-5-(5-methylfuran-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 7.75 (d, J = 2 Hz, 1H), 7.69-7.66 (m, 2H), 7.27 (s, 1H), 7.20 (d, J = 8.4 Hz, 1H), 6.55 (d, J = 3.2 Hz, 1H), 6.43-6.36 (m, 1H), 6.31-6.27 (m, 1H), 6.09-6.08 (m, 1H), 5.80-5.77 (m, 1H), 5.28 (s, 1H), 4.64-4.60 (m, 1H), 4.47-4.44 (m, 1H), 4.16-4.11 (m, 4H), 3.87 (s, 3H), 2.33 (d, J = 0.8 Hz, 3H); MS (ESI): m/z=501 [M+1]+	4	5.93 90 (a)
51		1-(3-((7-methoxy-4-((2-methoxy-5-(2-methylfuran-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.55 (s, 1H), 7.64-7.60 (m, 2H), 7.45-7.39 (m, 2H), 7.26-7.21 (m, 2H), 6.55 (d, J = 2 Hz, 1H), 6.43-6.36 (m, 1H), 6.32-6.27 (m, 1H), 5.80-5.77 (m, 1H), 5.29-5.25 (m, 1H), 4.64-4.60 (m, 1H), 4.47-4.44 (m, 1H), 4.17-4.13 (m, 1H), 4.09 (s, 3H), 3.89 (s, 3H), 3.60 (s, 2H), 2.44 (s, 3H); MS (ESI): m/z=508 [M+1]+	30	5.79 98 (a)
52		1-(3-((7-methoxy-4-((2-methoxy-4-methyl-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.52 (s, 1H), 7.56 (s, 1H), 7.42 (s, 1H), 7.36-7.34 (m, 1H), 7.17 (s, 1H), 7.05-7.00 (m, 3H), 6.35-6.29 (m, 1H), 6.24-6.19 (m, 1H), 5.73-5.70 (m, 1H), 5.20-5.19 (m, 1H), 4.78-4.76 (m, 1H), 4.54-4.53 (m, 1H), 4.38-4.36 (m, 1H), 4.08-4.07 (m, 1H), 4.02 (s, 3H), 3.81 (s, 3H); MS (ESI): m/z 503 [M+1]+	16	6.19 100 (a)
53		1-(4,4-difluoro-3-((4-((5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-5-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.73 (s, 1H), 8.43 (s, 1H), 7.68-7.66 (m, 1H), 7.58 (s, 1H), 7.29 (s, 1H), 7.23 (d, J = 8.8 Hz, 1H), 6.91 (s, 1H), 6.72-6.70 (m, 2H), 6.54-6.53 (m, 1H), 6.07-6.03 (m, 1H), 5.67-5.64 (m, 2H), 4.20-4.19 (m, 1H), 4.12-4.11 (m, 4H), 3.98 (s, 3H), 3.89-3.87 (m, 2H), 2.41-2.35 (m, 2H); MS (ESI): m/z 537 [M+H]+	41	11.02 100 (b)
54		1-(3-((4-((2-ethoxy-5-(thiophen-2-yl)phenyl)ami no)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.61 (s, 1H), 7.81 (d, J = 2.4 Hz, 1H), 7.67-7.64 (m, 2H), 7.35-7.32 (m, 2H), 7.27 (s, 1H), 7.20 (d, J = 8.8 Hz, 1H), 7.09-7.07 (m, 1H), 6.42-6.35 (m, 1H), 6.31-6.27 (m, 1H), 5.80-5.77 (m, 1H), 5.28 (br, 1H), 4.64-4.60 (m, 1H), 4.47-4.44 (m, 1H), 4.19-4.14 (m, 3H), 4.11 (s, 3H), 1. 33-1. 30 (m, 3H); MS (ESI): m/z=508 [M+1]+	27	6.21 99 (a)
55		1-(3-((4-((2-ethoxy-5-(furan-2-yl)phenyl)ami no)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.64 (s, 1H), 7.88-7.87 (m, 1H), 7.75-7.74 (m, 1H), 7.72-7.67 (m, 1H), 7.55-7.54 (m, 1H), 7.30 (s, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.71-6.70 (m, 1H), 6.53-6.52 (m, 1H), 6.44-6.41 (m, 1H), 6.40-6.29 (m, 1H), 5.82-5.79 (m, 1H), 5.30-5.28 (m, 1H), 4.70-4.63 (m, 2H), 4.49-4.48 (m, 2H), 4.21-4.17 (m, 1H), 4.15 (s, 3H), 4.13 (s, 3H); MS (ESI): m/z 487 [M+1]+	24	5.85 100 (a)
56		1-(3-((4-((5-([1,2,4]triaz olo[1,5-a] pyridin-7-yl)-2-ethoxyphenyl) amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.84(d, J = 7.2 Hz, 1H), 8.43 (s, 1H), 8.41 (s, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 0.8 Hz, 1H), 7.75-7.73 (m, 1H), 7.61-7.58 (m, 1H), 7.46 (s, 1H), 7.30 (d, J = 8.8 Hz, 1H), 7.26 (s, 1H), 6.41-6.38 (m, 1H), 6.33-6.32 (m, 1H), 5.81 (m, 1H), 5.30-5.28 (m, 1H), 4.63-4.60 (m, 1H), 4.51-4.47 (m, 1H), 4.27-4.22 (m, 4H), 4.06 (s, 3H), 1.43 (t, J = 6.8 Hz, 3H); MS (ESI) : m/z 538 [M+1]+	28	4.50 99 (a)
57		1-(3-((4-((5-(benzofuran-5-yl)-2-ethoxyphenyl) amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, DMSO-d6) δ 9.15 (s, 1H), 8.36 (s, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.94-7.90 (m, 3H), 7.66 (d, J = 8.4 Hz, 1H), 7.60-7.52 (m, 3H), 7.23-7.20 (m, 2H), 7.00 (s, 1H), 6.40-6.33 (m, 1H), 6.16-6.11 (m, 1H), 5.72-5.69 (m, 1H), 5.30-5.25 (m, 1H), 4.84-4.80 (m, 1H), 4.58-4.54 (m, 1H), 4.32-4.29 (m, 1H), 4.14-4.08 (m, 2H), 3.17 (d, J = 4.8 Hz, 1H), 1.28 (t, J = 7.2 Hz, 1H); MS (ESI): m/z 537 [M+1]+	17	6.50 100 (a)
58		1-(3-((7-methoxy-4-((4-methoxy-[1,1'-biphenyl]-3-yl) amino) quin azolin-6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, CDCl3) δ 8.99-8.97 (m, 1H), 8.74 (d, J = 5.2 Hz, 1H), 7.91 (s, 1H), 7.67-7.64 (m, 2H), 7.47-7.43 (m, 2H), 7.35-7.26 (m, 3H), 7.21 (d, J = 12.8 Hz, 1H), 7.04-7.01 (m, 1H), 6.53-6.39 (m, 2H), 5.75-5.68 (m, 1H), 5.19-5.08 (m, 1H), 4.04-3.79 (m, 10H), 2.48-2.26 (m, 3H); MS (ESI) : m/z 497 [M+1]+	25	6.08 100 (a)
59		1-(3-((7-methoxy-4-((2-methoxy-5-(pyridin-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.85 (d, J = 2.0 Hz, 1H), 8.51-8.50 (m, 1H), 8.38 (d, J = 4.0 Hz, 1H), 8.18-8.11 (m, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.78 (d, J = 11.6 Hz, 1H), 7.54-7.51 (m, 1H), 7.29-7.26 (m, 1H), 7.22 (d, J = 7.6 Hz, 1H), 6.67-6.64 (m, 1H), 6.34-6.30 (m, 1H), 5.81-5.78 (m, 1H), 5.31-5.28 (m, 1H), 3.99 (s, 3H), 3.83 (s, 3H), 3.82-3.78 (m, 4H), 2.56-2.34 (m, 2H); MS (ESI): m/z 498 [M+1]+	45	98*
60		1-(3-((4-((4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, Free base, Methanol-d4) δ 8.62 (d, J = 2.4 Hz 1H), 8.03 (s, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.69-7.62 (m, 3H), 7.31-7.26 (m, 2H), 7.22-7.16 (m, 2H), 6.73-6.59 (m, 1H), 6.36-6.31 (m, 1H), 5.83-5.77 (m, 1H), 5.33 (d, J = 21.6 Hz, 1H), 4.11-3.81 (m, 11H), 2.48-2.30 (m, 2H), 1.31 (s, 7H), 0.94-0.87 (m, 1H); MS (ESI): m/z=515 [M+1] +	58	6.19 99 (a)
61		1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-5-yl)phenyl)ami no)quinazolin -6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.38(d, J = 2.0 Hz, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.41-7.39 (m, 1H), 7.27-7.21 (m, 2H), 6.69-6.66 (m, 1H), 6.39-6.31 (m, 1H), 5.82-5.79 (m, 2H), 5.32-5.27 (m, 1H), 4.01 (s, 3H), 3.99 (s, 3H), 3.98-3.95 (m, 4H), 2.56-2.28 (m, 2H); MS (ESI): m/z 501 [M+1]+	50	4.44 98 (a)
62		1-(3-((7-methoxy-4-((2-methoxy-5-(thiazol-5-yl)phenyl) ami no) quinazolin -6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.94 (s, 1H), 8.42 (s, 1H), 8.12-8.11 (m, 1H), 8.07-8.06 (m, 1H), 7.80-7.79 (m, 1H), 7.63-7.61 (m, 1H), 7.24-7.22 (m, 2H), 6.78-6.61 (m, 1H), 6.36-6.31 (m, 1H), 5.84-5.71 (m, 1H), 5.36-5.27 (m, 1H), 4.02-3.73 (m, 6H), 1.91 (s, 3H), 1.89 (s, 3H); MS (ESI): m/z 504 [M+1] +	10	4.48 100 (a)
63		1-(3-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.36 (s, 1H), 7.99 (d, J = 1.2 Hz, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.58-7.55 (m, 1H), 7.34-7.31 (m, 2H), 7.22-7.15 (m, 2H), 7.09 (t, J = 8.0 Hz, 1H), 6.65-6.59 (m, 1H), 6.34-6.29 (m, 1H), 5.81-5.75 (m, 1H), 5.31-5.26 (m, 1H), 4.01-3.70 (m, 9H); MS (ESI): m/z 503 [M+1]+	40	5.86 100 (a)
64		1-(3-((4-((5-(furan-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.60 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 7.71 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.58 (s, 1H), 7.25 (s, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.80 (s, 1H), 6.78-6.66 (m, 1H), 6.36-6.31 (m, 1H), 5.83-5.80 (m, 1H), 4.16-3.60 (m, 11H), 2.55-2.29 (m, 2H); MS (ESI) : m/z 487 [M+1]+	48	5.21 97 (a)
65		1-(4-((7-methoxy-4-((4-methoxy-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, DMSO-d6) δ 8.39 (s, 1H), 7.97 (s, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.67-7.60 (m, 3H), 7.46-7.44 (t, J = 7.6 Hz, 2H), 7.34 (t, J = 7.2 Hz, 1H), 7.32-7.21 (m, 2H), 6.88-6.82 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.67 (m, 1H), 4.81-4.78 (m, 1H), 3.95-3.92 (m, 5H), 3.50-3.38 (m, 2H), 2.04-2.01 (m, 2H), 1.69-1.65 (m, 2H); MS (ESI): m/z 511 [M+1] +	50	6.32 98 (a)
66		1-(4-((7-methoxy-4-((2-methoxy-5-(pyridin-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.84 (d, J = 1.6 Hz, 1H), 8.51-8.50 (m, 1H), 8.36 (s, 1H), 8.14-8.11 (m, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.85 (s, 1H), 7.64-7.61 (m, 1H), 7.54-7.51 (m, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 6.88-6.81 (s, 1H), 6.26-6.21 (m, 1H), 5.80-5.76 (m, 1H), 5.00-4.98 (m, 1H), 4.08 (s, 3H), 4.02-3.99 (m, 2H), 3.98 (s, 3H), 3.82-3.79 (m, 2H), 2.21-2.10 (m, 2H), 2.02-1.95 (m, 2H); MS (ESI): m/z 521 [M+1]+	47	3.57 100 (a)
67		1-(4-((4-((4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.59 (s, 1H), 8.05 (br, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.67-7.60 (m, 3H), 7.28-7.23 (m, 2H), 7.18-7.14 (m, 2H), 6.85-6.78 (m, 1H), 6.25-6.20 (m, 1H), 5.78-5.75 (m, 1H), 4.90 (s, 1H), 4.08 (s, 3H), 3.98-3.90 (m, 5H), 3.63 (br, 2H), 2.11 (br, 2H), 1.91 (br, 2H); MS (ESI) : m/z=529 [M+1]+	63	6.39 99 (a)
68		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.33 (s, 1H), 7.85-7.84 (m, 1H), 7.79 (s, 1H), 7.54-7.41 (m, 2H), 7.19 (s, 1H), 7.17(s, 1H), 7.04-7.02 (m, 2H), 6.84-6.80 (m, 1H), 6.25-6.20 (m, 1H), 5.77-5.74 (m, 1H), 4.84-4.80 (m, 1H), 4.00-3.90 (m, 8H), 3.69-3.60 (m, 2H), 2.07-2.06 (m, 2H), 1.90-1.87 (m, 2H), 1. 92-1. 89 (m, 2H); MS (ESI): m/z 547 [M+1]+	50	6.48 100 (a)
69		1-(4-((4-((5-([1,2,4]triaz olo[1,5-a]pyridin-7-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.84 (d, J = 7.2 Hz, 1H), 8.43 (s, 1H), 8.38 (s, 1H), 8.23 (d, J = 2.4 Hz, 1H), 8.00 (s, 1H), 7.86 (s, 1H), 7.79-7.77 (m, 1H), 7.60-7.58 (m, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.24 (s, 1H), 6.88-6.81 (m, 1H), 6.26-6.22 (m, 1H), 5.80-5.77 (m, 1H), 4.66-4.61 (m, 1H), 4.04 (s, 3H), 4.00-3.99 (m, 2H), 3.98 (s, 3H), 3.71-3.68 (m, 2H), 2.11-2.10 (m, 2H), 1. 94-1. 91 (m, 2H); MS (ESI): m/z 552 [M+1]+	48	4.38 100 (a)
70		1-(4-((4-((5-(imidazo[1,2-a]pyridin-8-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.44-8.42 (m, 1H), 8.31 (s, 1H), 8.23-8.22 (m, 1H), 7.93-7.92 (m, 1H), 7.88-7.85 (m, 2H), 7.61-7.60 (m, 1H), 7.44-7.42 (m, 1H), 7.28-7.25 (m, 1H), 7.03-7.02 (m, 1H), 6.83-6.80 (m, 2H), 6.26-6.25 (m, 1H), 6.22-6.21 (m, 1H), 5.76-5.75 (m, 1H), 4.89 (s, 3H), 4.88-4.03 (m, 2H), 4.02 (s, 3H), 3.71-3.60 (m, 2H), 2.16-2.03 (m, 2H), 1.99-1.86 (m, 2H); MS (ESI): m/z 551 [M+1]+	1	3.48 100 (a)
71		1-(4-((4-((5-(benzofuran-5-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.59 (s, 1H), 8.05 (s, 1H), 7.82-7.78 (m, 3H), 7.70-7.67 (m, 1H), 7.54 (s, 2H), 7.28-7.25 (m, 2H), 6.88-6.79 (m, 2H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.08 (s, 3H), 3.99-3.92 (m, 5H), 3.68-3.60 (m, 2H), 2.11-2.08 (m, 2H), 1.91-1.89 (m, 2H); MS (ESI): m/z 551 [M+1] +	52	6.56 100 (a)
72		1-(4-((4-((5-(benzofuran-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.50 (s, 1H), 8.12 (d, J = 2 Hz, 1H), 7.95 (s, 1H), 7.92-7.89 (m, 1H), 7.59-7.56 (m, 1H), 7.50-7.48 (m, 1H), 7.29-7.19 (m, 4H), 7.10 (d, J = 0.8, 1H), 6.85-6.78 (m, 1H), 6.24-6.20 (m, 1H), 5.78-5.75 (m, 1H), 4.06 (s, 3H), 3.98-3.95 (m, 5H), 3.68-3.59 (m, 2H), 2.10 (s, 2H), 1.92 (s, 2H), 1.33-1.29 (m, 4H); MS (ESI): m/z=551 [M+1]+	36	6.79 99 (a)
73		1-(4-((4-((5-(benzofuran-3-yl)-2-methoxyphenyl ) amino) -7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.38 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.99 (s, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.85 (s, 1H), 7.64-7.61 (m, 1H), 7.57 (d, J = 7.2 Hz, 1H), 7.38-7.34 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.98-4.91 (m, 1H), 4.03 (s, 3H), 4.01-3.98 (m, 2H), 3.95 (s, 3H), 3.79-3.72 (m, 2H), 2.21-2.18 (m, 2H), 2.00-1.95 (m, 2H); MS (ESI) : m/z 551 [M+1]+	51	6. 63 98 (a)
74		1-(4-((4-((5-(2-hydroxytetrah ydro-2H-pyran-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) 8.34 (s, 2H), 8.03-8.00 (m, 1H), 7.83 (s, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.82-4.81 (m, 1H), 4.04 (s, 3H), 4.01-3.99 (m, 2H), 3.70-3.68 (m, 2H), 3.64 (t, J = 6.4 Hz, 2H), 3.08 (t, J = 6.4 Hz, 2H), 2.11-2.09 (m, 2H), 1.93-1.92 (m, 2H), 1. 84-1. 79 (m, 2H), 1.66-1.63 (m, 2H); MS (ESI) : m/z 535 [M+1]+	5	4.47 98 (a)
75		1-(4-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-5-yl)phenyl) ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.36 (s, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.84 (s, 1H), 7.51 (s, 1H), 7.42-7.40 (m, 1H), 7.28 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 6.88-6.81 (m, 1H), 6.39 (d, J = 2.0 Hz, 1H), 6.26-6.22 (m, 1H), 5.80-5.76 (m, 1H), 4.98-4.95 (m, 1H), 4.09 (s, 3H), 4.01-3.98 (m, 2H), 3.94 (s, 3H), 3.93 (s, 3H), 3.71-3.69 (m, 2H), 2.11-2.09 (m, 2H), 1. 94-1. 92 (m, 2H); MS (ESI): m/z 515 [M+1]+	39	4.79 92 (a)
76		1-(4-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.32 (s, 1H), 8.05 (s, 1H), 7.83 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.59 (s, 1H), 7.21 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 6.86-6.79 (m, 1H), 6.59 (s, 1H), 6.25 (d, J = 16.8 Hz, 1H), 5.78 (d, J = 10.8 Hz, 1H), 4.02 (s, 3H), 4.00-3.90 (m, 9H), 3.71-3.59 (m, 2H), 2.16-2.03 (m, 2H), 1.95-1.85 (m, 2H); MS (ESI): m/z=515 [M+1]+	47	4.76 100 (a)
77		1-(4-((7-methoxy-4-((2-methoxy-5-(thiazol-5-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.92 (s, 1H), 8.37 (s, 2H), 8.09 (s, 1H), 8.02 (d, J = 2.4 Hz, 1H), 7.82 (s, 1H), 7.59-7.57 (m, 1H), 7.22-7.20 (m, 2H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.02 (s, 3H), 3.98-3.92 (m, 5H), 3.71-3.63 (m, 2H), 2.09-2.08 (m, 2H), 1.93-1.89 (m, 2H); MS (ESI): m/z=518 [M+1] +	7	4.83 100 (a)
78		1-(4-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.52 (s, 1H), 7.95 (s, 1H), 7.85 (d, J = 2.4 Hz, 1H), 7.64-7.61 (m, 1H), 7.35-7.31 (m, 2H), 7.24 (s, 1H), 7.21 (d, J = 8.8 Hz, 1H), 7.09-7.07 (m, 1H), 6.86-6.79 (m, 1H), 6.26-6.21 (m, 1H), 5.79 (d, J = 8.8 Hz, 1H), 4.07 (s, 3H), 3.99-3.95 (m, 2H), 3.90 (s, 2H), 3.70-3.61 (m, 2H), 2.12-2.10 (m, 2H), 1. 92-1.91 (m, 2H); MS (ESI): m/z 517 [M+1]+	53	6.09 100 (a)
79		1-(4-((7-methoxy-4-((2-methoxy-5-(thiophen-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, Free base, Methanol-d4) δ 8.30 (s, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.82 (s, 1H), 7.60-7.57 (m, 1H), 7.55-7.53 (m, 1H), 7.47-7.42 (m, 2H), 7.20-7.15 (m, 2H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.01-3.89 (m, 9H), 3.70-3.61 (m, 2H), 2.08-2.07 (m, 2H), 1.96-1.88 (m, 2H), 1.39-1.31 (m, 4H); MS (ESI): m/z=517 [M+1]+	39	6.07 94 (a)
80		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, HCl salt, DMSO-d6) δ 10.91 (s, 1H), 8.72 (s, 1H), 8.15 (s, 1H), 7.76-7.72 (m, 3H), 7.30-7.27 (m, 2H), 6.89-6.82 (m, 2H), 6.59-6.58 (m, 1H), 6.14-6.10 (m, 1H), 5.71-5.68 (m, 1H), 4.85 (s, 1H), 4.01 (s, 3H), 3.91-3.88 (m, 2H), 3.83 (s, 3H), 3.51-3.50 (m, 2H), 2.08-2.07 (m, 2H), 1.72-1.71 (m, 2H); MS (ESI): m/z=501 [M+1]+	85	5.87 100 (a)
81		1-(4-((4-((5-(furan-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.59 (s, 1H), 8.04 (s, 1H), 7.88 (s, 1H), 7.70 (s, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 7.27 (s, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.87-6.79 (m, 2H), 6.27 (d, J = 16.8 Hz, 1H), 5.80 (d, J = 10.4 Hz, 1H), 4.10 (s, 3H), 4.00-3.90 (m, 2H), 3.89 (s, 3H), 3.75-3.60 (m, 2H), 2.21-2.08 (m, 2H), 2.00-1.88 (m, 2H); MS (ESI): m/z=501 [M+1]+	52	5.69 100 (a)
82		1-(4-((7-methoxy-4-((2-methoxy-5-(3-methylthiophe n-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, CDCl3) δ 8.93 (s, 1H), 8.69 (s, 1H), 7.89 (s, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 7.19-7.17 (m, 2H), 7.01 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 5.2 Hz, 1H), 6.66-6.62 (m, 1H), 6.34-6.29 (m, 1H), 5.74-5.71 (m, 1H), 4.69-4.68 (m, 1H), 3.99-3.91 (m, 2H), 3.87-3.85 (m, 1H), 3.52-3.48 (m, 1H), 2.41 (s, 3H), 2.03-1.97 (m, 4H); MS (ESI) : m/z 531 [M+1]+	38	6.40 100 (a)
83		1-(4-((7-methoxy-4-((2-methoxy-5-(4-methylthiophe n-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, CDCl3) δ 9.03 (s, 1H), 8.76 (s, 1H), 7.87 (s, 1H), 7.30-7.24 (m, 3H), 7.12 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.83 (s, 1H), 6.66-6.59 (m, 1H), 6.34-6.29 (m, 1H), 5.74-5.71 (m, 1H), 4.66-4.65 (m, 1H), 4.01 (s, 3H), 3.99-3.98 (m, 2H), 3.72-3.69 (m, 1H), 3.59-3.55 (m, 1H), 2.31 (s, 3H), 2.04-1.96 (m, 4H), 1.56 (s, 3H); MS (ESI) : m/z 531 [M+1]+	34	6.48 99 (a)
84		1-(4-((7-methoxy-4-((2-methoxy-5-(2-methylfuran-3-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.58 (s, 1H), 8.04 (s, 1H), 7.55 (d, J = 2 Hz, 1H), 7.47-7.45 (m, 1H), 7.39 (d, J = 1.6 Hz, 1H), 7.23-7.22 (m, 2H), 6.85-6.79 (m, 1H), 6.55 (d, J = 2 Hz, 1H), 6.25-6.20 (m, 1H), 5.78-5.75 (m, 1H) 4.08 (s, 3H), 3.98-3.92 (m, 2H), 3.88 (s, 3H), 3.68 (s, 2H), 2.43 (s, 3H), 2.11 (s, 2H), 1.91 (s, 2H); MS (ESI): m/z=515 [M+1] +	24	6.19 100 (a)
85		1-(4-((4-((5-(isoxazol-4-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.01 (s, 1H), 8.81 (s, 1H), 8.32 (s, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.82 (s, 1H), 7.56-7.53 (m, 1H), 7.21-7.18 (m, 2H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.01-3.90 (m, 8H), 3.68-3.65 (m, 2H), 2.07-2.03 (m, 2H), 1. 92-1. 89 (m, 2H); MS (ESI): m/z 502 [M+1]+	5	5.01 100 (a)
86		1-(4-((7-methoxy-4-((2-methoxy-5-(5-methylfuran-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.49 (s, 1H), 7.99-7.91 (m, 1H), 7.65-7.64 (m, 1H), 7.58-7.56 (m, 1H), 7.15 (s, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.75-6.69 (m, 1H), 6.45-6.44 (m, 1H), 6.14 (d, J = 1.6 Hz, 1H), 6.11-5.98 (m, 1H), 5.69-5.65 (m, 1H), 4.06 (s, 3H), 3.99-3.84 (m, 2H), 3.77 (s, 3H), 3.22-3.20 (m, 2H), 2.23 (s, 3H), 2.11-2.00 (m, 2H), 1.89-1.78 (m, 2H); MS (ESI): m/z 515 [M+1]+	38	6.27 100 (a)
87		1-(4-((4-((5-(5-ethylfuran-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.32 (s, 1H), 7.91-7.90 (m, 1H), 7.84 (s, 1H), 7.60-7.57 (m, 1H), 7.23 (s, 1H), 7.16 (d, J = 8.8 Hz, 1H), 6.87-6.80 (m, 1H), 6.55-6.54 (m, 1H), 6.26 (d, J = 2.0 Hz, 1H), 6.11-6.10 (m, 1H), 5.79-5.76 (m, 1H), 4.18-4.10 (m, 1H), 4.03 (s, 3H), 3.89 (s, 3H), 2.72 (q, J = 7.16, 7.56, 7.48 Hz, 1H), 2.16-2.00 (m, 3H), 1. 98-1. 79 (m, 2H), 1.69-1.61 (m, 2H); MS (ESI): m/z 529 [M+1]+	18	6.66 95 (a)
88		1-(4-((4-((5-(5-fluorofuran-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.33 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.80 (s, 1H), 7.52-7.49 (m, 1H), 7.20 (s, 1H), 7.15 (d, J = 8.8 Hz, 1H), 6.85-6.78 (m, 1H), 6.59 (tr, J = 3.2 Hz, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 5.62-5.59 (m, 1H), 4.01 (s, 3H), 3.99-3.93 (m, 2H), 3.88 (s, 3H), 3.70-3.63 (m, 2H), 2.08-2.07 (m, 2H), 1. 91-1. 90 (m, 2H); MS (ESI): m/z 519 [M+1]+	10	10.03 94 (b)
89		1-(4-((7-methoxy-4-((2-methoxy-5-(3-methylfuran-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 515 [M+1]+
90		1-(4-((7-methoxy-4-((2-methoxy-5-(4-methylfuran-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 515 [M+1]+	49	10.30 99 (b)
91		1-(4-((4-((5-(3,5-dimethylfuran -2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 529 [M+1]+
92		5-(3-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )furan-2-carbonitrile	MS (ESI): m/z 526 [M+1] +
93		1-(4-((7-methoxy-4-((2-methoxy-5-(tetrahydrofu ran-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 505 [M+1]+
94		1-(4-((7-methoxy-4-((2-methoxy-5-(tetrahydro-2H-pyran-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 519 [M+1]+
95		1-(4-((7-methoxy-4-((2-methoxy-4-methyl-5-(thiophen-2-yl))amino)qui nazolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.44 (s, 1H), 7.90 (s, 1H), 7.55 (s, 1H), 7.42 (d, J = 4.4 Hz, 1H), 7.20 (s, 1H), 7.11-7.08 (m, 3H), 6.86-6.79 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.87-4.83 (m, 1H), 4.04 (s, 3H), 3.96-3.94 (m, 2H), 3.88 (s, 3H), 3.67-3.61 (m, 2H), 3.36 (s, 1H), 2.46(s, 3H), 2.11-2.08 (m, 2H), 1.91-1.87 (m, 2H); MS (ESI): m/z 531 [M+1]+	43	6.46 100 (a)
96		1-(4-((4-((5-(furan-2-yl)- 2-methoxy-4-methylphenyl) amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.29 (s, 1H), 7.85 (s, 1H), 7.84 (s, 1H), 7.57 (s, 1H), 7.20 (s, 1H), 7.05 (s, 1H), 6.88-6.81 (m, 1H), 6.57-6.54 (m, 2H), 6.26-6.22 (m, 1H), 5.79-5.76 (m, 1H), 4.85-4.84 (m, 1H), 4.03 (s, 3H), 4.00-3.96 (m, 2H), 3.88 (s, 3H), 3.68-3.66 (m, 2H), 2.55 (s, 3H), 2.10-2.09 (m, 2H), 1.92-1.90 (m, 2H); MS (ESI) : m/z 515 [M+1]+	5	6.11 95 (a)
97		1-(4-((4-((3-(furan-2-yl)-6-methoxy-2,4-dimethylpheny 1)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 529 [M+1]+
98		1-(4-((4-((2-fluoro-3-(furan-2-yl)-6-methoxy-4-methylphenyl) amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 533 [M+1]+
99		1-(3,3-difluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-5-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.76 (s, 2H), 7.65-7.62 (m, 1H), 7.55 (s, 1H), 7.24-7.19 (m, 2H), 6.89-6.88 (m, 2H), 6.89 (s, 1H), 6.71 (s, 1H), 6.54-6.52 (m, 1H), 6.29-6.28 (m, 1H), 5.87-5.84 (m, 1H), 4.72-4.71 (m, 1H), 4.33-4.32 (m, 1H), 4.01 (s, 3H), 3.93 (s, 3H), 3.90-3.89 (m, 1H), 3.42-3.41 (m, 1H), 2.52-2.50 (m, 1H), 2.15-2.13 (m, 1H); MS (ESI): m/z 537 [M+H]+	51	10.95 100 (b)
100		1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-5-yl)oxy)-4,4-difluoropiper idin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.68 (s, 1H), 8.28 (s, 1H), 7.58-7.49 (m, 2H), 7.29-7.26 (m, 2H), 7.11-7.06 (m, 2H), 6.91 (s, 1H), 6.78-6.76 (m, 1H), 6.06-6.02 (m, 1H), 5.68-5.43 (m, 2H), 4.21-4.20 (m, 1H), 4.11-4.08 (m, 4H), 4.01 (s, 3H), 3.99-3.81 (m, 2H), 2.45-2.42 (m, 2H); MS (ESI): m/z 583 [M+H]+	47	11.59 100 (b)
101		1-(4-((4-((3-fluoro-5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, DMSO-d6) δ 9.12 (s, 1H), 8.42 (s, 1H), 7.90 (s, 1H), 7.85 (s, 1H), 7.79 (d, J = 12.4 Hz, 1H), 7.40 (d, J = 6.8 Hz, 1H), 7.22 (s, 1H), 6.88-6.82 (m, 2H), 6.69-6.68 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.67 (m, 1H), 4.82 (s, 1H), 4.12-4.08 (m, 1H), 3.94-3.90 (m, 9H), 3.17 (d, J = 5.2 Hz, 3H), 2.07-2.03 (m, 3H), 1.68 (s, 3H); MS (ESI): m/z=519 [M+1]+	1	6.19 99 (a)
102		1-(4-((4-((4-fluoro-5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.42 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.92 (s, 1H), 7.58 (s, 1H), 7.23 (s, 1H), 7.11 (d, J = 12.8 Hz, 1H), 6.87-6.77 (m, 2H), 6.58-6.57 (m, 1H), 6.26-6.22 (m, 1H), 5.79-5.77 (m, 1H), 5.00-4.99 (m, 1H), 4.06 (s, 3H), 4.00-3.95 (m, 2H), 3.89 (s, 3H), 3.68-3.53 (m, 2H), 2.19-2.11 (m, 2H), 2.00-1.89 (m, 2H); MS (ESI): m/z 519 [M+1]+	67	6.07 100 (a)
103		1-(4-((4-((2-fluoro-3-(furan-2-yl)-6-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 519 [M+1] +
104		1-(4-((4-((5-(furan-2-yl)- 2-methoxypyridi n-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.67 (s, 1H), 8.47 (d, J = 2.0 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.04 (s, 1H), 7.58 (s, 1H), 7.30 (s, 1H), 6.86-6.76 (m, 2H), 6.54 (s, 1H), 6.25-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.10 (s, 3H), 4.00-3.92 (m, 6H), 3.73-3.70 (m, 2H), 3.36-3.20 (m, 2H), 2.13-2.11 (m, 2H), 1.94-1.92 (m, 2H); MS (ESI): m/z 502 [M+1] +	85	5.64 98 (a)
105		1-(4-((4-((2-(furan-2-yl)- 5-methoxypyridi n-4-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.82 (s, 1H), 8.66 (s, 1H), 8.27 (s, 1H), 7.73 (s, 1H), 7.66 (s, 1H), 7.30 (s, 1H), 7.01 (d, J = 3.6 Hz, 1H), 6.88-6.81 (m, 1H), 6.61-6.60 (m, 1H), 6.27-6.22 (m, 1H), 5.80-6.77 (m ,1H), 4.93-4.91 (m, 1H), 4.11 (s, 3H), 4.05 (s, 3H), 3.99-3.96 (m, 2H), 3.82-3.79 (m, 2H), 2.11-2.09 (m, 2H), 1.95-1.93 (m, 2H); MS (ESI): m/z 502 [M+H]+	14	4.31 100 (a)
106		1-(4-((4-((2-(furan-2-yl)-5-methoxypyrimi din-4-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 503 [M+1]+
107		1-(4-((4-((6-(furan-2-yl)-3-methoxypyridi n-2-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 502 [M+1]+
108		1-(4-((4-((6-(furan-2-yl)-3-methoxypyrazi n-2-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 503 [M+1]+
109		1-(4-((4-((6-(furan-2-yl)-3-methoxypyrida zin-4-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 503 [M+1]+
110		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-2-methylpiperid in-1-yl)prop-2-en-1-one	MS (ESI): m/z 515 [M+1]+
111		1-(3,3-difluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.37 (s, 1H), 8.04 (d, J = 2.0 Hz, 1H), 7.99 (s, 1H), 7.63-7.61 (m, 1H), 7.53-7.52 (m, 1H), 7.25 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 6.88-6.81 (m, 1H), 6.51-6.50 (m, 1H), 6.31-6.27 (m, 1H), 5.85-5.82 (m, 1H), 5.01-4.96 (m, 1H), 4.21-4.19 (m, 3H), 4.08 (s, 3H), 3.99 (s, 3H), 3.97-3.96 (m, 2H), 2.23-2.19 (m, 2H); MS (ESI): m/z 537 [M+H]+	37	6.37 99 (a)
112		1-(3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 519 [M+1] +
113		1-(4,4-difluoro-3-((4-((5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.42 (s, 1H), 8.20 (s, 1H), br), 8.04-8.00 (m, 2H), 7.66-7.63 (m, 1H), 7.54-7.53 (m, 1H), 7.23 (s, 1H), 7.20-7.18 (m, 1H), 6.68-6.54 (m, 2H), 6.51-6.50 (m, 1H), 6.19-6.14 (m, 1H), 5.85-5.55 (m, 1H), 4.88-4.55 (m, 2H), 4.02 (s, 3H), 3.92 (s, 3H), 3.78-3.50 (m, 2H), 3.20-3.10 (m, 1H), 2.60-2.08 (m, 2H); MS (ESI): m/z 537 [M+1]+	25	6.56 99 (a)
114		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-2-(trifluoromet hyl)piperidin -1-yl)prop-2-en-1-one	MS (ESI): m/z 569 [M+1] +
115		1-(5-((4-((5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-2-azabicyclo[2. 2.1]heptan-2-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ8.79 (s, 1H), 8.41 (s, 1H), 7.57-7.52 (m, 1H), 7.45-7.43 (m, 1H), 7.38-7.34 (m, 2H), 7.10-7.09 (m, 1H), 6.99-6.97 (m, 1H), 6.65-6.56 (m, 2H), 6.06-5.99 (m, 1H), 5.72-5.55 (m, 1H), 5.33-5.25 (m, 1H), 5.10-5.01 (m, 2H), 4.34-4.30 (m, 2H), 3.91-3.90 (m, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 2.37-2.32 (m, 2H); MS (ESI): m/z 513 [M+1]+	23	5.98 100 (a)
116		1-(4-((4-((5-(furan-2-yl)-2-(trifluoromet hoxy) phenyl) a mino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl) prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.38 (s, 1H), 8.03 (s, 1H), 7.87 (s, 1H), 7.74-7.72 (m, 1H), 7.62-7.61 (m, 1H), 6.89-6.87 (m, 1H), 6.85-6.81 (m, 1H), 6.58-6.56 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.05 (s, 3H), 4.04-3.93 (m, 2H), 3.70-3.69 (m, 3H), 2.15-2.03 (m, 2H), 1.97-1.89 (m, 2H); MS (ESI): m/z 555 [M+1] +	19	6.50 92 (a)
117		1-(4-((4-((2-ethoxy-5-(thiophen-2-yl) phenyl) ami no)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl) prop-2-en-1-one	1H NMR (400 MHz, HCl salt, Methanol-d4) δ 8.62 (s, 1H), 8.04 (s, 1H), 7.78 (d, J = 2 Hz, 1H), 7.67-7.64 (m, 1H), 7.35-7.31 (m, 2H), 7.24-7.19 (m, 2H), 7.09-7.06 (m, 1H), 6.86-6.79 (m, 1H), 6.25-6.20 (m, 1H), 5.78-5.75 (m, 1H), 4.18-4.13 (m, 2H), 4.09 (s, 3H), 3.97-3.93 (m, 2H), 3.67-3.66 (m, 2H), 3.51-3.46 (m, 1H), 2.12 (s, 2H), 1.92 (s, 2H), 1. 32-1. 29 (m, 3H), 1.19-1.16 (m, 1H); MS (ESI): m/z=531 [M+1] +	69	6.52 100 (a)
118		1-(4-((4-((2-ethoxy-5-(furan-2-yl)phenyl) ami no)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, CDCl3) δ 9.13-9.12 (m, 1H), 8.79 (s, 1H), 8.11 (s, 1H), 7.48-7.47 (m, 1H), 7.39-7.36 (m, 1H), 7.26 (s, 1H), 7.20 (s, 1H), 6.97-6.95 (m, 1H), 6.65-6.63 (m, 2H), 6.62-6.60 (m, 1H), 6.49-6.48 (m, 1H), 5.74-5.74 (m, 1H), 4.71-4.62 (m, 1H), 4.23-4.21 (m, 2H), 4.02 (s, 3H), 3.60-3.50 (m, 1H), 2.03-2.01 (m, 4H), 1.55 (t, J = 7.2, 6.8 Hz, 3H); MS (ESI): m/z 515 [M+1]+	2	6.05 100 (a)
119		(E)-4-(dimethylamin o)-1-(4-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl) ami no) quinazolin -6-yl) oxy) piperi din-1-yl) but-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.57 (s, 1H), 8.32 (s, 1H), 7.94 (d, J = 2.4Hz, 1H), 7.78 (s, 1H), 7.54-7.52 (m, 1H), 7.31-7.28 (m, 2H), 7.19 (s, 1H), 7.14 (d, J = 8.8 Hz, 1H), 7.06-7.04 (m, 1H), 6.60-6.57(m, 1H), 6.15-6.09 (m, 1H), 3.99-3.84 (m, 8H), 3.66-3.56 (m, 4H), 2.57 (s, 6H), 2.14-2.06 (m, 2H), 1.92-1.86 (m, 2H); MS (ESI): m/z 574 [M+1]+	5	5.08 99 (a)
120		(E)-4-(dimethylamin o)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)but-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) 8.42 (s, 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.89 (s, 1H), 7.68-7.66 (m, 1H), 7.54-7.53 (m, 1H), 7.24 (s, 1H), 7.21 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 11.6 Hz, 1H), 6.69-6.68 (m, 1H), 6.52-6.51 (m, 1H), 6.27-6.24 (m, 1H), 4.98-4.97 (m, 1H), 4.05 (s, 3H), 4.02-4.01 (m, 2H), 4.00-3.99 (m, 2H), 3.98 (s, 3H), 3.78-3.77 (m, 2H), 2.99 (s, 6H), 2.14-2.11 (m, 2H), 1. 97-1. 95 (m, 2H); MS (ESI): m/z 558 [M+1]+	33	5.10 100 (a)
121		2-((dimethylami no)methyl)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.20 (s, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.62 (s, 1H), 7.51-7.49 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.07-7.04 (m, 2H), 6.55 (d, J = 3.2 Hz, 1H), 6.39-6.37 (m, 1H), 5.38 (s, 1H), 5.19 (s, 1H), 4.52-4.48 (m, 1H), 3.89 (s, 3H), 3.77 (s, 3H), 3.16 (s, 2H), 3.03 (s, 3H), 2.90 (s, 3H), 2.76-2.75 (m, 2H), 2.34 (t, J = 8.8 Hz, 2H), 2.00-1.96 (m, 2H), 1. 82-1.79 (m, 2H); MS (ESI): m/z 558 [M+1]+	22	4.85 99 (a)
122		(E)-3-fluoro-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 519 [M+1]+
123		2-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-carbonyl)acry lonitrile	MS (ESI): m/z 526 [M+1]+
124		(E)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)-3-(1-methylpyrroli din-2-yl)prop-2-en-1-one	MS (ESI): m/z 584 [M+1]+
125		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinol in-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.18 (d, J = 6.4 Hz, 1H), 7.91 (s, 1H), 7.73-7.70 (m, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.29 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 6.84-6.78 (m, 1H), 6.68 (d, J = 3.6 Hz, 1H), 6.50-6.49 (m, 1H), 6.45 (d, J = 6.4 Hz, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.04 (s, 3H), 3.98-3.94 (m, 2H), 3.87 (s, 3H), 3.67-3.61 (m, 2H), 2.08-2.07 (m, 2H), 1. 92-1. 89 (m, 2H); MS (ESI): m/z=500 [M+1]+
126		6-((1-acryloylpiper idin-4-yl)oxy)-4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinol in-3-carbonitrile	MS (ESI): m/z=525 [M+1]+
127		1-(4-((4-((2-(furan-2-yl)-5-methoxypyrimi din-4-yl)amino)-7-methoxyquinol in-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=502 [M+1]+
128		1-(3-((4-((5-([1,2,4]triaz olo[1,5-a]pyridin-5-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, MeOD-d4) δ 8.64 (s, 1H), 8.49 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.14-8.11 (m, 1H), 7.85-7.81 (m, 2H), 7.73 (s, 1H), 7.44-7.42 (m, 2H), 7.30 (s, 1H), 6.41-6.29 (m, 2H), 5.82-5.79 (m, 1H), 5.36-5.31 (m, 1H), 5.03-4.99 (m, 1H), 4.71-4.68 (m, 1H), 4.66-4.65 (m, 1H), 4.19-4.18 (m, 1H), 4.15 (s, 3H), 4.13 (s, 3H); MS (ESI): m/z 524 [M+1]+	10	4.02 100
129		1-(4-((4-((3'-(3,3-difluoroazeti din-1-yl)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.32 (s, 1H), 7.87-7.85 (m, 2H), 7.55-7.53 (m, 1H), 7.22 (s, 1H), 7.20 (s, 1H), 7.11-7.08 (m, 2H), 6.87-6.84 (m, 2H), 6.26-6.22 (m, 1H), 5.80-5.77 (m, 1H), 4.88-4.87 (m, 1H), 4.40-4.36 (m, 4H), 4.03-4.02 (m, 4H), 3.91 (s, 3H), 3.72-3.70 (m, 2H), 2.13-2.11 (m, 2H), 1.98-1.96 (m, 2H); MS (ESI): m/z 620 [M+H] +	17	11.40 100 (b)
130		1-(4-((7-methoxy-4-((2-methoxy-5- (oxazol-5-yl)phenyl) ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.34 (s, 1H), 8.21 (s, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.83 (s, 1H), 7.68-7.65 (m, 1H), 7.42 (s, 1H), 7.24-7.18 (m, 2H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.02 (s, 3H), 3.98-3.92 (m, 5H), 3.68-3.59 (m, 2H), 2.03 (brs, 2H), 1.93-1.90 (m, 2H); MS (ESI): m/z 502 [M+1] +	1	4.80 90 (a)
131		1-(4-((4-((2'-fluoro-4-methoxy-4'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ8.32 (s, 1H), 7.84 (s, 1H), 7.82 (s, 1H), 7.51-7.48 (m, 1H), 7.43-7.39 (m, 1H), 7.22-7.20 (m, 2H), 7.09 (d, J = 8.0 Hz, 1H), 7.03 (d, J = 12.0 Hz, 1H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.62-4.61 (m, 1H), 4.01 (s, 3H), 3.99-3.98 (m, 2H), 3.91 (s, 3H), 3.69-3.67 (m, 2H), 2.39 (s, 3H), 2.11-2.09 (m, 2H), 1.92-1.90 (m, 2H); MS (ESI): m/z 543 [M+H]+	33	11.02 98 (b)
132		(S)-1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)pyrrol idin-1-yl)prop-2-en-1-one	MS (ESI): m/z 487 [M+H]+
133		1-(4-((4-((5-(6-fluoropyridin -3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.44 (d, J = 2.4 Hz, 1H), 8.21-8.16 (m, 2H), 7.98 (d, J = 2.4 Hz, 1H), 7.84 (s, 1H), 7.58-7.56 (m, 1H), 7.25 (d, J = 8.4 Hz, 1H), 7.21 (s, 1H), 7.15-7.12 (m, 1H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.02 (s, 3H), 3.98-3.92 (m, 5H), 3.71-3.63 (m, 2H), 2.09-2.08 (m, 2H), 1.93-1.91 (m, 2H); MS (ESI): m/z 530 [M+1]+	83	5.69 100 (a)
134		3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-2-fluoro-4'-methoxy-[1,1'- biphenyl]-3-carbonitrile	1H NMR (400 MHz, free base, Methanol-d4) δ 8.34 (s, 1H), 7.94 (s, 1H), 7.89-7.85 (m, 2H), 7.73-7.72 (m, 1H), 7.55-7.52 (m, 1H), 7.47-7.43 (m, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 6.87-6.81 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.62-4.60 (m, 1H), 4.03 (s, 3H), 3.98-3.94 (m, 5H), 3.70-3.68 (m, 2H), 2.11-2.09 (m, 2H), 1.93-1.92 (m, 2H); MS (ESI): m/z 554 [M+H]+	19	6.12 94 (a)
135		1-(4-((4-((3'-chloro-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.34 (s, 1H), 7.85-7.84 (m, 2H), 7.51-7.41 (m, 3H), 7.25-7.20 (m, 3H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.02 (s, 3H), 3.98-3.92 (m, 5H), 3.70-3.63 (m, 2H), 2.09-2.08 (m, 2H), 1.91-1.89 (m, 2H); MS (ESI): m/z 564 [M+1]+	30	6.86 100 (a)
136		1-(4-((4-((2'-fluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.30 (s, 1H), 7.84-7.83 (m, 2H), 7.54-7.48 (m, 2H), 7.34-7.30 (m, 1H), 7.26-7.14 (m, 4H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.01-3.91 (m, 8H), 3.69-3.64 (m, 2H), 2.08-2.07 (m, 2H), 1.90-1.89 (m, 2H); MS (ESI): m/z 529 [M+1]+	97	6.37 99 (a)
137		1-(4-((4-((2' ,3'-difluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, Methanol-d4) δ 8.49 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.61-7.59 (m, 1H), 7.32-7.23 (m, 5H), 6.88-6.81 (m, 1H), 6.27-6.22 (m, 1H), 5.80-5.77 (m, 1H), 4.87-4.85 (m, 1H), 4.07 (s, 3H), 3.98-3.96 (m, 2H), 3.94 (s, 3H), 3.70-3.68 (m, 2H), 2.18-2.07 (m, 2H), 2.00-1.89 (m, 2H); MS (ESI): m/z 547 [M+1] +	94	6.48 99 (a)
138		1-(4-((4-((2'-fluoro-4-methoxy-3'-(trifluoromet hyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.34 (s, 1H), 7.90 (s, 1H), 7.85-7.81 (m, 2H), 7.69-7.66 (m, 1H), 7.55-7.52 (m, 1H), 7.46-7.42 (m, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 6.87-6.81 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.66-4.65 (m, 1H), 4.03 (s, 3H), 3.99-3.95 (m, 5H), 3.70-3.67 (m, 2H), 2.11-2.09 (m, 2H), 1.93-1.91 (m, 2H); MS (ESI): m/z 597 [M+H] +	54	7.01 100 (a)
139		1-(4-((7-methoxy-4-((4-methoxy-3'-(trifluoromet hyl)-[1,1'-biphenyl]-3-y1)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, DMSO-d6) δ 10.83 (s, 1H), 8.63 (s, 1H), 8.19 (s, 1H), 8.01-7.97 (m, 2H), 7.90 (d, J = 2.4 Hz, 1H), 7.83-7.80 (m, 1H), 7.70-7.69 (m, 2H), 7.34 (d, J = 8.8 Hz, 1H), 7.28 (s, 1H), 7.26 (t, J = 10.8 Hz, 1H), 6.88-6.82 (m, 1H), 6.14-6.09 (m, 1H), 5.71-5.67 (m, 1H), 4.88-4.86 (m, 1H), 4.05-3.91 (m, 8H), 2.08-2.07 (m, 2H), 1.75-1.69 (m, 2H); MS (ESI): m/z 579 [M+1] +	91	6.88 99 (a)
140		1-(3-fluoro-4-((4-((4-fluoro-5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.54 (d, J = 1.6 Hz, 1H), 8.08 (s, 1H), 7.85-7.82 (m, 1H), 7.49 (d, J = 2.4 Hz, 1H), 7.20 (s, 1H), 7.06 (d, J = 12.4 Hz, 1H), 6.77-6.69 (m, 2H), 6.49-6.48 (m, 1H), 6.19-6.14 (m, 1H), 5.73-5.70 (m, 1H), 5.01-5.00 (m, 2H), 4.02 (s, 3H), 3.99-3.97 (m, 2H), 3.94 (s, 3H), 3.79-3.77 (m, 2H), 2.22-1.91 (m, 2H); MS (ESI): m/z 537 [M+H]+	27	6.30, 100 (a)
141		1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-4,4-difluoropiper idin-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.37 (s, 1H), 7.98 (s, 1H), 7.92-7.88 (m, 1H), 7.59-7.53 (m, 1H), 7.48-7.46 (m, 1H), 7.24-7.22 (m, 2H), 7.08-7.03 (m, 2H), 6.91-6.51 (m, 1H), 6.17-6.13 (m, 1H), 5.88-5.56 (m, 1H), 4.88-4.60 (m, 2H), 4.01 (s, 3H), 3.95 (s, 3H), 3.71-3.50 (m, 2H), 2.47-2.16 (m, 2H); MS (ESI): m/z 583 [M+1]+	9	7.03 99 (a)
142		1-(4-((4-((4'-fluoro-4-methoxy-3'- (trifluoromet hyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.35 (s, 1H), 7.99 (d, J = 2.0 Hz, 1H), 7.95-7.89 (m, 2H), 7.84 (s, 1H), 7.59-7.56 (m, 1H), 7.44-7.39 (m, 1H), 7.27-7.23 (m, 2H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.61-4.60 (m, 1H), 4.03 (s, 3H), 3.98-3.94 (m, 5H), 3.35-3.32 (m, 2H), 2.11-2.09 (m, 2H), 1.93-1.91 (m, 2H); MS (ESI): m/z 597 [M+H]+	57	7.12, 100 (a)
143		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-3-fluoropiperid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, MeOD) δ 8.33 (s, 1H), 7.95-7.85 (m, 2H), 7.57-7.51 (m, 1H), 7.47-7.44 (m, 1H), 7.23-7.21 (m, 2H), 7.06-7.02 (m, 2H), 6.85-6.78 (m, 1H), 6.26 (d, J = 16.8 Hz, 1H), 5.81 (d, J = 16.8 Hz, 1H), 4.70-4.60 (m, 2H), 4.20-3.70 (m, 9H), 3.65-3.45 (m, 1H), 2.30-1.90 (m, 2H); MS (ESI): m/z 565 [M+1]+	55	6.52 100
144		1-(3-fluoro-4-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.36 (s, 1H), 7.96-7.94 (m, 2H), 7.57-7.54 (m, 1H), 7.32-7.30 (m, 2H), 7.23 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.08-7.05 (m, 1H), 6.85-6.77 (m, 1H), 6.24 (d, J = 16.8 Hz, 1H), 5.80-5.77 (m, 1H), 4.79 (s, 1H), 4.13-3.95 (m, 6H), 3.89 (s, 3H), 3.85-3.71 (m, 1H), 2.23-2.14 (m, 1H), 1.99-1.97 (m, 1H); MS (ESI): m/z 535 [M+1] +	18	6.36 99 (a)
145		1-(4-((4-((5-(2,5-difluoropyrid in-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.42 (s, 1H), 8.18-8.17 (m, 1H), 8.03 (s, 1H), 7.90 (s, 1H), 7.72 (d, J = 1.6 Hz, 1H), 7.33-7.24 (m, 2H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.80-5.77 (m, 1H), 5.02-5.01 (m, 1H), 4.05 (s, 3H), 3.96-3.95 (m, 5H), 3.69-3.68 (m, 2H), 2.11-2.10 (m, 2H), 1. 93-1. 92 (m, 2H); MS (ESI): m/z 548 [M+H] +	36	5.74, 90 (NMR) (a)
146		1-(4-((4-((3'-amino-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.47 (s, 1H), 7.95 (s, 1H), 7.78 (d, J = 1.2 Hz, 1H), 7.57-7.55 (m, 1H), 7.24-7.21 (m, 2H), 7.11-7.09 (m, 1H), 7.01-6.99 (m, 1H), 6.90-6.80 (m, 2H), 6.26-6.25 (m, 1H), 5.80-5.78 (m, 1H), 4.91-4.90 (m, 1H), 4.07 (s, 3H), 3.91-3.89 (m ,5H), 3.71-3.70 (m, 2H), 2.05-2.04 (m, 2H), 1. 99-1. 98 (m, 2H); MS (ESI): m/z 544 [M+H] +	11	5.32, 98 (a)
147		1-(4-((4-((5-(2,6-difluoropyrid in-3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, DMSO-d6) δ 9.23 (s, 1H), 8.35-8.32 (m, 1H), 8.30 (s, 1H), 7.93 (s, 1H), 7.76 (s, 1H), 7.54-7.52 (m, 1H), 7.30-7.28 (m, 2H), 7.20 (s, 1H), 6.89-6.82 (m, 1H), 6.15-6.10 (m, 1H), 5.76-5.68 (m, 1H), 4.81-4.80 (m, 1H), 3.95-3.92 (m, 5H), 3.84 (s, 1H), 3.60-3.50 (m, 2H), 2.09-2.05 (m, 2H), 1. 70-1. 69 (m, 2H); MS (ESI): m/z 548 [M+1] +	61	6.07 100 (a)
148		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-3-methylpiperid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.36 (s, 1H), 7.98-7.97 (m, 1H), 7.85-7.83 (m, 1H), 7.65-7.63 (m, 1H), 7.53-7.52 (m, 1H), 7.23-7.22 (m, 1H), 7.20-7.17 (m, 1H), 6.98-6.97 (m, 1H), 6.51-6.50 (m, 1H), 6.26-6.10 (m, 1H), 5.78-5.70 (m, 1H), 4.88-4.83 (m, 1H), 4.50-4.10 (m, 1H), 4.05 (s, 3H), 3.90 (s, 3H), 3.88-3.80 (m, 1H), 3.73-3.42 (m, 2H), 2.40-2.00 (m, 2H), 1.92-1.63 (m, 1H), 1.13-1.10 (m, 3H); MS (ESI): m/z 515 [M+1]+	45	6.27 100 (a)
149		1-(4-((7-methoxy-4-((2-methoxy-5-(pyridin-4-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.56 (s, 2H), 8.37 (s, 1H), 8.15 (d, J = 2.4 Hz, 1H), 7.85 (s, 1H), 7.76-7.73 (m, 3H), 7.29 (d, J = 8.4 Hz, 1H), 7.22 (s, 1H), 6.86-6.79 (m, 1H), 6.24-6.20 (m, 1H), 5.78-5.75 (m, 1H), 4.02 (s, 3H), 3.99-3.93 (m, 5H), 3.72-3.64 (m, 2H), 2.09-2.08 (m, 2H), 1.94-1.91 (m, 2H); MS (ESI): m/z 512 [M+1]+	72	3.46 94 (a)
150		1-(4-((4-((5-(5-fluoropyridin -3-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.69 (s, 1H), 8.40 (s, 2H), 8.04 (d, J = 2 Hz, 1H), 7.90-7.85 (m, 2H), 7.66-7.63 (m, 1H), 7.27 (d, J = 8.8 Hz, 1H), 7.21 (s, 1H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.02 (s, 3H), 4.00-3.93 (m, 5H), 3.68-3.66 (m, 2H), 2.08 (brs, 2H), 1.94-1.91 (m, 2H); MS (ESI): m/z 530 [M+1]+	10	4.86 94 (a)
151		1-(4-((4-((3'-(dimethylamin o)-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.41 (s, 1H), 7.89 (s, 1H), 7.67-7.66 (m, 1H), 7.55-7.52 (m, 1H), 7.18-7.12 (m, 3H), 6.87-6.84 (m, 2H), 6.75-6.68 (m, 2H), 6.15-6.10 (m, 1H), 5.68-5.65 (m, 1H), 4.85-4.75 (m, 1H), 3.97 (s, 3H), 3.90-3.81 (m, 2H), 3.80 (s, 3H), 3.62-3.50 (m, 2H), 2.88 (s, 6H), 2.10-2.00 (m, 2H), 1. 98-1. 84 (m, 2H); MS (ESI): m/z 554 [M+1]+	6	4.48 90 (NMR) (a)
152		1-((3S,4S)-4-((4-((2',4'-difluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-3-fluoropiperid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, Methanol-d4) δ 8.33 (s, 1H), 7.89 (s, 1H), 7.88 (s, 1H), 7.54-7.48 (m, 1H), 7.43-7.40 (m, 1H), 7.19-7.17 (m, 2H), 7.04-7.02 (m, 2H), 6.84-6.76 (m, 1H), 6.26 (d, J = 16.8 Hz, 1H), 5.80-5.77 (m, 1H), 4.88-4.77 (m, 2H), 4.14-3.53 (m, 9H), 2.22-2.10 (m, 1H), 1.97-1.95 (m, 1H); MS (ESI): m/z 565 [M+1]+	52	6.50 98 (a)
153		1-(4-((4-((5-(benzo[d][1,3 ]dioxol-5-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 11.01 (s, 1H), 8.74 (s, 1H), 8.14 (s, 1H), 7.70-7.66 (m, 2H), 7.29-7.24 (m, 3H), 7.15-7.13 (m, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.88-6.81 (m, 1H), 6.14-6.10 (m, 1H), 6.09 (s, 2H), 5.71-5.65 (m, 1H), 4.01 (s, 3H), 3.89 (s, 3H), 2.33-2.32 (m, 2H), 1. 70-1. 68 (m, 2H); MS (ESI): m/z 555 [M+1]+	79	6.10 100 (a)
154		1-((3R,4S)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, HCl salt, Methanol-d4) δ 8.54 (s, 1H), 8.04 (s, 1H), 7.86-7.85 (d, J = 2.14 Hz, 1H), 7.72-7.70 (d, J = 8.66 Hz, 1H), 7.52-7.51 (d, J = 1.65 Hz, 1H), 7.25-7.20 (t, 2H), 6.87-6.76 (m, 1H), 6.68-6.67 (d, J = 3.34 Hz, 1H), 6.51-6.50 (m, 1H), 6.25-6.21 (d, J = 16.63 Hz, 1H), 5.80-5.77 (d, J = 10.57 Hz, 1H), 5.12-5.06 (m, 1H), 4.55-4.35 (m, 2H), 4.08 (s, 3H), 3.88 (s, 3H), 3.69-3.56 (m, 1H), 3.24-3.15 (m, 1H), 2.22-2.04 (m, 2H); MS (ESI): m/z=519 [M+1]+	34	9.72 97 (b)
155		1-(4-((4-((3'- (dimethylamin o)-2',4'-difluoro-4-methoxy-[1,1' - biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.30 (s, 1H), 7.83 (s, 1H), 7.77 (s, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.22-7.12 (m, 3H), 7.00-6.93 (m, 1H), 6.85-6.78 (m, 1H), 6.22 (dd, J = 16.8, 1.9 Hz, 1H), 5.76 (dd, J = 10.6, 1.9 Hz, 1H), 4.83-4.78 (m, 1H), 4.01 (s, 3H), 3.99-3.93 (m, 2H), 3.91 (s, 3H), 3.70-3.63 (m, J = 16.8 Hz, 2H), 2.91-2.88 (m, 6H), 2.14-2.05 (m, 2H), 1.94-1.86 (m, 2H); MS (ESI): m/z=590 [M+1]+	56	10.77 98 (b)
156		1-(4-((4-((2,4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 10.65 (s, 1H), 8.70 (s, 1H), 8.11 (s, 1H), 7.61-7.56 (m, 3H), 7.34-7.29 (m, 3H), 7.19 (d, J = 8.8 Hz, 1H), 6.88-6.81 (m, 1H), 6.14-6.10 (m, 1H), 5.71-5.67 (m, 1H), 5.23-5.20 (m, 1H), 4.01 (s, 3H), 3.91-3.90 (m, 2H), 3.89 (s, 3H), 2.07-2.05 (m, 2H), 1.71-1.68 (m, 2H); MS (ESI): m/z 547 [M+1] +	64	6.22 98 (a)
157		1-(4-((7-methoxy-4-((2',4',6-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 11.13 (s, 1H), 8.72 (s, 1H), 8.26 (s, 1H), 7.53-7.50 (m, 2H), 7.47-7.37 (m, 1H), 7.33-7.30 (m, 2H), 7.24-7.19 (m, 1H), 6.88-6.81 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.65 (m, 1H), 4.91-4.85 (m, 1H), 3.99 (s, 3H), 3.95-3.91 (m, 2H), 3.85 (s, 3H), 2.08-2.07 (m, 2H), 1. 67-1. 65 (m, 2H); MS (ESI): m/z 565 [M+1]+	46	6.46 100 (a)
158		1-(4-((4-((3'-amino-2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.33 (s, 1H), 7.85 (s, 1H), 7.80 (s, 1H), 7.47-7.45 (m, 1H), 7.22-7.20 (m, 2H), 6.91-6.75 (m, 3H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.88-4.85 (m, 1H), 4.03 (s, 3H), 4.02-3.97 (m, 2H), 3.96 (s, 3H), 3.70-3.69 (m, 2H), 2.09-1.92 (m, 4H); MS (ESI): m/z 562 [M+1] +	37	8.57 99 (b)
159		1-(4-((4-((3'-(azetidin-1-yl)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, CDCl3) δ 8.83 (s, 1H), 8.70 (s, 1H), 8.14 (s, 1H), 7.45 (s, 1H), 7.25-7.24 (m, 1H), 7.01-6.78 (m, 2H), 6.93-6.92 (m, 1H), 6.69-6.66 (m, 1H), 6.63-6.59 (m, 1H), 6.34-6.29 (m, 1H), 5.75-5.72 (m, 1H), 4.68-4.65 (m, 1H), 4.06-4.01 (m, 14H), 3.72-3.65 (m, 2H), 2.01-1.99 (m, 4H); MS (ESI): m/z 584 [M+H]+	13	10.95 100 (b)
160		1-(4-((4-((5-(2,3-dihydrobenzo[ b][1,4]dioxin -6-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, CDCl3) δ 8.93-8.92 (d, J = 2.20 Hz, 1H), 8.73 (s, 1H), 7.89 (s, 1H), 7.30 (s, 1H), 7.25-7.23 (m, 2H), 7.17-7.12 (m, 2H), 7.01-6.93 (m, 2H), 6.66-6.59 (m, 1H), 6.34-6.29 (dd, J = 16.83 Hz, 1H), 5.74-5.71 (dd, J = 10.56 Hz, 1H), 4.70-4.65 (m, 1H), 4.31 (s, 4H), 4.01-4.00 (d, J=2.19Hz, 7H), 3.94-3.86 (m, 1H), 3.73-3.65 (m, 1H), 3.57-3.48 (m, 1H), 2.07-1.93 (m, 4H); MS (ESI): m/z=569 [M+1]+	64	10.13 98 (b)
161		1-(4-((4-((5'-amino-4'-fluoro-4-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, DMSO-d6) δ 10.86 (s, 1H), 8.73 (s, 1H), 8.11 (s, 1H), 7.34-7.26 (m, 4H), 6.95-6.82 (m, 1H), 6.68 (d, J = 9.6 Hz, 1H), 6.15-6.10 (m, 1H), 5.76 (s, 1H), 5.72-5.69 (m, 1H), 4.83-4.82 (m, 1H), 4.01 (s, 3H), 3.84-3.80 (m, 5H), 3.56-3.54 (m, 2H), 2.12-2.10 (m, 5H), 1.72-1.70 (m, 2H); MS (ESI): m/z 558 [M+H] +	99	5.30 57 (a)
162		1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.61 (s, 1H), 8.08 (d, J = 17.6 Hz, 1H), 7.86-7.84 (m, 1H), 7.76-7.74 (m, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.26-7.23 (m, 2H), 6.87-6.59 (m, 2H), 6.53-6.52 (m, 1H), 6.27-6.21 (m, 1H), 5.80-5.62 (m, 1H), 4.15-4.11 (m, 2H), 4.09 (s, 3H), 4.06 (s, 3H), 3.91-3.77 (m, 3H), 2.18-2.03 (m, 3H), 1.31-1.24 (m, 1H); MS (ESI): m/z 501 [M+H]+	5	6.14 100 (a)
163		1-(4-((4-((3'-amino-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.07 (s, 1H), 7.71 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.30-7.26 (m, 2H), 7.08-7.04 (m, 1H), 6.97-6.81 (m, 3H), 6.27-6.22 (m, 1H), 5.80-5.78 (m, 1H), 5.02-5.01 (m, 1H), 4.11 (s, 3H), 3.99-3.93 (m, 5H), 3.70-3.69 (m, 2H), 2.17-2.15 (m, 2H), 2.02-1.99 (m, 2H); MS (ESI): m/z 544 [M+H] +	76	5.08 99 (a)
164		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-2-(trifluoromet hyl)piperidin -1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.37 (s, 1H), 8.33 (s, 1H), 8.08 (s, 1H, formic acid), 7.79 (s, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.52 (s, 1H), 7.22 (s, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.88-6.81 (m, 1H), 6.67 (s, 1H), 6.50 (s, 1H), 6.32-6.20 (m, 1H), 5.86 (d, J = 10.4Hz, 1H), 4.70-4.50 (m, 2H), 4.30-4.10 (m, 1H), 4.01 (s, 3H), 3.90 (s, 3H), 3.55-3.45 (m, 1H), 2.60-2.50 (m, 1H), 2.44-2.36 (m, 1H), 2.20-1.95 (m, 2H); MS (ESI): m/z 569 [M+1]+	24	6.80 93 (a)
165		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-2-(trifluoromet hyl)piperidin -1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.35 (s, 1H), 8.30 (s, 1H), 7.91 (s, 1H, formic acid), 7.86 (s, 1H), 7.57-7.54 (m, 1H), 7.47-7.44 (m, 1H), 7.23-7.20 (m, 2H), 7.06-7.01 (m, 2H), 6.88-6.81 (m, 1H), 6.32-6.20 (m, 1H), 5.86 (d, J = 10.4 Hz, 1H), 4.70-4.50 (m, 2H), 4.30-4.10 (m, 1H), 4.01 (s, 3H), 3.93 (s, 3H), 3.55-3.45 (m, 1H), 2.60-2.50 (m, 1H), 2.44-2.36 (m, 1H), 2.20-1.95 (m, 2H); MS (ESI): m/z 615 [M+1]+	48	7.21 92 (a)
166		1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-8-azabicyclo[3. 2.1]octan-8-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.59 (s, 1H), 7.87 (s, 1H), 7.81 (s, 1H), 7.74-7.72 (m, 1H), 7.52 (s, 1H), 7.25-7.21 (m, 2H), 6.78-6.68 (m, 2H), 6.51-6.50 (m, 1H), 6.35-6.30 (m, 1H), 5.80-5.77 (m, 1H), 4.96-4.95 (m, 1H), 4.11 (s, 3H), 3.89 (s, 3H), 2.33-2.16 (m, 10H); MS (ESI): m/z 527 [M+H]+	21	6.29 100 (a)
167		1-((1R,3r,5S)-3-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-8-azabicyclo[3. 2.1]octan-8-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.54 (s, 1H), 7.83-7.82 (m, 2H), 7.72-7.69 (m, 1H), 7.52-7.51 (m, 1H), 7.24-7.20 (m, 2H), 6.77-6.67 (m, 2H), 6.50-6.49 (m, 1H), 6.34-6.30 (m, 1H), 5.80-5.77 (m, 1H), 4.71-4.57 (m, 2H), 4.09 (s, 3H), 3.87 (s, 3H), 2.45-1.51 (m, 8H); MS (ESI): m/z 527 [M+1]+	3	10.24 94 (b)
168		1-(4-((4-((4'-fluoro-3'-hydroxy-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, DMSO-d6) δ 9.99 (s, 1H), 9.19 (s, 1H), 8.31 (s, 1H), 7.92 (s, 1H), 7.71 (s, 1H), 7.49-7.46 (m, 1H), 7.21-7.16 (m, 4H), 7.06-7.05 (m, 1H), 6.88-6.82 (m, 1H), 6.14-6.10 (m, 1H), 5.71-5.68 (m, 1H), 4.80-4.79 (m, 1H), 4.14-4.13 (m, 5H), 3.93 (s, 3H), 3.36-3.35 (m, 2H), 2.04-2.02 (m, 2H), 1. 79-1. 77 (m, 2H); MS (ESI): m/z 545 [M+H] +	47	9.31 99 (b)
169		1-((3R,4S)-4-((4-((5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-3-methylpiperid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, Methanol-d4) δ 8.48 (s, 1H), 7.93 (s, 1H), 7.73-7.72 (m, 1H), 7.65-7.63 (m, 1H), 7.43-7.42 (m, 1H), 7.14-7.12 (m, 2H), 6.80-6.72 (m, 1H), 6.60-6.59 (m, 1H), 6.42-6.40 (m, 1H), 6.16-6.12 (m, 1H), 5.70-5.67 (m, 1H), 4.40-4.10 (m, 2H), 3.99 (s, 3H), 3.98-3.80 (m, 1H), 3.79 (s, 3H), 3.21-2.80 (m, 1H), 2.30-1.88 (m, 2H), 1. 63-1. 08 (m, 2H), 1.06-1.01 (m, 3H); MS (ESI): m/z 515 [M+1] +	31	10.02 96 (b)
170		1-(4-((4-((5'-amino-2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.30 (s, 1H), 7.83 (s, 1H), 7.76 (s, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.20 (s, 2H), 7.00-6.78 (m, 3H), 6.22 (d, J = 16.8 Hz, 1H), 5.76 (d, J = 10.4 Hz, 1H), 4.01-3.89 (m, 8H), 3.66 (s, 2H), 2.66 (s, 1H), 2.08 (s, 2H), 1.90 (s, 2H); MS (ESI): m/z 562 [M+1]+	23	5.46 100 (a)
171		1-(trans-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-3-fluoropiperid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.55 (s, 1H), 8.13 (s, 1H), 7.74 (s, 1H), 7.58-7.52 (m, 2H), 7.30-7.27 (m, 2H), 7.09-7.05 (m, 2H), 6.87-6.80 (m, 1H), 6.28-6.24 (m, 1H), 5.83-5.79 (m, 1H), 4.81-4.80 (m, 2H), 4.12-4.03 (m, 5H), 3.92 (s, 3H), 3.88-3.50 (m, 2H), 2.31-2.17 (m, 1H), 2.05-2.01 (m, 1H); MS (ESI): m/z 565 [M+H] +	25	6.88 100 (a)
172		1-((1R,3s,5S)-3-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-8-azabicyclo[3. 2.1]octan-8-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.58 (s, 1H), 7.95 (s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.75-7.73 (m, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.26-7.21 (m, 2H), 6.78-6.67 (m, 2H), 6.51-6.50 (m, 1H), 6.37-6.32 (m, 1H), 5.82-5.79 (m, 1H), 5.13-5.10 (m, 1H), 4.77-4.64 (m, 2H), 4.10 (s, 3H), 3.90 (s, 3H), 2.44-1.72 (m, 8H); MS (ESI): m/z 527 [M+1]+	10	10.07 95 (b)
173		1-((3R,4R)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, HCl salt, Methanol-d4) δ 8.60 (s, 1H), 8.17 (s, 1H), 7.87 (d, J = 2.4 Hz, 1H), 7.76-7.73 (m, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.28-7.23 (m, 2H), 6.87-6.80 (m, 1H), 6.70 (d, J = 3.6 Hz, 1H), 6.53-6.52 (m, 1H), 6.29-6.24 (m, 1H), 5.83-5.80 (m, 1H), 5.01-5.00 (m, 2H), 4.11-4.04 (m, 5H), 3.93-3.91 (m, 4H), 3.66-3.59 (m, 1H), 2.32-2.30 (m, 1H), 2.02-1.99 (m, 1H); MS (ESI): m/z 519 [M+H]+	82	9.96 99 (b)
174		1-((3S,4S)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, HCl salt, DMSO-d6) δ 11.02 (s, 1H), 8.74 (s, 1H), 8.33 (s, 1H), 7.75-7.71 (m, 3H), 7.31-7.28 (m, 2H), 6.90-6.83 (m, 2H), 6.59-6.58 (m, 1H), 6.17-6.12 (m, 1H), 5.75-5.72 (m, 1H), 4.94-4.75 (m, 2H), 4.08-3.99 (m, 4H), 3.83 (s, 3H), 3.68 (brs, 2H), 2.21-2.13 (m, 1H), 1.77-1.75 (m, 1H); MS (ESI): m/z=519 [M+1]+	74	9.97 95 (b)
175		5-(3-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )furan-2-carboxylic acid	1H NMR (400MHz, TFA salt, DMSO-d6) δ 11.00 (s, 1H), 8.77 (s, 1H), 8.13 (s, 1H), 7.95-7.87 (m, 2H), 7.38-7.22 (m, 3H), 7.09 (d, J = 3.6 Hz, 1H), 6.97-6.82 (m, 1H), 6.15-6.12 (m, 1H), 5.77-5.75 (m, 1H), 4.84-4.82 (m, 1H), 4.02 (s, 3H), 3.97-3.84 (m, 5H), 2.34-2.32 (m, 2H), 1.07-1.07 (m, 2H); MS (ESI): m/z 545 [M+1]+	4	4.96 98 (a)
176		1-(4-((4-((5-(2,3-dihydrothieno [3,4-b][1,4]dioxin -5-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.31 (s, 1H), 7.99 (d, J = 2.0 Hz, 1H), 7.82 (s, 1H), 7.64-7.61 (m, 1H), 7.22 (s, 1H), 7.15 (d, J = 8.8 Hz, 1H), 6.87-6.80 (m, 1H), 6.32 (s, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.62-4.61 (m, 1H), 4.31-4.29 (m, 2H), 4.25-4.23 (m, 2H), 4.03-3.97 (m, 5H), 3.88 (s, 3H), 3.68-3.66 (m, 2H), 2.10-2.08 (m, 2H), 1.91-1.88 (m, 2H); MS (ESI): m/z 475 [M+H]+	42	10.16 95 (b)
177		1-(4-((4-((5-(2-hydroxytetrah ydrofuran-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.35 (s, 1H), 8.31 (d, J = 2 Hz, 1H), 8.03-8.00 (m, 1H), 7.84 (S, 1H), 7.25-7.20 (m, 2H), 6.85-6.79 (m, 1H), 6.24-6.19 (m, 1H), 5.78-5.74 (m, 1H), 4.02 (s, 3H), 3.98-3.93 (m, 5H), 3.68-3.63 (m, 4H), 3.13-3.08 (m, 2H), 2.16-2.03 (m, 2H), 1.97-1.91 (m, 4H); MS (ESI): m/z 521 [M+1]+	39	7.78 93 (b)
178		1-((3S,4R)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, DMSO-d6) δ 11.22 (s, 1H), 8.73 (s, 1H), 8.37 (s, 1H), 7.75-7.71 (m, 3H), 7.31 (s, 1H), 7.29 (d, J = 9.2 Hz, 1H), 6.89-6.79 (m, 2H), 6.58-6.57 (m, 1H), 6.16-6.15 (m, 1H), 5.71-5.70 (m, 1H), 5.00-4.95 (m, 2H), 4.38-4.31 (m, 1H), 4.01 (s, 3H), 3.77 (s, 3H), 3.07 (t, J = 12.0 Hz, 1H), 2.32-1.80 (m, 4H); MS (ESI): m/z 519 [M+1]+	69	5.79 100 (a)
179		1-(trans-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.63 (s, 1H), 8.19 (s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.77-7.75 (m, 1H), 7.55 (s, 1H), 7.28-7.24 (m, 2H), 6.87-6.80 (m, 1H), 6.71 (d, J = 3.2 Hz, 1H), 6.53-6.52 (m, 1H), 6.29 (d, J = 16.8 Hz, 1H), 5.83-5.50 (m, 1H), 5.02-5.01 (m, 2H), 4.12 (s, 3H), 4.09-4.00 (m, 2H), 3.98 (s, 3H), 3.74-3.71 (m, 2H), 2.34-2.33 (m, 1H), 2.01-2.00 (m, 1H); MS (ESI): m/z 519 [M+H] +	23	6.24 100 (a)
180		1-(4-((4-((3'-amino-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, Free base, Methanol-d4) δ 8.31 (s, 1H), 7.86 (d, J = 2 Hz, 1H), 7.81 (s, 1H), 7.51-7.49 (m, 1H), 7.19-7.13 (m, 3H), 6.99 (s, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.84-6.77 (m, 1H), 6.69-6.67 (m, 1H), 6.23-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.00-3.88 (m, 8H), 3.66-3.61 (m, 2H), 2.07-2.03 (m, 2H), 1.89 (brs, 2H); MS (ESI): m/z 527 [M+1]+	5	4.24 100 (a)
181		1-(cis-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.09 (s, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.74-7.72 (m, 1H), 7.52 (d, J = 1.2 Hz, 1H), 7.27 (s, 1H), 7.23 (d, J = 8.8 Hz, 1H), 6.86-6.75 (m, 1H), 6.68 (d, J = 3.6 Hz, 1H), 6.50-6.49 (m, 1H), 6.25 (d, J = 16.8 Hz, 1H), 5.80 (d, J = 10.8 Hz, 1H), 5.10-4.95 (m, 1H), 4.49-4.34 (m, 2H), 4.09-4.03 (m, 4H), 3.88 (s, 3H), 3.68-3.53 (m, 2H), 2.09-2.08 (m, 2H); MS (ESI): m/z 519 [M+1]+	15	6.09 98 (a)
182		1-(cis-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-3-fluoropiperid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.59 (s, 1H), 8.10 (s, 1H), 7.67 (s, 1H), 7.59-7.49 (m, 2H), 7.29 (s, 1H), 7.27 (s, 1H), 7.07-7.03 (m, 2H), 6.86-6.75 (m, 1H), 6.25 (d, J = 16.8 Hz, 1H), 5.80 (d, J = 10.4Hz, 1H), 5.10-4.96 (m, 1H), 4.51-4.34 (m, 2H), 4.09 (s, 3H), 3.90 (s, 3H), 3.68-3.48 (m, 2H), 2.19-2.09 (m, 2H); MS (ESI): m/z 564 [M+1]+	20	6.66 99 (a)
183		5-(3-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )furan-2-carbonitrile	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.63 (s, 1H), 8.07 (s, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.89-7.86 (m, 1H), 7.42 (d, J = 4.0 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 6.95 (d, J = 4.0 Hz, 1H), 6.88-6.81 (m, 1H), 6.27-6.22 (m, 1H), 5.81-5.78 (m, 1H), 5.01-5.00 (m, 1H), 4.13 (s, 3H), 3.99-3.96 (m, 5H), 3.70-3.68 (m, 2H), 2.13-2.10 (m, 2H), 1.99-1.97 (m, 2H); (ESI): m/z 526 [M+H] +	41	9.69 99 (b)
184		2-fluoro-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.32 (s, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.76 (s, 1H), 7.59-7.56 (m, 1H), 7.50-7.49 (m, 1H), 7.17 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.63-6.62 (m, 1H), 6.48-6.46 (m, 1H), 5.25-5.23 (m, 1H), 5.19-5.12 (m, 1H), 4.83-4.80 (m, 1H), 3.99 (s, 3H), 3.92-3.86 (m, 5H), 3.65-3.64 (m, 2H), 2.11-2.04 (m, 2H), 1.96-1.90 (m, 2H); MS (ESI): m/z 519 [M+1]+	33	6.16 100 (a)
185		1-(4-((4-((2-fluoro-3-(furan-2-yl)- 6-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 10.36 (s, 1H), 8.62 (s, 1H), 8.07 (s, 1H), 7.84-7.80 (m, 2H), 7.28 (s, 1H), 7.19 (d, J = 8.4 Hz, 1H), 6.89-6.82 (m, 1H), 6.75 (t, J = 3.6 Hz, 1H), 6.64-6.63 (m, 1H), 6.15-6.11 (m, 1H), 5.71-5.69 (m, 1H), 4.84-4.80 (m, 1H), 4.00-3.86 (m, 8H), 2.07-2.05 (m, 2H), 1.72-1.71 (m, 2H); MS (ESI): m/z 519 [M+1]+	67	5.82 96 (a)
186		1-(4-((7-methoxy-4-((2,2',4'-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, DMSO-d6) δ 10.54 (s, 1H), 8.67 (s, 1H), 8.09 (s, 1H), 7.58-7.51 (m, 2H), 7.43-7.37 (m, 1H), 7.28-7.19 (m, 3H), 6.89-6.82 (m, 1H), 6.15-6.10 (m, 1H), 5.71-5.68 (m, 1H), 4.83-4.81 (m, 1H), 4.00-3.87 (m, 8H), 2.08-2.06 (m, 2H), 1. 72-1. 71 (m, 2H); MS (ESI): m/z 565 [M+1]+	51	6.26 100 (a)
187		2-chloro-1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)-2-fluoroethan-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.59 (d, J = 7.1 Hz, 1H), 8.05 (s, 1H), 7.68 (d, J = 3.5 Hz, 1H), 7.63 - 7.47 (m, 2H), 7.33 - 7.21 (m, 2H), 7.11 - 6.94 (m, 3H), 4.94 - 4.90 (m, 1H), 4.09 (d, J = 7.0 Hz, 3H), 3.95 - 3.56 (m, 9H), 3.17 - 3.09 (m, 1H), 2.23 - 1.90 (m, 4H); MS (ESI): m/z 587 [M+1]+	79	11.18 98 (b)
188		2-chloro-2-fluoro-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)ethan-1-one	1H NMR (400 MHz, TFA salt, CDCl3) δ 9.66 (s, 1H), 8.53 (s, 1H), 8.30 (s, 1H), 7.59-7.56 (m, 2H), 7.43 (s, 1H), 7.39-7.37 (d, J = 7.05 Hz, 1H), 7.04-7.02 (d, J = 8.68 Hz, 1H), 6.57-6.55 (t, 1H), 6.43 (s, 1H), 4.83 (s, 1H), 3.97-3.86 (m, 8H), 3.72-3.60 (m, 2H), 2.14-2.06 (m, 2H), 2.00-1.89 (m, 2H); MS (ESI): m/z=541 [M+1]+	36	10.45 96 (b)
189		1-((3S,4R)-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-3-fluoropiperid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, HCl salt, Methanol-d4) δ 8.56 (s, 1H), 8.03 (s, 1H), 7.72 (s, 1H), 7.60-7.52 (m, 2H), 7.31-7.26 (m, 2H), 7.10-7.05 (m, 2H), 6.85-6.82 (m, 1H), 6.27-6.23 (m, 1H), 5.82-5.79 (m, 1H), 5.24-5.21 (m, 1H), 4.62-4.59 (m, 2H), 4.41 (s, 3H), 4.11 (s, 3H), 3.67-3.49 (m, 3H), 2.12-2.10 (m, 2H); MS (ESI): m/z 565 [M+H]+	52	10.59 100 (b)
190		1-(4-((7-methoxy-4-((2',4',6'-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, DMSO-d6) δ 11.05 (s, 1H), 8.72 (s, 1H), 8.20 (s, 1H), 7.50-7.49 (m, 2H), 7.36-7.29 (m, 4H), 6.88-6.81 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.67 (m, 1H), 4.86-4.84 (m, 1H), 4.00-3.84 (m, 8H), 3.53-3.50 (m, 1H), 2.08-2.07 (m, 2H), 1.68-1.66 (m, 2H); MS (ESI): m/z 565 [M+1]+	78	10.63 100 (b)
191		1-(4-((4-((2'-chloro-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, DMSO-d6) δ 11.01 (s, 1H), 8.71 (s, 1H), 8.27 (s, 1H), 7.58-7.55 (m, 1H), 7.50-7.45 (m, 3H), 7.34-7.29 (m, 3H), 6.88-6.81 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.67 (m, 1H), 4.87-4.86 (m, 1H), 3.99-3.84 (m, 8H), 3.51-3.50 (m, 1H), 2.08-2.07 (m, 2H), 1.68-1.66 (m, 2H); MS (ESI): m/z 564 [M+1]+	81	10.89 100 (b)
192		1-(4-((4-((2'-fluoro-4-methoxy-5'-(trifluoromet hyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, HCl salt, DMSO-d6) δ 11.09 (s, 1H), 8.70 (s, 1H), 8.25 (s, 1H), 7.90-7.88 (m, 1H), 7.82-7.78 (m, 1H), 7.72-7.68 (m, 2H), 7.60 (t, J = 9.2 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.30 (s, 1H), 6.88-6.81 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.67 (m, 1H), 4.88-4.86 (m,1H), 4.00-3.85 (m, 8H), 3.52-3.50 (m, 1H), 2.08-2.07 (m, 2H), 1.68-1.66 (m, 2H); MS (ESI): m/z 597 [M+1]+	75	11.21 100 (b)
193		1-(4-((4-((5-(benzo[b]thio phen-6-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.35 (s, 1H), 8.14 (s, 1H), 8.00-7.99 (d, J = 2.12 Hz, 1H), 7.90-7.88 (d, J = 8.32 Hz, 1H), 7.85 (s, 1H), 7.66-7.63 (dd, J = 8.38 Hz, 2H), 7.56-7.55 (d, J = 5.44 Hz, 2H), 7.38-7.37 (d, J = 5.40 Hz, 1H), 7.25-7.23 (d, J = 8.60 Hz, 1H) 7.21 (s, 1H) 6.85-6.78 (m, 1H), 6.24-6.20 (d, J = 16.89 Hz, 1H), 5.77-5.75 (d, J = 10.70 Hz, 1H), 4.85 (m, 1H), 4.02 (s, 3H), 3.99-3.92 (m, 6H), 3.71-3.62 (m, 2H), 2.13-2.06 (m, 2H), 1.96-1.86 (m, 2H); MS (ESI): m/z=567 [M+1]+	57	11.12 98 (b)
194		1-(4-((4-((5-(benzo[d]thia zol-6-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, DMSO-d6) δ 9.38 (s, 1H), 9.22 (s, 1H), 8.48 (d, J = 1.6 Hz, 1H), 8.45 (s, 1H), 8.31 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.95 (s, 1H), 7.92 (d, J = 2.3 Hz, 1H), 7.85 (dd, J = 8.6, 1.8 Hz, 1H), 7.69 (dd, J = 8.6, 2.3 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H), 7.20 (s, 1H), 6.85 (dd, J = 16.7, 10.5 Hz, 1H), 6.12 (dd, J = 16.7, 2.4 Hz, 1H), 5.69 (dd, J = 10.5, 2.4 Hz, 1H), 4.83-4.76 (m, 1H), 3.97-3.87 (m, 5H), 3.84 (s, 3H), 3.53-3.44 (m, 2H), 2.11-2.01 (m, 2H), 1.75-1.62 (m, 2H); MS (ESI): m/z 568 [M+1] +	82	9. 67 97 (b)
195		1-(3,3-difluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-5-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.76 (s, 2H), 7.65-7.62 (m, 1H), 7.55 (s, 1H), 7.24-7.19 (m, 2H), 6.89-6.88 (m, 2H), 6.79 (s, 1H), 6.71 (s, 1H), 6.54-6.52 (m, 1H), 6.29-6.28 (m, 1H), 5.87-5.84 (m, 1H), 4.72-4.71 (m, 1H), 4.33-4.32 (m, 1H), 4.01 (s, 3H), 3.93 (s, 3H), 3.90-3.89 (m, 1H), 3.42-3.41 (m, 1H), 2.52-2.50 (m, 1H), 2.15-2.13 (m, 1H); MS (ESI): m/z 537 [M+H] +	51	10.95 100 (b)
196		1-(4-((4-((3--(difluorometh yl)-4'-fluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.06 (s, 1H), 7.82-7.78 (m, 3H), 7.71-7.68 (m, 1H), 7.34-7.29 (m, 2H), 7.24 (s, 1H), 7.04 (tr, J = 54.4 Hz, 1H), 6.85-6.79 (m, 1H), 6.25-6.20 (m, 1H), 5.78-5.75 (m, 1H)4.09 (s, 3H), 3.98-3.91 (m, 6H), 3.68 (brs, 2H), 2.16-2.11 (m, 2H), 1.92 (brs, 2H); MS (ESI): m/z 579 [M+1]+	27	10.73 99 (b)
197		1-(4-((7-methoxy-4-((4-methoxy-3'-nitro-[1,1'-biphenyl]-3-yl)amino) quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.49-8.46 (m, 1H), 8.37 (s, 1H), 8.22 (s, 1H), 8.20-8.16 (m, 1H), 8.07-8.03 (m, 2H), 7.86 (s, 1H), 7.71-7.65 (m, 2H), 7.28 (d, J = 8.6 Hz, 1H), 7.22 (s, 1H), 6.82 (dd, J = 16.8, 10.7 Hz, 1H), 6.22 (dd, J = 16.8, 1.9 Hz, 1H), 5.76 (dd, J = 10.7, 1.9 Hz, 1H), 4.03 (s, 3H), 4.01-3.95 (m, 2H), 3.94 (s, 3H), 3.72-3.62 (m, 2H), 2.14-2.06 (m, 2H), 1.96-1.87 (m, 2H); MS (ESI): m/z 556 [M+1]+	48	10.34 95 (b)
198		1-(4-((7-methoxy-4-((2',3',4',5' ,6'-pentafluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino))qui nazolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.61 (s, 1H), 8.05 (s, 1H), 7.87 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 15.2 Hz, 1H), 7.26 (s, 1H), 6.88-6.81 (m, 1H), 6.27-6.22 (m, 1H), 5.80-5.77 (m, 1H), 4.92-4.91 (m, 1H), 4.10 (s, 3H), 3.99-3.94 (m, 5H), 3.70-3.68 (m, 2H), 2.17-2.12 (m, 2H), 1.94-1.92 (m, 2H); MS (ESI): m/z 601 [M+H]+	13	11.18 100 (b)
199		1-(3-((4-((3'-(dimethylamin o)-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.64-8.63 (m, 1H), 7.88 (s, 1H), 7.79-7.68 (m, 3H), 7.64-7.61 (m, 1H), 7.49-7.47 (m, 1H), 7.35 (s, 1H), 7.33 (s, 1H), 6.45-6.40 (m, 1H), 6.38-6.29 (m, 1H), 5.81-5.79 (m, 1H), 5.31-5.30 (m, 1H), 4.89-4.88 (m, 1H), 4.66-4.62 (m, 1H), 4.49-4.46 (m, 1H), 4.17-4.13 (m, 1H), 4.12 (s, 3H), 3.97 (s, 3H), 3.27 (s, 6H); MS (ESI): m/z 525 [M+1]+	43	8.31 97 (b)
200		1-(3-((4-((2'4'-difluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)quin azolin-5-yl)oxy)-4,4-difluoropiper idin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.77 (s, 1H), 8.35 (s, 1H), 8.11-8.07 (m, 1H), 7.73-7.71 (m, 1H), 7.59-7.52 (m, 3H), 7.30 (d, J = 8.4 Hz, 1H), 7.12-7.09 (m, 2H), 6.78-6.76 (m, 1H), 6.06-6.01 (m, 1H), 5.65-5.42 (m, 2H), 4.23-4.22 (m, 1H), 4.09-4.00 (m, 5H), 3.96-3.90 (m, 2H), 2.40-2.38 (m, 2H); MS (ESI): m/z 553 [M+H]+	47	11.50 100 (b)
201		1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-5-yl)oxy)-4,4-difluoropiper idin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.68 (s, 1H), 8.28 (s, 1H), 7.58-7.49 (m, 2H), 7.29-7.26 (m, 2H), 7.11-7.06 (m, 2H), 6.91 (s, 1H), 6.78-6.76 (m, 1H), 6.06-6.02 (m, 1H), 5.68-5.43 (m, 2H), 4.21-4.20 (m, 1H), 4.11-4.08 (m, 4H), 4.01 (s, 3H), 3.99-3.81 (m, 2H), 2.45-2.42 (m, 2H); MS (ESI): m/z 583 [M+H]+	47	11.59 100 (b)
202		1-(4-((4-((2',4'-difluoro-4-methoxy-3'-(trifluoromet hyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.05 (s, 1H), 7.84-7.78 (m, 1H), 7.71-7.00 (m, 1H), 7.61-7.58 (m, 1H), 7.34-7.25 (m, 3H), 6.86-6.79 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 4.90 (m, 1H), 4.09 (s, 3H) 3.98-3.93 (m, 6H), 3.68 (brs, 2H), 2.13 (brs, 2H), 1.94 (brs, 2H); MS (ESI): m/z 615 [M+1]+	83	11.11 100 (b)
203		1-(4-((7-methoxy-4-((2',3',4'-trifluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.61 (s, 1H), 8.07 (s, 1H), 7.73-7.72 (m, 1H), 7.63-7.60 (m, 1H), 7.34-7.28 (m, 2H), 7.23-7.21 (m, 2H), 6.87-6.81 (m, 1H), 6.27-6.22 (m, 1H), 5.80-5.77 (m, 1H), 5.00-4.88 (m, 1H), 4.11 (s, 3H), 3.97-3.94 (m, 2H), 3.93 (s, 3H), 3.71-3.70 (m, 2H), 2.20-1.89 (m, 4H); MS (ESI): m/z 564 [M+1]+	50	10.82 100 (b)
204		methyl 3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-carboxylate	1H NMR (400 MHz, free base, DMSO) δ 9.22 (s, 1H), 8.30 (s, 1H), 8.19-8.17 (m, 1H), 7.97-7.89 (m, 3H), 7.84 (d, J = 2.3 Hz, 1H), 7.65-7.58 (m, 2H), 7.26 (d, J = 8.7 Hz, 1H), 7.19 (s, 1H), 6.85 (dd, J = 16.7, 10.5 Hz, 1H), 6.12 (dd, J = 16.7, 2.4 Hz, 1H), 5.69 (dd, J = 10.5, 2.4 Hz, 1H), 4.83-4.76 (m, 1H), 3.98-3.93 (m, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 3.83 (s, 3H), 3.55-3.42 (m, 2H), 2.09-2.01 (m, 2H), 1. 74-1. 63 (m, 2H); MS (ESI): m/z=569 [M+1]+	40	10.30 99 (b)
205		1-(4-((7-methoxy-4-((4-methoxy-3'-(methylthio)-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.58 (s, 1H), 8.06 (s, 1H), 7.75-7.74 (d, J = 2.4 Hz 1H), 7.67-7.65 (m, 1H), 7.47 (m, 1H), 7.37-7.21 (m, 5H), 6.82-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.78-5.74 (m, 1H), 4.90 (m, 1H), 4.07 (s, 3H), 3.98-3.91 (m, 2H), 3.89 (s, 3H), 3.66 (brs, 2H), 2.51 (s, 3H), 2.10 (brs, 2H), 1.90 (brs, 2H); MS (ESI): m/z 557 [M+1]+	69	10.60 99 (b)
206		1-(4-((7-methoxy-4-((2-methoxy-5-(quinoxalin-6-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.89-8.85 (m, 2H), 8.60 (s, 1H), 8.28 (s, 1H), 8.20-8.14 (m, 2H), 8.05 (s, 1H), 8.01 (d, J = 2.4 Hz 1H), 7.91-7.89 (m, 1H), 7.37-7.34 (d, J = 8.8 Hz 1H), 7.23 (d, J = 1.2 Hz 1H), 6.80-6.76 (m, 1H), 6.22-6.18 (m, 1H), 5.76-5.73 (m, 1H), 4.89 (m, 1H), 4.07 (s, 3H), 3.95 (brs, 2H), 3.91 (s, 3H), 3.66 (brs, 2H), 2.10 (brs, 2H), 1.90 (brs, 2H); MS (ESI): m/z 563 [M+1]+	60	9.02 99 (b)
207		1-(4-((4-((2',4'-difluoro-4-methoxy-3'-methyl-[1,1'-biphenyl] -3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.59 (s, 1H), 8.05 (s, 1H), 7.69-7.68 (m, 1H), 7.59-7.57 (m, 1H), 7.36-7.25 (m, 3H), 7.02-7.01 (m, 1H), 6.87-6.81 (m, 1H), 6.27-6.22 (m, 1H), 5.80-5.77 (m, 1H), 5.06-5.02 (m, 1H), 4.10 (s, 3H), 3.99-3.93 (m, 5H), 3.69-3.67 (m, 2H), 2.27 (s, 3H), 2.18-2.17 (m, 2H), 2.01-1.99 (m, 2H); MS (ESI): m/z 561 [M+H] +	92	10.95 100 (b)
208		N-(3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-yl)acrylamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.22 (s, 1H), 8.31 (s, 1H), 8.02 (s, 1H), 7.93 (s, 1H), 7.59-7.53 (m, 1H), 7.40-7.38 (m, 2H), 7.26-7.24 (m, 2H), 7.20 (s, 1H), 6.90-6.80 (m, 1H), 6.42-6.41 (m, 1H), 6.30-6.29 (m, 1H), 6.15-6.14 (m, 1H), 5.71-5.70 (m, 1H), 5.68-5.67 (m, 1H), 4.85-4.75 (m, 1H), 4.00-3.94 (m, 5H), 3.83 (s, 3H), 3.54-3.51 (m, 2H), 2.55 (s, 6H), 2.20-2.00 (m, 3H), 1.80-1.60 (m, 3H), 1. 40-1. 39 (m, 5H), 1.25 (s 6H); MS (ESI): m/z 579 [M+1]+	22	9.44 94 (b)
209		3'-((6-((1-acryloylpiper idin-4-yl)amino)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-carbaldehyde	1H NMR (400 MHz, TFA salt, DMSO-d6) δ 10.10 (s, 1H), 9.23 (s, 1H), 8.31 (s, 1H), 8.21 (s, 1H), 8.04-8.02 (s, 1H), 7.95-7.85 (m, 2H), 7.71-7.70 (m, 1H), 7.69-7.66 (m, 2H), 7.29-7.27 (m, 1H), 7.20 (s, 1H), 6.89-6.85 (m, 1H), 6.15-6.10 (m, 1H), 5.71-5.68 (m, 1H), 4.81-4.80 (m, 1H), 3.98 (s, 3H), 3.82 (s, 3H), 3.60-3.30 (m, 2H), 2.05-2.00 (m, 2H), 1.80-1.60 (m, 2H); MS (ESI): m/z 538 [M+1]+	24	9.64 92 (b)
210		1-(4-((4-((2' ,4'-difluoro-3',4-dimethoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.35 (s, 1H), 8.16 (s, 1H), 7.86 (s, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.49-7.44 (m, 1H), 7.25-7.16 (m, 3H), 7.08-7.02 (m, 1H), 6.82 (dd, J = 16.8, 10.7 Hz, 1H), 6.22 (dd, J = 16.8, 1.9 Hz, 1H), 5.76 (dd, J = 10.7, 1.9 Hz, 1H), 4.02 (s, 3H), 3.99 (s, 3H), 3.97-3.93 (m, 2H), 3.91 (s, 3H), 3.73-3.62 (m, 2H), 2.14-2.05 (m, 2H), 1. 95-1. 85 (m, 2H); MS (ESI): m/z 577 [M+1] +	26	10.39 98 (b)
211		1-(4-((7-methoxy-4-((4-methoxy-3'-(trifluoromet hoxy)-[1,1'-biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.61 (s, 1H), 8.06 (s, 1H), 7.81-7.80 (d, J = 2.4 Hz 1H), 7.74-7.71 (m, 1H), 7.65-7.63 (m, 1H), 7.56-7.52 (tri, J = 8.0 Hz 1H), 7.50 (s, 1H), 7.32-7.30 (d, J = 8.8 Hz 1H), 7.27-7.26 (m, 2H), 6.83-6.79 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.90 (m, 1H), 4.13 (s, 3H), 3.99-3.96 (m, 2H), 3.95 (s, 3H), 3.69 (brs, 2H), 2.12 (brs, 2H), 1.94 (brs, 2H); MS (ESI): m/z 595 [M+1]+	70	11.44 100 (b)
212		1-(4-((4-((2',4'-difluoro-4-methoxy-5'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 561 [M+1]+
213		1-(4-((4-((2',4'-difluoro-4,5'-dimethoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.31 (s, 1H), 7.83 (s, 1H), 7.81 (s, 1H), 7.50-7.45 (m, 1H), 7.24-7.15 (m, 3H), 7.09-7.02 (m, 1H), 6.82 (dd, J = 16.8, 10.7 Hz, 1H), 6.22 (dd, J = 16.8, 2.0 Hz, 1H), 5.76 (dd, J = 10.6, 1.9 Hz, 1H), 4.84-4.82 (m, 1H), 4.01 (s, 3H), 3.99-3.93 (m, 2H), 3.91 (s, 6H), 3.72-3.61 (m, 2H), 2.13-2.05 (m, 2H), 1.96-1.84 (m, 2H); MS (ESI): m/z 576 [M]+	74	10.51 99 (b)
214		1-(4-((4-((4'-fluoro-4-methoxy-3'-(2,2,2-trifluoroetho xy)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.06 (s, 1H), 7.79-7.77 (d, J = 2.4 Hz 1H), 7.71-7.68 (m, 1H), 7.42-7.39 (m, 1H), 7.33-7.21 (m, 4H), 6.84-6.79 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 4.90 (m, 1H), 4.72-4.65 (m, 2H), 4.10 (s, 3H), 3.99-3.93 (m, 2H), 3.91 (s, 3H), 3.69 (brs, 2H), 2.16 (brs, 2H), 1.93 (brs, 2H); MS (ESI): m/z 627 [M+1]+	35	11.17 99 (b)
215		1-(4-((7-methoxy-4-((4-methoxy-3'-vinyl-[1,1'- biphenyl]-3-yl)amino)quin azolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.61 (s, 1H), 7.81 (s, 1H), 7.80 (s, 1H), 7.73-7.71 (m, 1H), 7.66 (s, 1H), 7.53 (d, J = 6.8 Hz, 1H), 7.43-7.41 (m, 2H), 7.31-7.27 (m, 2H), 6.84-6.79 (m, 2H), 6.26-6.22 (m, 1H), 5.89-5.77 (m, 2H), 5.31 (d, J = 10.8 Hz, 1H), 5.01-5.00 (m, 1H), 4.10 (s, 3H), 3.93-3.91 (m, 5H), 3.71-3.69 (m, 2H), 2.17-2.16 (m, 2H), 1.99-1.97 (m, 2H); MS (ESI): m/z 601 [M+H] +	29	10.70 100 (b)
216		1-(4-((4-((5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.31 (s, 1H), 7.79 (s, 1H), 7.76-7.75 (m, 1H), 7.38-7.35 (m, 1H), 7.19 (s, 1H), 7.10-7.08 (m, 1H), 6.86-6.79 (m, 1H), 6.25-6.21 (m, 1H), 6.14-6.13 (m, 1H), 5.79-5.75 (m, 1H), 4.87-4.80 (m, 1H), 4.30-4.29 (m, 2H), 4.02 (s, 3H), 4.01-3.91 (m, 4H), 3.87 (s, 3H), 3.70-3.60 (m, 2H), 3.33 (m, 2H), 3.32 (s, 3H), 2.52-2.50 (m, 2H), 2.15-1. 80 (m, 4H); MS (ESI): m/z 517 [M+1]+	45	8.90 92 (b)
217		1-(3-((4-((5-(5-chloro-1-((3S,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.36 (s, 1H), 8.00 (s, 1H), 7.89 (s, 1H), 7.56-7.53 (m, 1H), 7.46 (s, 1H), 7.24-7.19 (m, 2H), 6.45-6.38 (m, 1H), 6.32-6.28 (m, 1H), 5.81-5.76 (m, 1H), 5.27-5.25 (m, 1H), 5.12-5.11 (m, 1H), 4.61-4.40 (m, 7H), 4.19-4.18 (m, 1H), 4.05 (s, 3H), 3.96 (s, 3H), 3.72-3.69 (m, 2H), 2.92-2.91 (m, 1H), 2.20-2.15 (m, 5H); MS (ESI): m/z 665 [M+H] +	12	4.27 90*
218		1-(6-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-2-azaspiro[3.3] heptan-2-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 7.83 (s, 1H), 7.76-7.72 (m, 2H), 7.54 (d, J = 1.2 Hz, 1H), 7.26 (s, 1H), 7.23 (s, 1H), 6.70 (d, J = 3.2 Hz, 1H), 6.52-6.51 (m, 1H), 6.37-6.22 (m, 2H), 5.76-5.73 (m, 1H), 4.41-4.35 (m, 2H), 4.18-4.09 (m, 5H), 3.90 (d, J = 2.0 Hz, 3H), 3.01-2.87 (m, 2H), 2.51-2.46 (m, 2H); MS (ESI): m/z 513 [M+1] +	5	5.80 100 (a)
219		1-(6-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-2-azaspiro[3.3] heptan-2-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.59 (s, 1H), 7.73-7.69 (m, 2H), 7.61-7.51 (m, 2H), 7.31 (d, J = 8.4 Hz, 1H), 7.26 (s, 1H), 7.09 (t, J = 8.4 Hz, 1H), 6.37-6.22 (m, 2H), 5.76-5.73 (m, 1H), 4.41-4.35 (m, 2H), 4.18-4.09 (m, 5H), 3.92 (s, 3H), 3.01-2.97 (m, 2H), 2.51-2.46 (m, 2H); MS (ESI): m/z 559 [M+1] +	3	6.38 100 (a)
220		1-(2-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-6-azaspiro[3.4] octan-6-yl)prop-2-en-1-one	1H NMR (400 MHz,FA salt, Methanol-d4) δ 8.38 (s, 1H), 8.22 (s, 1H), 8.00-7.95 (m, 1H), 7.66-7.60 (m, 1H), 7.52-7.45 (m, 2H), 7.19-7.13 (m, 2H), 6.68-6.53 (m, 2H), 6.50-6.47 (m, 1H), 6.30-6.23 (m, 1H), 5.77-5.70 (m, 1H), 5.01-4.94 (m, 1H), 4.02 (s, 3H), 3.88 (s, 3H), 3.72-3.50 (m, 4H), 2.75-2.67 (m, 2H), 2.33-2.25 (m, 2H), 2.16-2.02 (m, 2H); MS (ESI): m/z=527 [M+1]+	13	10.00 100 (b)
221		1-(6-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)-2-azaspiro[3.4] octan-2-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 7.84 (s, 1H), 7.83 (s, 1H), 7.77-7.75 (m, 1H), 7.54 (s, 1H), 7.26-7.23 (m, 2H), 6.71 (d, J = 3.2 Hz, 1H), 6.53-6.52 (m, 1H), 6.36-6.28 (m, 2H), 5.77-5.74 (m, 1H), 5.15-5.14 (m, 1H), 4.28-4.26 (m, 2H), 4.10 (s, 3H), 4.02-4.01 (m, 2H), 3.90 (s, 3H), 2.35-2.32 (m, 4H), 2.06-2.04 (m, 2H); MS (ESI): m/z 527 [M+H]+	20	10.03 100 (b)
222		1-(6-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)-2-azaspiro[3.4] octan-2-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.32 (s, 1H), 7.87 (s, 1H), 7.65 (d, J = 1.2 Hz, 1H), 7.57-7.55 (m ,1H), 7.45 (d, J = 8.8 Hz, 1H), 7.24-7.19 (m, 2H), 7.08-7.03 (m, 2H), 6.35-6.32 (m, 1H), 6.28-6.23 (m, 1H), 5.77-5.74 (m, 1H), 5.14-5.13 (m, 1H), 5.51-5.50 (m, 1H), 4.35-4.32 (m, 1H), 4.12-4.10 (m, 5H), 4.00 (s, 3H), 2.35-2.34 (m, 4H), 2.04-2.03 (m, 2H); MS (ESI): m/z 573 [M+H]+	24	10.77 98 (b)
223		bicyclo[1.1.0 ]butan-1-yl(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)methanone	MS (ESI): m/z 527 [M+1]+
224		N-(3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-yl)acetamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.56 (s, 1H), 8.02 (s, 1H), 7.98-7.97 (d, J = 1.35 Hz, 1H), 7.80-7.79 (d, J = 2.28 Hz, 1H), 7.67-7.65 (dd, J = 8.6 Hz 1H), 7.39-7.35 (m, 3H), 7.28-7.24 (t, 2H), 6.85-6.79 (m, 1H), 6.25-6.20 (dd, J = 16.81 Hz, 1H), 5.78-5.75 (dd, J = 10.66 Hz, 1H), 4.86 (m, 1H), 4.08 (s, 3H), 3.99-3.91 (m, 5H), 3.71-3.65 (m, 2H), 2.15-2.08 (m, 5H), 1.97-1.86 (m, 2H); MS (ESI): m/z 568 [M+1]+	8	9.03 97 (b)
225		1-(4-((4-((3'-(azetidin-1-yl)-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, CDCl3) δ 8.94 (d, J = 2.1 Hz, 1H), 8.70 (s, 1H), 8.11 (s, 1H), 7.89 (s, 1H), 7.34-7.27 (m, 4H), 7.01 (dd, J = 8.3, 3.1 Hz, 2H), 6.70-6.58 (m, 2H), 6.45 (dd, J = 7.9, 1.8 Hz, 1H), 6.31 (dd, J = 16.8, 1.8 Hz, 1H), 5.72 (dd, J = 10.6, 1.8 Hz, 1H), 4.71-4.63 (m, 1H), 4.01 (s, 6H), 3.97-3.85 (m, 7H), 3.74-3.48 (m, 3H), 2.44-2.34 (m, 2H), 2.04-1.95 (m, 2H); MS (ESI): m/z 566 [M+1]+	14	9.74 97 (b)
226		N-(3'-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-fluoro-4'-methoxy-[1,1'- biphenyl]-3-yl)acetamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.24-8.23 (d, J = 7.23 Hz, 1H), 8.05 (s, 1H), 7.75 (s, 1H), 7.66-7.64 (d, J = 7.24 Hz, 1H), 7.41-7.38 (m, 1H), 7.28-7.20 (m, 3H), 6.85-6.79 (m, 1H), 6.25-6.21 (d, J = 16.75 Hz, 1H), 5.78-5.76 (d, J = 10.65 Hz, 1H), 4.85 (m, 1H), 4.09 (s, 3H), 3.98-3.90 (m, 5H), 3.71-3.62 (m, 2H), 2.20 (s, 3H), 2.17-2.08 (m, 2H), 1. 98-1. 85 (m, 2H); MS (ESI): m/z 586 [M+1]+	42	9.15 96 (b)
227		N-(3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-yl)cyclopropa ncarboxamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.62 (s, 1H), 8.01 (s, 1H), 7.79-7.68 (m, 3H), 7.38-7.27 (m, 5H), 6.39-6.28 (m, 2H), 5.81 (d, J = 11.2 Hz, 1H), 5.29 (s, 1H), 4.66-4.61 (m, 1H), 4.47-4.45 (m, 1H), 4.17-4.12 (m, 4H), 3.92 (s, 3H), 1.82-1.78 (m, 1H), 0.97-0.87 (m, 4H); MS (ESI): m/z 566 [M+1]+	30	5.54 100 (a)
228		1-(4-((7-methoxy-4-((2-methoxy-5-(1,2,5-trimethyl-1H-pyrrol-3-yl)phenyl)ami no)quinazolin -6-yl)oxy) piperidin-1-yl)prop-2-en-1-one	MS (ESI): m/z 542 [M+1]+
229		1-(4-((4-((3'-(dimethylamin o)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, CDCl3) δ 8.92 (d, J = 2.4 Hz, 1H), 8.71 (s, 1H), 8.15 (s, 1H), 7.52 (s, 1H), 7.28-7.27 (m, 1H), 7.13-7.00 (m, 4H), 6.66-6.59 (m, 1H), 6.34-6.29 (m, 1H), 5.74-5.71 (m, 1H), 4.70-4.68 (m, 1H), 4.12-4.10 (m, 8H), 3.82-3.56 (m, 2H), 2.99 (s, 6H), 2.04-1.98 (m, 4H); MS (ESI): m/z 572 [M+H]+	5	9.84 97 (b)
230		1-(4-((4-((5'-bromo-2'3'4'-trifluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 643 [M+H]+

Example 231. Preparation of 4-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)-N-(3-fluorophenethyl)thiophen-2-carboxamide

[0063] 

[Step-1] Preparation of methyl 4-(4-methoxy-3-nitrophenyl)thiophen-2-carboxylate

[0064] In 1,4-dioxane (0.1 M) and water (0.5 M), 4-bromo-1-methoxy-2-nitrobenzene (1.0 equiv.), (5-(methoxycarbonyl)thiophen-3-yl)boronic acid (2.0 equiv.), and K₃PO₄ (2.2 equiv.) were dissolved, and degassed using nitro gas. Then, Xphos Pd G2 (0.13 equiv.) was added at 80 °C, and the mixture was stirred at 100 °C for 1 hour. The reaction mixture was filtered through a celite filter, and concentrated. The reaction mixture was purified by MPLC (DCM / MeOH) to obtain the target compound as a yellow solid (yield: 100%, MS (ESI): m/z 294 [M+1]⁺).

[Step-2] Preparation of 4-(4-methoxy-3-nitrophenyl)thiophen-2-carboxylic acid

[0065] In THF (0.05 M) and MeOH (0.05 M), methyl 4-(4-methoxy-3-nitrophenyl)thiophen-2-carboxylate (1.0 equiv.) obtained in Step-1 above was dissolved, and 5M KOH (1.2 equiv.) dissolved in distilled water was further added and stirred at 60 °C for 2 hours. The reaction product was vacuum dried at 50 °C to obtain the target compound as a white solid (yield: 100%, MS (ESI): m/z 280 [M+1]⁺).

[Step-3] Preparation of 4-(3-amino-4-methoxyphenyl)thiophen-2-carboxylic acid

[0066] In THF (0.3 M), 4-(4-methoxy-3-nitrophenyl)thiophen-2-carboxylic acid (1.0 equiv.) obtained in Step-2 above was dissolved at 0 °C, and then acetic acid (20 equiv.) and zinc (10 equiv.) were added. The reaction mixture was stirred at room temperature for 2 hours. The mixture was filtered through a celite filter and concentrated. The concentrate was neutralized by adding a saturated NaHCO₃ aqueous solution at 0 °C, the organic materials were extracted with DCM, and the collected organic layer was concentrated by removing remaining water using Na₂SO₄. The concentrate was purified by prep-HPLC to obtain the target compound as a yellow solid (yield: 84%, MS (ESI): m/z 250 [M+1]⁺).

[Step-4] Preparation of 4-(3-((6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)thiophen-2-carboxylic acid

[0067] In sec-BuOH (0.1 M), 4-(3-amino-4-methoxyphenyl)thiophen-2-carboxylic acid (1.2 equiv.) obtained in Step-3 above and tert-butyl 4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) were dissolved. Then, 4M HCl (0.2 equiv.) dissolved in 1,4-dioxane was further added, and stirred at 80 °C for 2 hours, and then concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 100%, MS (ESI): m/z 607 [M+1]⁺).

[Step-5] Preparation of tert-butyl 4-((4-((5-(5-((3-fluorophenethyl)carbamoyl)thiophen-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate

[0068] In acetonitrile (0.1 M), 4-(3-((6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)thiophen-2-carboxylic acid (1.0 equiv.) obtained in Step-4 above and 2-(3-fluorophenyl)ethan-1-amine (1.0 equiv.) were dissolved. Then, HATU (2.0 equiv.) and DIPEA (3.0 equiv.) were added, and stirred at room temperature for 5 hours, and then concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 100%, MS (ESI): m/z 728 [M+1]⁺).

[Step-6] Preparation of N-(3-fluorophenethyl)-4-(4-methoxy-3-((7-methoxy-6-(piperidin-4-yloxy)quinazolin-4-yl)amino)phenyl)thiophen-2-carboxamide

[0069] In DCM (0.1 M), tert-butyl 4-((4-((5-(5-((3-fluorophenethyl)carbamoyl)thiophen-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-5 above was dissolved. Then, TFA (10 equiv.) was added and the reaction mixture was stirred at room temperature for 1 hour and then concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 95%, MS (ESI): m/z 628 [M+1]⁺).

[Step-7] Preparation of 4-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)-N-(3-fluorophenethyl)thiophen-2-carboxamide

[0070] In THF (0.1 M), N-(3-fluorophenethyl)-4-(4-methoxy-3-((7-methoxy-6-(piperidin-4-yloxy)quinazolin-4-yl)amino)phenyl)thiophen-2-carboxamide (1.0 equiv.) obtained in Step-6 above and saturated NaHCO₃ aqueous solution (5.0 equiv.) were dissolved. Then, acryloyl chloride (1.0 equiv.) was added at 0 °C and the reaction mixture was stirred for 10 minutes and then concentrated.

[0071] The reaction mixture was purified by prep-HPLC to obtain the target compound as a pale yellow solid (yield: 13%, MS (ESI): m/z 682 [M+1]⁺).

Preparation of Compounds of Examples 232 to 235

[0072] Compounds of Examples 232 to 235 according to the present invention were prepared in a similar manner to Example 231 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 2 below.

[Table 2]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t. (min) Purity (%) (method)
231		4-(3-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )-N-(3-fluoropheneth yl)thiophen-2-carboxamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.06 (s, 1H), 7.82-7.78 (m, 3H), 7.71-7.68 (m, 1H), 7.34-7.29 (m, 2H), 7.24 (s, 1H), 7.04 (tr, J = 54.4 Hz, 1H), 6.85-6.79 (m, 1H), 6.25-6.20 (m, 1H), 5.78-5.75 (m, 1H), 4.09 (s, 3H), 3.98-3.91 (m, 6H), 3.68 (brs, 2H), 2.16-2.11 (m, 2H), 1.92 (brs, 2H); MS (ESI): m/z 579 [M+1] +	27	10.73 99 (b)
232		4-(3-((6-((1-acryloylpiper idin-4-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )-N-benzylthiophe n-2-carboxamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.59 (s, 1H), 8.05 (d, J = 1.2 Hz, 1H), 7.82-7.81 (m, 2H), 7.73-7.71 (m, 1H), 7.37-7.31 (m, 4H), 7.27-7.24 (m, 3H), 6.85-6.78 (m, 1H), 6.25-6.20 (m, 1H), 5.78-5.75 (m, 1H), 4.57 (m, 2H), 4.09 (s, 3H), 3.98-3.89 (m, 5H), 3.67 (brs, 2H), 2.11 (brs, 2H), 1.91 (brs, 2H); MS (ESI): m/z 650 [M+1] +	21	6.30 100 (a)
233		N-(6-(3-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )benzo[d]thia zol-2-yl)cyclopropa ncarboxamide	1H NMR (400 MHz, free base, Methanol-d4) δ 8.38 (s, 1H), 8.11 (s, 1H), 8.04 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.49 (s, 1H), 7.26-7.24 (m, 2H), 6.41-6.38 (m, 1H), 6.32-6.28 (m, 1H), 5.80 (d, J = 10.8 Hz, 1H), 5.51-5.48 (m, 1H), 4.62-4.60 (m, 2H), 4.46-4.44 (m, 1H), 4.18-4.12 (m, 1H), 4.05 (s, 3H), 3.95 (s, 3H), 3.62-3.60 (m, 1H), 1.05-1.03 (m, 2H), 0.97-0.90 (m, 2H); MS (ESI): m/z 623 [M+H]+	22	5.76 100 (a)
234		N-(7-(3-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )isothiazolo[ 4,3-b]pyridin-3-yl)cyclopropa ncarboxamide	1H NMR (400MHz, FA salt, DMSO-d6) δ 9.37 (s, 1H), 8.69 (d, J = 4.0 Hz, 1H), 8.41 (d, J = 2.0 Hz, 1H), 8.28 (s, 1H), 8.23-8.20 (m, 1H), 7.69 (d, J = 4.4 Hz, 1H), 7.56 (s, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.22 (s, 1H), 6.42-6.35 (m, 1H), 6.16-6.12 (m, 1H), 5.73-5.69 (m, 1H), 5.23-5.22 (m, 1H), 4.78-4.77 (m, 1H), 4.59-4.55 (m, 1H), 4.40-4.29 (m, 1H), 3.95 (s, 3H), 3.86 (s, 3H), 1.32-1.10 (m, 5H); MS (ESI): m/z 624 [M+1]+	31	5.17 100 (a)
235		N-(5-(3-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4-methoxyphenyl )pyridin-3-yl)-3-fluorobenzami de	1H NMR (400MHz, FA salt, Methanol-d4) δ 9.18-9.10 (s, 1H), 8.85 (s, 1H), 8.80-8.70 (m, 1H), 8.67 (s, 1H), 8.01-8.00 (s, 1H), 7.88-7.84 (m, 2H), 7.80-7.79 (m, 1H), 7.77-7.74 (m, 1H), 7.61-7.60 (m, 1H), 7.41-7.40 (m, 2H), 7.33 (s, 1H), 6.41-6.38 (m, 1H), 6.34-6.30 (m, 1H), 5.82-5.80 (m, 1H), 5.32-5.25 (m, 1H), 4.94-4.91 (m, 1H), 4.90-4.89 (m, 1H), 4.58-4.47 (m, 1H), 4.15-4.14 (m, 1H), 4.13 (s, 3H), 3.98 (s, 3H); MS (ESI): m/z 621 [M+1]+	22	4.76 99 (a)

Example 236. Preparation of (R)-N-(3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)-2-oxo-4-phenyloxazolidin-3-carboxamide

[0073] 

[Step-1] Preparation of tert-butyl 3-((4-((3'-amino-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-carboxylate

[0074] In 1,4-dioxane:distilled water = 5:1 (v/v) (0.1 M), tert-butyl 3-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-carboxylate (1.0 equiv.), (3-aminophenyl)boronic acid (3.0 equiv.), and K₃PO₄ (2.0 equiv.) were dissolved, then degassed with nitrogen, and stirred at 100 °C for 3 minutes under nitrogen. Then, Xphos Pd G2 (0.13 equiv.) was added at 100 °C, and the reaction mixture was stirred for 1 hour and then concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a pale yellow solid (yield: 630, MS (ESI): m/z 544 [M+1]⁺).

[Step-2] Preparation of tert-butyl 3-((7-methoxy-4-((4-methoxy-3'-(((4-nitrophenoxy)carbonyl)amino)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)azetidin-1-carboxylate

[0075] In DCM (0.1 M), tert-butyl 3-((4-((3'-amino-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-carboxylate (1.0 equiv.) obtained in Step-1 above was dissolved, and then pyridine (3.0 equiv.) was added. The reaction mixture was cooled to 0 °C, then 4-nitrophenylchloroformate (1.5 equiv.) was added and stirred at room temperature for 2 hours. The target compound obtained as a brown solid was used in the next reaction without further purification (yield: 100%, MS (ESI): m/z 709 [M+1]⁺).

[Step-3] Preparation of tert-butyl (R)-3-((7-methoxy-4-((4-methoxy-3'-(2-oxo-4-phenyloxazolidin-3-carboxamido)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)azetidin-1-carboxylate

[0076] In DMF (0.1 M), (R)-4-phenyloxazolidin-2-one (2.2 equiv.) was dissolved, then NaH (2.2 equiv.) was added, and the mixture was stirred at room temperature for 20 minutes. To tert-butyl 3-((7-methoxy-4-((4-methoxy-3'-(((4-nitrophenoxy)carbonyl)amino)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)azetidin-1-carboxylate obtained in Step-2 above, the reaction mixture was added and stirred at room temperature for 15 minutes. Organic materials were extracted from the reaction mixture with saturated NaHCO₃ and EA, and the collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a brown solid was used in the next reaction without further purification (yield: 100%, MS (ESI): m/z 733 [M+1]⁺).

[Step-4] Preparation of (R)-N-(3'-((6-(azetidin-3-yloxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)-2-oxo-4-phenyloxazolidin-3-carboxamide

[0077] In a solution of DCM:TFA (10:1 v/v) (0.1 M), tert-butyl (R)-3-((7-methoxy-4-((4-methoxy-3'-(2-oxo-4-phenyloxazolidin-3-carboxamido)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)azetidin-1-carboxylate (1.0 equiv.) obtained in Step-3 above was dissolved, and stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 38%, MS (ESI): m/z 633 [M+1]⁺).

[Step-5] Preparation of (R)-N-(3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)-2-oxo-4-phenyloxazolidin-3-carboxamide

[0078] In THF (0.1 M), (R)-N-(3'-((6-(azetidin-3-yloxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)-2-oxo-4-phenyloxazolidin-3-carboxamide (1.0 equiv.) obtained in Step-4 above was dissolved, and cooled to 0 °C. To the mixture, 1M NaHCO₃ solution (2.0 equiv.) was added, and acryloyl chloride (1.2 equiv.) was added and stirred at 0 °C for 30 minutes. Saturated NaHCO₃ aqueous solution was added to the reaction mixture, then organic materials were extracted with EA, and the collected organic layer was concentrated by removing remaining water using MgSO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 49%, MS (ESI): m/z 687 [M+1]⁺).

Preparation of Compound of Example 237

[0079] A compound of Example 237 according to the present invention was prepared in a similar manner to Example 236 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 3 below.

[Table 3]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
236		(R)-N-(3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-yl)-2-oxo-4-phenyloxazoli din-3-carboxamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 10.11 (s, 1H), 8.54 (d, J = 2.4 Hz, 1H), 7.77-7.64 (m, 4H), 7.42-7.23 (m, 10H), 6.38-6.28 (m, 2H), 5.81-5.78 (m, 1H), 5.56-5.53 (m, 1H), 5.25-5.24 (m, 1H), 4.63-4.59 (m, 1H), 4.44-4.42 (m, 1H), 4.30-4.26 (m, 1H), 4.13-4.10 (s, 4H), 3.89 (s, 3H); MS (ESI): m/z 687 [M+1]+	49	6.69 100 (a)
237		(S)-N-(3'-((6-((1-acryloylazeti din-3-yl)oxy)-7-methoxyquinaz olin-4-yl)amino)-4'-methoxy-[1,1'- biphenyl]-3-yl)-2-oxo-4-phenyloxazoli din-3-carboxamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 10.11 (s, 1H), 8.54 (d, J = 2.8 Hz, 1H), 7.77-7.64 (m, 4H), 7.42-7.23 (m, 10H), 6.42-6.28 (m, 2H), 5.81-5.78 (m, 1H), 5.57-5.53 (m, 1H), 5.25-5.24 (m, 1H), 4.63-4.59 (m, 1H), 4.44-4.42 (m, 1H), 4.30-4.27 (m, 1H), 4.14-4.10 (s, 4H), 3.89 (s, 3H); MS (ESI): m/z 687 [M+1] +	45	6.68 100 (a)

Example 238. Preparation of 1-(4-((7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one

[0080] 

[Step-1] Preparation of methyl 3,4-dihydroxybenzoate

[0081] 3,4-Dihydroxybenzoic acid (1.0 equiv.) and thionyl chloride (1.0 equiv.) were added to methanol (0.5 M). The mixture was heated at 70 °C for 2 hours and then concentrated. The residue was diluted with ethyl acetate, and the residue was washed with sat. NaHCO₃ solution and brine. The collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 98%).

[Step-2] Preparation of methyl 4-ethoxy-3-hydroxybenzoate

[0082] Methyl 3,4-dihydroxybenzoate (1.0 equiv.) obtained in Step-1 above and K₂CO₃ (1.0 equiv.) were added to DMF (0.2 M). The mixture was stirred at 0 °C for 20 minutes, and iodoethane (4.0 equiv.) was added dropwise. After the addition was completed, the mixture was stirred at 0 °C for an additional 12 hours. The desired product was confirmed through LC-MS. The mixture was passed through a celite filter and DMF was removed under reduced pressure. The residue was redissolved in ethyl acetate and washed with 1M HCl. The collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 37%, MS (ESI): m/z 197 [M+1]⁺).

[Step-3] Preparation of methyl 3-(benzyloxy)-4-ethoxybenzoate

[0083] Methyl 4-ethoxy-3-hydroxybenzoate obtained in Step-2 above, K₂CO₃ (1.5 equiv.) and benzyl bromide (1.1 equiv.) were added to DMF (0.2 M). The mixture was heated at 100 °C for 12 hours. The mixture was cooled to room temperature, water was added, and organic materials were extracted with ethyl acetate. The collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 91%, MS (ESI): m/z 287 [M+1]⁺).

[Step-4] Preparation of methyl 5-(benzyloxy)-4-ethoxy-2-nitrobenzoate

[0084] Methyl 3-(benzyloxy)-4-ethoxybenzoate (1.0 equiv.) obtained in Step-3 above was dissolved in a minimal amount of acetic acid. To this solution, concentrated nitric acid (2.9 equiv., 70%) was added. After stirring the mixture at 50 °C for 1 hour, ice water was poured to form a solid, and the resulting solid was washed with water and vacuum dried to obtain the target compound as a yellow solid (yield: 92%) .

[Step-5] Preparation of methyl 2-amino-4-ethoxy-5-hydroxybenzoate

[0085] Methyl 5-(benzyloxy)-4-ethoxy-2-nitrobenzoate (1.0 equiv.) obtained in Step-4 above was dissolved in methanol (0.1 M), and then Pd/C (10% purity, 0.05 equiv.) was added. The mixture was stirred at room temperature for 1 hour under hydrogen. The mixture was filtered through a celite filter, then washed with methanol, and the filtrate was concentrated. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 100%, MS (ESI) : m/z 212 [M+1]⁺).

[Step-6] Preparation of 7-ethoxyquinazolin-4,6-diol

[0086] Methyl 2-amino-4-ethoxy-5-hydroxybenzoate (1.0 equiv.) obtained in Step-5 above and formamidine acetate (2.0 equiv.) were dissolved in 2-methoxyethanol (0.1 M), and the mixture was stirred at 120 °C for 1 hour. The solvent was concentrated, washed with water, and dried. The target compound obtained as a light brown solid was used in the next reaction without further purification (yield: 77%, MS (ESI): m/z 207 [M+1]⁺).

[Step-7] Preparation of 7-ethoxy-4-hydroxyquinazolin-6-ylacetate

[0087] Pyridine (2.5 equiv.) was added to 7-ethoxyquinazolin-4,6-diol (1.0 equiv.) obtained in Step-6 above and acetic anhydride (1.1 equiv.), and the mixture was heated at 120 °C for 4 hours. Ice water was added to the reaction mixture, followed by filtration to obtain a solid, and the obtained solid was vacuum dried. The target compound obtained as a light brown solid was used in the next reaction without further purification (yield: 91%, MS (ESI): m/z 249 [M+1]⁺).

[Step-8] Preparation of 4-chloro-7-ethoxyquinazolin-6-ylacetate

[0088] 7-Ethoxy-4-hydroxyquinazolin-6-ylacetate (1.0 equiv.) obtained in Step-7 above and thionyl chloride (20.0 equiv.) were dissolved in DMF (0.3 M), and heated at 120 °C for 2 hours. Excess thionyl chloride was removed under reduced pressure, and the reaction mixture was purified using MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 47%, MS (ESI) : m/z 267 [M+1]⁺).

[Step-9] Preparation of 4-chloro-7-ethoxyquinazolin-6-ol

[0089] 4-Chloro-7-ethoxyquinazolin-6-ylacetate (1.0 equiv.) obtained in Step-8 above and ammonia solution (65 equiv., 28% in water) were dissolved in MeOH (0.1 M), and stirred at room temperature for 1 hour. The reaction mixture was concentrated, then ethyl ether was added to obtain a solid, and the obtained solid was filtered. The obtained solid was vacuum dried at 60 °C to obtain the target compound as a white solid (yield: 52%, MS (ESI): m/z 225 [M+1]⁺).

[Step-10] Preparation of tert-butyl 4-((4-chloro-7-ethoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate

[0090] 4-Chloro-7-ethoxyquinazolin-6-ol (1.0 equiv.) obtained in Step-9 above, tert-butyl 4-hydroxypiperidine-1-carboxylate (2.0 equiv.) and triphenylphosphine (1.5 equiv.) were dissolved in DCM (0.1 M). Then, DTBAD (1.5 equiv.) was added at 0 °C, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated and purified by MPLC to obtain the target compound as a white solid (yield: 73%, MS (ESI) : m/z 408 [M+1]⁺).

[Step-11] Preparation of tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-ethoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate

[0091] tert-Butyl 4-((4-chloro-7-ethoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-10 above and 5-bromo-2-methoxyaniline (1.2 equiv.) were dissolved in sec-BuOH (0.1 M), then 4M HCl (0.2 equiv.) dissolved in dioxane was added and stirred at 100 °C for 1 hour. Ethyl ether was added to the mixture to produce a solid, and the obtained solid was filtered and washed with ethyl ether. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 94%, MS (ESI) : m/z 574 [M+1]⁺).

[Step-12] Preparation of N-(5-bromo-2-methoxyphenyl)-7-ethoxy-6-(piperidin-4-yloxy)quinazolin-4-amine

[0092] tert-Butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-ethoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-11 above was dissolved in DCM (0.1 M), and then TFA (10 equiv.) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo, and purified using MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 94%, MS (ESI): m/z 474 [M+1]⁺).

[Step-13] Preparation of 7-ethoxy-N-(5-(furan-2-yl)-2-methoxyphenyl)-6-(piperidin-4-yloxy)quinazolin-4-amine

[0093] N-(5-Bromo-2-methoxyphenyl)-7-ethoxy-6-(piperidin-4-yloxy)quinazolin-4-amine (1.0 equiv.) obtained in Step-12 above, furan-2-ylboronic acid (2.2 equiv.) and K₃PO₄ (2.0 equiv.) were dissolved in dioxane (0.1 M) and water (0.5 M), then the mixture was degassed with nitro gas, Xphos Pd G2 (0.13 equiv.) was added at 80 °C, and the mixture was stirred at 90 °C for 20 minutes. The mixture was filtered through a celite filter, and the filtrate was concentrated to obtain the target compound as a brown solid, which was used in the next reaction without further purification (MS (ESI): m/z 461 [M+1]⁺).

[Step-14] Preparation of 1-(4-((7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one

[0094] 7-Ethoxy-N-(5-(furan-2-yl)-2-methoxyphenyl)-6-(piperidin-4-yloxy)quinazolin-4-amine (1.0 equiv.) obtained in Step-13 above and saturated NaHCO₃ aqueous solution (5.0 equiv.) were dissolved in THF (0.1 M), and then acryloyl chloride (1.0 equiv.) was added at 0 °C and stirred for 10 minutes. The reaction mixture was concentrated and purified using prep-HPLC to obtain the target compound as a yellow solid (yield: 22%, MS (ESI) : m/z 515 [M+1]⁺).

Preparation of Compound of Example 239

[0095] A compound of Example 239 according to the present invention was prepared in a similar manner to Example 238 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 4 below.

[Table 4]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
238		1-(4-((7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl ) amino) quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.60 (s, 1H), 8.09 (s, 1H), 7.84 (s, 3H), 7.77-7.75 (m, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.26 (s, 1H), 7.24 (s, 1H), 6.88-6.81 (m, 1H), 6.71 (d, J = 2.8 Hz, 1H), 6.53-6.52 (m, 1H), 6.27-6.22 (m, 1H), 5.81-5.77 (m, 1H), 4.36-4.31 (m, 2H), 3.95-3.93 (m, 2H), 3.90 (s, 3H), 3.74-3.72 (m, 2H), 2.19-2.11 (m, 2H), 2.02-1.98 (m, 2H), 1. 59-1. 55 (m, 3H); MS (ESI): m/z 515 [M+1]+	22	6.24 100 (a)
239		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-ethoxyquinazo lin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.60 (s, 1H), 8.07 (s, 1H), 7.70 (s, 1H), 7.69-7.54 (m, 2H), 7.32 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 7.10-7.07 (m, 1H), 6.88-6.81 (m, 2H), 6.27-6.22 (m, 1H), 5.80-5.77 (m, 1H), 5.01-5.00 (m, 1H), 4.36-4.31 (m, 2H), 4.00-3.95 (m, 4H), 3.79-3.77 (m, 2H), 2.12-2.10 (m, 2H), 1.99-1.97 (m, 2H), 1.56-1.55 (m, 5H); MS (ESI): m/z 561 [M+H]+	13	10.91 100 (b)

Preparation Example 2. Preparation of 2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)aniline

[0096] 

[Step-1] Preparation of 1-methylpyrrolidin-3-ylmethanesulfonate

[0097] In DCM (1.0 M), 1-methylpyrrolidin-3-ol (1.0 equiv.) was dissolved at 0 °C, then DIPEA (1.2 equiv.) and methylsulfonyl chloride (1.1 equiv.) were added. The reaction mixture was stirred at 0 °C for 1 hour and then stirred at room temperature for 16 hours. After confirming the reaction through TLC, water was added to the reaction mixture, and organic materials were extracted with DCM. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The target compound obtained as a brown solid was used in the next reaction without further purification (yield: 80%).

[Step-2] Preparation of 3-(4-bromo-2-nitrophenoxy)-1-methylpyrrolidine

[0098] In DMF (0.6 M), 1-methylpyrrolidin-3-ylmethanesulfonate (1.0 equiv.) obtained in Step-1 above, 4-bromo-2-nitrophenol (1.5 equiv.) and K₂CO₃ (2.0 equiv.) were dissolved, and stirred at 100 °C for 16 hours. Water was added to the reaction mixture, and organic materials were extracted with ethyl acetate. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The reaction mixture was purified by MPLC (hexane:EA) to obtain the target compound as a brown solid (yield: 80%, MS (ESI) : m/z 301 [M+1]⁺).

[Step-3] Preparation of 5-bromo-2-((1-methylpyrrolidin-3-yl)oxy)aniline

[0099] In THF (0.3 M), 3-(4-bromo-2-nitrophenoxy)-1-methylpyrrolidine (1.0 equiv.) obtained in Step-2 was dissolved at 0 °C, and then acetic acid (20 equiv.) and zinc (10 equiv.) were added. The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with methanol, filtered through a celite filter, and concentrated. The concentrate was neutralized by adding a saturated NaHCO₃ aqueous solution at 0 °C, and organic materials were then extracted with DCM. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 77%, MS (ESI): m/z 271 [M+1]⁺).

[Step-4] Preparation of 2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)aniline

[0100] In dioxane (0.1 M) and water (0.5 M), 5-bromo-2-((1-methylpyrrolidin-3-yl)oxy)aniline (1.0 equiv.) obtained in Step-3 above, 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolane (2.0 equiv.) and K₃PO₄ (2.0 equiv.) were dissolved. The reaction mixture was degassed using nitro gas, and Xphos Pd G2 (0.13 equiv.) was added to the mixture at 80 °C, followed by stirring at 100 °C for 1 hour. The mixture was filtered through a celite filter and the filtrate was concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a brown solid (yield: 64%, MS (ESI) : m/z 275 [M+1]⁺).

Example 240. Preparation of 1-(3-((7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one

[0101] 

[Step-1] Preparation of 7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-ol

[0102] In sec-BuOH (0.1 M), 2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)aniline (1.2 equiv.) obtained in Preparation Example 2 and 4-chloro-7-methoxyquinazolin-6-ol (1.0 equiv.) were dissolved, and 4M HCl (0.2 equiv.) dissolved in 1,4-dioxane was added, followed by stirring at 100 °C for 16 hours. Ethyl ether was added to the mixture, and the resulting solid was filtered and washed with ethyl ether to obtain the target compound as a yellow solid (yield: 84%, MS (ESI): m/z 449 [M+1]⁺).

[Step-2] Preparation of tert-butyl 3-((7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-carboxylate

[0103] In DMF (0.1 M), 7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-ol (1.0 equiv.) obtained in Step-1 above, tert-butyl 3-(tosyloxy)azetidin-1-carboxylate (1.2 equiv.), and K₂CO₃ (2.0 equiv.) were dissolved, and the mixture was stirred at 100 °C for 16 hours. The solution was cooled to room temperature, and organic materials were extracted by adding DCM and brine. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 33%, MS (ESI): m/z 604 [M+1]⁺).

[Step-3] Preparation of 6-(azetidin-3-yloxy)-7-methoxy-N-(2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)quinazolin-4-amine

[0104] In DCM (0.2 M), tert-butyl 3-((7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-carboxylate (1.0 equiv.) obtained in Step-2 above was dissolved, and TFA (50.0 equiv.) was then added and stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 92%, MS (ESI) : m/z 504 [M+1]⁺).

[Step-4] Preparation of 1-(3-((7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one

[0105] In THF (0.1 M), 6-(azetidin-3-yloxy)-7-methoxy-N-(2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)quinazolin-4-amine (1.0 equiv.) obtained in Step-3 above and saturated NaHCO₃ aqueous solution (5.0 equiv.) were dissolved, and then acryloyl chloride (1.0 equiv.) was added at 0 °C and stirred for 30 minutes. The reaction mixture was concentrated and purified using prep-HPLC to obtain the target compound as a yellow solid (yield: 30%, MS (ESI) : m/z 558 [M+1]⁺).

Preparation of Compounds of Examples 241 to 261

[0106] Compounds of Examples 241 to 271 according to the present invention were prepared in a similar manner to Example 240 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 5 below.

[Table 5]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
240		1-(3-((7-methoxy-4-((2-((1-methylpyrroli din-3-yl)oxy)-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetidin-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.68 (s, 1H), 7.73-7.71 (m, 3H), 7.41-7.38 (m, 2H), 7.33 (s, 1H), 7.24-7.22 (m, 1H), 7.12-7.10 (m, 1H), 6.42-6.38 (m, 1H), 6.34-6.29 (m, 1H), 5.83-5.80 (m, 1H), 5.32-5.30 (m, 2H), 4.87 (s, 3H), 4.70-4.61 (m, 1H), 4.58-4.48 (m, 1H), 4.15-4.14 (m, 4H), 4.13 (s, 3H), 3.38-3.32 (m, 2H), 2.96-2.88 (m, 2H); MS (ESI): m/z 558 [M+1]+	29	4.61 100 (a)
241		1-(3-((4-((5-(furan-2-yl)-2-((1-methylpyrroli din-3-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2en-1-one	MS (ESI): m/z 542 [M+1] +
242		1-(3-((4-((5-([1,2,4]triaz olo[1,5-a]pyridin-7-yl)-2-((1-methylpyrroli din-3-yl)oxy))pheny l)amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.87 (d, J = 7.2 Hz, 1H), 8.46 (s, 1H), 8.42 (s, 1H), 8.32 (s, 1H), 8.23 (s, 1H), 8.03 (s, 1H), 7.83-7.80 (m, 1H), 7.61-7.57 (m, 2H), 7.31-7.27 (m, 2H), 6.42-6.30 (m, 2H), 5.83-5.80 (m, 1H), 5.32-5.29 (m, 2H), 4.99-4.91 (m, 1H), 4.72-4.69 (m, 2H), 4.52-4.50 (m, 2H), 4.22-4.19 (m, 1H), 4.06 (s, 3H), 3.50-3.48 (m, 1H), 3.22-3.18 (m, 1H), 2.75 (s, 3H), 2.61-2.57 (m, 1H), 2.33-2.31 (m, 1H); MS (ESI) : m/z 593 [M+1]+	9	97*
243		1-(3-((4-((5-(furan-2-yl)-2-((tetrahydrof uran-3-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	MS (ESI): m/z 557 [M+1] +
244		1-(3-((4-((2-cyclopropoxy-5-(furan-2-yl)phenyl)ami no)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	MS (ESI): m/z 499 [M+1] +
245		1-(3-((4-((5-(furan-2-yl)-2-((1-methylazetidi n-3-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	MS (ESI): m/z 528 [M+1]+
246		1-(3-((4-((5-(furan-2-yl)-2-(oxetan-3-yloxy)phenyl) amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	MS (ESI): m/z 515 [M+1] +
247		1-(3-((4-((5-(furan-2-yl)-2-((1-methylpiperid in-4-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	MS (ESI): m/z 556 [M+1]+
248		1-(3-((7-methoxy-4-((2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.38 (s, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.55-7.53 (m, 1H), 7.41 (s, 1H), 7.34-7.31 (m, 2H), 7.24-7.13 (m, 2H), 7.09-7.06 (m, 1H), 6.42-6.31 (m, 2H), 5.79-5.76 (m, 1H), 5.23-5.18 (m, 1H), 4.82-4.81 (m, 1H), 4.66-4.52 (m, 2H), 4.44-4.41 (m, 1H), 4.18-4.12 (m, 1H), 3.72-3.68 (m, 2H), 3.53-3.48 (m, 2H), 2.00-1.97 (m, 2H), 1. 67-1. 64 (m, 1H); MS (ESI): m/z 559 [M+1] +	64	5.78 100 (a)
249		1-(3-((4-((5-(furan-2-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)azetid in-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.38 (s, 1H), 8.01 (s, 1H), 7.64-7.61 (m, 1H), 7.54 (s, 1H), 7.26 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 3.2 Hz, 1H), 6.52-6.51 (m, 1H), 6.41-6.32 (m, 1H), 6.31-6.28 (m, 1H), 5.81-5.78 (m, 1H), 5.28-5.26 (m, 1H), 4.86-4.84 (m, 1H), 4.78-4.75 (m, 1H), 4.74-4.69 (m, 1H), 4.45-4.40 (m, 1H), 4.26-4.21 (m, 1H), 4.06 (s, 3H), 3.71-3.69 (m, 2H), 3.54-3.50 (m, 2H), 2.01-1. 98 (m, 2H), 1.77-1.74 (m, 2H); MS (ESI): m/z 543 [M+1]+	45	5.68 100 (a)
250		1-(4-((7-methoxy-4-((2-((1-methylpyrroli din-3-yl)oxy)-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.43 (s, 1H), 8.22-8.21 (m, 1H), 7.93 (s, 1H), 7.50-7.48 (m, 1H), 7.35-7.33 (m, 1H), 7.24 (s, 1H), 7.10-7.04 (m, 2H), 6.88-6.81 (m, 1H), 6.26-6.22 (m, 1H), 5.80-5.76 (m, 1H), 4.04 (s, 3H), 4.00-3.92 (m, 2H), 3.76-3.68 (m, 2H), 3.61 (s, 3H), 3.00-2.98 (m, 2H), 2.43-2.40 (m, 1H), 2.14-1. 87 (m, 8H); MS (ESI): m/z 586 [M+1]+	22	4.87 100 (a)
251		1-(4-((4-((5-(furan-2-yl)-2-((1-methylpyrroli din-3-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 570 [M+1] +
252		1-(4-((4-((5-(furan-2-yl)-2-((tetrahydrof uran-3-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 557 [M+1] +
253		1-(4-((4-((2-cyclopropoxy-5-(furan-2-yl)phenyl)ami no)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.34 (s, 1H), 7.93 (d, J = 2 Hz ,1H), 7.76 (s, 1H), 7.63-7.60 (m, 1H), 7.51 (d, J = 1.6 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.19 (s, 1H), 6.84-6.77 (m, 1H), 6.65 (d, J = 3.6 Hz, 1H), 6.49-6.48 (m, 1H), 6.23-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.83-4.79 (m, 1H), 4.01 (s, 3H), 3.96-3.86 (m, 3H), 3.68-3.61 (m, 2H), 2.07-2.06 (m, 2H), 1. 90-1. 89 (m, 2H), 0.81-0.76 (m, 2H), 0.67-0.63 (m, 2H); MS (ESI): m/z=527 [M+1] +	31	6.54 100 (a)
254		1-(4-((4-((5-(furan-2-yl)-2-((1-methylazetidi n-3-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, free base, Methanol-d4) δ 8.46 (s, 1H), 7.65 (d, J = 5.2Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.11 (s, 1H), 6.85 (s, 1H), 6.77-6.70 (m, 2H), 6.50 (d, J = 3.2 Hz, 1H), 6.46-6.45 (m, 1H), 6.42-6.36 (m, 1H), 6.20 (s, 1H), 6.16 (s, 1H), 5.74 (d, J = 10.4 Hz, 1H), 4.71-4.70 (m, 1H), 4.65-4.63 (m, 1H), 4.32-4.30 (m, 1H), 3.91 (s, 3H), 3.82-3.79 (m, 3H), 3.62-3.61 (m, 1H), 3.50-3.44 (m, 3H), 3.22-3.20 (m, 2H), 1.93-1.92 (m, 2H), 1.82-1.80 (m, 2H); MS (ESI): m/z 556 [M+H] +	6	6.17 94 (a)
255		1-(4-((4-((5-(furan-2-yl) - 2- (oxetan-3-yloxy) phenyl) amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.67 (s, 1H), 8.07 (s, 1H), 7.87 (s, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.56 (s, 1H), 7.29 (s, 1H), 6.88-6.81 (m, 2H), 6.74 (d, J = 3.2 Hz, 1H), 6.54 (s, 1H), 6.27-6.23 (m, 1H), 5.81-5.78 (m, 1H), 5.43-5.40 (m, 1H), 5.04-5.00 (m, 2H), 4.60-4.58 (m, 2H), 4.12 (s, 3H), 3.97-3.95 (m, 2H), 3.69-3.67 (m, 2H), 3.37-3.35 (m, 1H), 2.14-2.12 (m, 2H), 1.95-1.93 (m, 2H); MS (ESI): m/z 543 [M+H]+	21	5.59 100 (a)
256		1-(4-((4-((5-(furan-2-yl)-2-((1-methylpiperid in-4-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=584 [M+1]+
257		1-(4-((7-methoxy-4-((2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(thiophen-2-yl)phenyl)ami no)quinazolin -6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.62 (s, 1H), 7.99 (s, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.67-7.64 (m, 1H), 7.36-7.32 (m, 2H), 7.27-7.25 (m, 2H), 7.09-7.07 (m, 1H), 6.85-6.78 (m, 1H), 6.24-6.19 (m, 1H), 5.78-5.75 (m, 1H), 4.73-4.67 (m, 1H), 4.09 (s, 3H), 3.97-3.91 (m, 2H), 3.75-3.66 (m, 4H), 3.59-3.47 (m, 2H), 2.15-2.10 (m, 2H), 2.02-1.91 (M, 4H), 1.65-1.57 (m, 2H); MS (ESI): m/z=587 [M+1]+	36	6.17 99 (a)
258		1-(4-((4-((5-(furan-2-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)phenyl )amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.65 (s, 1H), 8.07 (s, 1H), 7.85-7.84 (m, 1H), 7.75-7.73 (m, 1H), 7.55-7.54 (m, 1H), 7.30-7.28 (m, 2H), 6.83-6.80 (m, 1H), 6.72-6.71 (m, 1H), 6.54-6.53 (m, 1H), 6.27-6.22 (m, 1H), 5.81-5.77 (m, 1H), 4.80-4.71 (m, 1H), 4.11 (s, 3H), 4.02-3.97 (m, 2H), 3.74-3.1 (m, 5H), 3.56-3.54 (m, 3H), 2.22-1.88 (m, 7H); MS (ESI): m/z 571 [M+1]+	3	5.94 100 (a)
259		1-(4-((4-((5-(furan-2-yl)- 2-(2-methoxyethoxy )phenyl)amino )-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.43 (s, 1H), 8.26 (s, 1H), 7.82 (s, 1H), 7.59-7.54 (m, 2H), 7.24 (s, 1H), 7.20 (d, J = 8.4 Hz, 1H), 6.87-6.81 (m, 1H), 6.70 (d, J = 3.6 Hz, 1H), 6.53-6.51 (m, 1H), 6.26-6.21 (m, 1H), 5.79-5.76 (m, 1H), 5.01-5.00 (m, 1H), 4.28-4.25 (m, 2H), 4.04 (s, 3H), 3.97-3.95 (m, 2H), 3.72-3.70 (m, 4H), 3.32 (s, 3H), 2.12-2.09 (m, 2H), 1.99-1.97 (m, 2H); MS (ESI): m/z 545 [M+H]+	9	6.06 100 (a)
260		1-(4-((4-((4-cyclopropoxy-2',4'-difluoro-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, DMSO-d6) δ 9.11 (s, 1H), 8.29 (s, 1H), 7.87 (s, 1H), 7.68 (s, 1H), 7.63-7.56 (m, 1H), 7.50-7.42 (m, 2H), 7.38-7.32 (m, 1H), 7.21-7.16 (m, 2H), 6.88-6.82 (m, 1H), 6.14-6.09 (m, 1H), 5.70-5.67 (m, 1H), 4.80-4.76 (m, 1H), 3.97-3.93 (m, 7H), 2.04 (brs, 2H), 1.68 (brs, 2H), 0.79-0.74 (m, 2H), 0.60-0.56 (m, 2H); MS (ESI): m/z 573 [M+1]+	52	6.88 100 (a)
261		1-(4-((4-((2',4'-difluoro-4-((1-methylpyrroli din-3-yl)oxy)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.56 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.45-7.39 (m, 1H), 7.21 (S, 1H), 7.02-6.97 (m, 2H), 6.81-6.64 (m, 4H), 6.21 (d, J = 16.8 Hz, 1H), 5.74-5.72 (m, 1H), 4.52-4.51 (m ,1H), 4.29-4.28 (m, 1H), 4.18-4.11 (m, 4H), 3.86-3.85 (m, 2H), 3.71-3.67 (m, 5H), 2.39-2.35 (m, 3H), 2.06-2.05 (m, 3H), 1.87-1.85 (m, 3H); MS (ESI): m/z 616 [M+H]+	4	6.93, 98 (a)

Example 262. Preparation of 1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one

[0107] 

[Step-1] Preparation of 7-(2-methoxyethoxy)-6-nitroquinazolin-4(1H)-one

[0108] In anhydrous THF (1.5 M), 2-methoxyethanol (1.0 equiv.) was dissolved, and cooled to 0 °C under nitrogen, then NaH (0.68 equiv.) was added, and the mixture was stirred at room temperature for 1 hour. To the reaction mixture, 7-fluoro-6-nitroquinazolin-4(1H)-one (0.3 equiv.) was added and stirred at 75 °C for 12 hours. The reaction mixture was adjusted to pH 7 with a saturated NaHCO₃ aqueous solution, and organic materials were extracted with chloroform. The collected organic layer was concentrated by removing remaining water using MgSO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 54%, MS (ESI): m/z 266 [M+1]⁺).

[Step-2] Preparation of 4-chloro-7-(2-methoxyethoxy)-6-nitroquinazoline

[0109] To 7-(2-methoxyethoxy)-6-nitroquinazolin-4(1H)-one (1.0 equiv.) obtained in Step-1 above, SOCl₂ (0.4 M) and DMF (0.2 equiv.) were added and stirred at 120 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the target compound as a yellow solid, which was used in the next reaction without further purification (yield: 70%, MS (ESI): m/z 284 [M+1]⁺).

[Step-3] Preparation of N-(5-bromo-2-methoxyphenyl)-7-(2-methoxyethoxy)-6-nitroquinazolin-4-amine

[0110] In isopropyl alcohol (0.2 M), 4-chloro-7-(2-methoxyethoxy)-6-nitroquinazoline (1.0 equiv.) obtained in Step-2 above was dissolved, then 5-bromo-2-methoxyaniline (1.0 equiv.) was added and stirred at 60 °C for 2 hours. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a pale yellow solid (yield: 80%, MS (ESI): m/z 450 [M+1]⁺).

[Step-4] Preparation of N⁴-(5-bromo-2-methoxyphenyl)-7-(2-methoxyethoxy)quinazolin-4,6-diamine

[0111] In EA (0.2 M), N-(5-bromo-2-methoxyphenyl)-7-(2-methoxyethoxy)-6-nitroquinazolin-4-amine (1.0 equiv.) obtained in Step-3 above was dissolved, and tin(II) chloride dihydrate (5.0 equiv.) was added and stirred at 60 °C for 3 hours. The reaction mixture was cooled to room temperature, then aqueous ammonia was added thereto, and the mixture was concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 86%, MS (ESI): m/z 420 [M+1]⁺).

[Step-5] Preparation of tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)amino)piperidine-1-carboxylate

[0112] In AcOH (0.2 M), N⁴-(5-bromo-2-methoxyphenyl)-7-(2-methoxyethoxy)quinazolin-4,6-diamine (1.0 equiv.) obtained in Step-4 above was dissolved, and tert-butyl 4-oxopiperidine-1-carboxylate (2.0 equiv.) was added. The mixture was stirred at room temperature for 2 hours, then sodium triacetoxyborohydride (1.2 equiv.) was added, and the mixture was stirred at room temperature for 12 hours. Saturated NaHCO₃ aqueous solution was added to the reaction mixture, then organic materials were extracted with EA, and the collected organic layer was concentrated by removing remaining water using MgSO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a pale yellow solid (yield: 58%, MS (ESI): m/z 603 [M+1]⁺).

[Step-6] Preparation of N⁴-(5-bromo-2-methoxyphenyl)-7-(2-methoxyethoxy)-N⁶-(piperidin-4-yl)quinazolin-4,6-diamine

[0113] In DCM:TFA (10:1 v/v) (0.2 M), tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)amino)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-5 above was dissolved, and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and purified by MPLC (DCM:MeOH) to obtain the target compound as a pale yellow solid (yield: 99%, MS (ESI) : m/z 503 [M+1]⁺).

[Step-7] Preparation of N⁴-(5-(furan-2-yl)-2-methoxyphenyl)-7-(2-methoxyethoxy)-N⁶-(piperidin-4-yl)quinazolin-4,6-diamine

[0114] In 1,4-dioxane:distilled water = 5:1 (v/v) (0.2 M), N⁴-(5-bromo-2-methoxyphenyl)-7-(2-methoxyethoxy)-N⁶-(piperidin-4-yl)quinazolin-4,6-diamine (1.0 equiv.) obtained in Step-6 above, furan-2-yl boronic acid (2.2 equiv.), and K₃PO₄ (3.0 equiv.) were dissolved, and degassed with nitrogen. The reaction mixture was heated at 100 °C for 5 minutes under nitrogen, and Xphos Pd G2 (0.1 equiv.) was added and stirred for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 98%, MS (ESI): m/z 490 [M+1]⁺).

[Step-8] Preparation of 1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one

[0115] In THF (0.1 M), N⁴-(5-(furan-2-yl)-2-methoxyphenyl)-7-(2-methoxyethoxy)-N⁶-(piperidin-4-yl)quinazolin-4,6-diamine (1.0 equiv.) obtained in Step-7 above was dissolved, then cooled to 0 °C, and 1M NaHCO₃ aqueous solution (1.5 equiv.) and acryloyl chloride (1.0 equiv.) were added, followed by stirring at 0 °C for 30 minutes. The reaction mixture was concentrated and purified using prep-HPLC to obtain the target compound as a yellow solid (yield: 40%, MS (ESI): m/z 544 [M+1]⁺).

Preparation of Compounds of Examples 263 to 286

[0116] Compounds of Examples 263 to 286 were prepared in a similar manner to Example 262 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 6 below.

[Table 6]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
262		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-methoxyethoxy )quinazolin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.25 (s, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.62-7.60 (m, 1H), 7.51 (d, J = 1.2 Hz 1H), 7.25 (s, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.09 (s, 1H), 6.85-6.78 (m, 1H), 6.66 (d, J = 3.6 Hz, 1H), 6.49-6.48 (m, 1H), 6.23-6.18 (m, 1H), 5.77-5.74 (m, 1H), 4.58 (d, J = 13.2 Hz, 1H), 4.36-4.34 (m, 2H), 4.20 (d, J = 12.8 Hz, 1H), 3.89-3.82 (m, 4H), 3.47 (s, 3H), 3.36-3.34 (m, 1H), 3.02-3.01 (m, 1H), 2.23-2.21 (m, 2H), 1.55-1.50 (m, 2H); MS (ESI): m/z 544 [M+1]+	40	6.23 100 (a)
263		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-methoxyethoxy )quinazolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=545 [M+1]+
264		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-morpholinoeth oxy)quinazoli n-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=600 [M+1]+
265		1- (4-((7-(2-(dimethylamin o)ethoxy)-4-((5-(furan-2-yl)-2-methoxyphenyl )amino)quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=558 [M+1]+
266		1-(4-((7-(2-(2-(dimethylamin o)ethoxy)etho xy)-4-((5-(furan-2-yl)-2-methoxyphenyl )amino)quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=602 [M+1]+
267		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(3-methoxypropox y)quinazolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=559 [M+1]+
268		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(4-methoxybutoxy ) quinazolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z=573 [M+1]+
269		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(3-morpholinopro poxy)quinazol in-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.47 (s, 1H), 7.70-7.69 (m, 1H), 7.61-7.52 (m, 3H), 7.31 (d, J = 8.8 Hz, 1H), 7.19 (s, 1H), 7.10-7.05 (m, 2H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.80-5.77 (m, 1H), 4.71-4.70 (m, 1H), 4.43-4.40 (m, 2H), 4.23-4.22 (m, 1H), 4.15-4.14 (m, 2H), 3.93-3.81 (m, 5H), 3.51-3.49 (m, 2H), 3.47-3.46 (m, 2H), 3.37-3.35 (m, 2H), 3.21-3.20 (m, 2H), 3.01-3.00 (m, 1H), 2.46-2.45 (m, 2H), 2.21-2.18 (m, 2H), 1. 66-1. 64 (m, 2H); MS (ESI): m/z 659 [M+H]+	7	6.02, 100 (a)
270		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-((tetrahydrof uran-3-yl)oxy)quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.24 (s, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.63-7.60 (m, 1H), 7.53 (d, J = 2.4Hz, 1H), 7.26 (s, 1H), 7.18 (d, J = 8.8, 1H), 7.05 (s, 1H), 6.87-6.80 (m, 1H), 6.68 (d, J = 3.2 Hz, 1H), 6.51-6.50 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 5.29-5.25 (m, 1H), 4.12-4.05 (m, 4H), 3.94-3.91 (m, 5H), 3.12-3.11 (m, 1H), 2.52-2.50 (m, 1H), 2.28-2.27 (m, 3H), 1. 59-1. 57 (m, 2H), 1.32-1.30 (m, 2H); MS (ESI): m/z 556 [M+H]+	3	6.23, 100 (a)
271		N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-morpholinoeth oxy)quinazoli n-6-yl)acrylamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.21 (s, 1H), 8.67 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.75-7.73 (m, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.47 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 6.76-6.70 (m, 2H), 6.55-6.51 (m, 2H), 5.95-5.92 (m, 1H), 4.78 (t, J = 4.4 Hz, 2H), 4.00-3.85 (m, 10H), 3.52-3.49 (m, 4H) ; MS (ESI): m/z 516 [M+1]+	16	5.10 97 (a)
272		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-morpholinoeth oxy)quinazoli n-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.34 (s, 1H), 7.92 (d, J = 2.4 Hz, 1H), 7.67-7.64 (m, 1H), 7.51 (d, J = 1.6 Hz, 1H), 7.34 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.13 (s, 1H), 6.85-6.81 (m, 1H), 6.67-6.66 (m, 1H), 6.50-6.48 (m, 1H), 6.24-6.19 (m, 1H), 5.77-5.74 (m, 1H), 4.62 (d, J = 12.8 Hz, 1H), 4.43-4.40 (m, 2H), 4.23 (d, J = 14.4 Hz, 1H), 3.88-3.77 (m, 8H), 3.10-3.09 (m, 2H), 3.07-2.98 (m, 1H), 2.75-2.74 (m, 4H), 2.25-2.15 (m, 2H), 1.57-1.52 (m, 2H); MS (ESI): m/z 599 [M+1]+	16	5.32 93 (a)
273		N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(3-methoxypropox y)quinazolin-6-yl)acrylamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.06 (s, 1H), 8.52 (s, 1H), 8.29 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.54 (s, 1H), 7.26 (s, 1H), 7.19 (d, J = 8.4 Hz, 1H), 6.69-6.65 (m, 2H), 6.52-6.48 (m, 2H), 5.91-5.88 (m, 1H), 4.41-4.38 (m, 2H), 3.97 (s, 3H), 3.68-3.65 (m, 2H), 3.41 (s, 3H), 2.45-2.18	5	6.66, 100 (a)
			(m, 2H); MS (ESI): m/z 475 [M+H]+
274		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(3-methoxypropox y)quinazolin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.45 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.75-7.72 (m, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.44 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.13 (s, 1H), 6.87-6.81 (m, 1H), 6.71 (d, J = 2.4 Hz, 1H), 6.53-6.52 (m, 1H), 6.26-6.22 (m, 1H), 5.80-5.77 (m, 1H), 4.62-4.61 (m, 1H), 4.40-4.38 (m, 2H), 4.22-4.21 (m, 1H), 3.92-3.90 (m, 5H), 3.66-3.64 (m, 2H), 3.40 (s, 3H), 3.01-2.99 (m, 1H), 2.25-2.22 (m, 4H), 1.69-1.67 (m, 2H); MS (ESI): m/z 558 [M+H]+	25	6.46, 100 (a)
275		N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-methoxyethoxy )quinazolin-6-yl)acrylamide	1H NMR (400MHz, TFA salt, DMSO-d6) δ 11.15 (s, 1H), 9.83 (s, 1H), 9.15 (s, 1H), 8.73 (s, 1H), 7.75-7.69 (m, 3H), 7.36 (s, 1H), 7.27 (d, J = 8.8 Hz, 1H), 6.85 (d, J = 3.6 Hz, 1H), 6.58-6.57 (m, 1H), 6.37-6.32 (m, 1H), 5.90-5.87 (m, 1H), 4.44-4.42 (m, 2H), 3.85-3.82 (m, 5H), 3.33 (s, 3H); MS (ESI): m/z 461 [M+1]+	32	6.27 96 (a)
276		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(2-methoxyethoxy ) quinazolin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.25 (s, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.62-7.60 (m, 1H), 7.51 (d, J = 1.2 Hz 1H), 7.25 (s, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.09 (s, 1H), 6.85-6.78 (m, 1H), 6.66 (d, J = 3.6 Hz, 1H), 6.49-6.48 (m, 1H), 6.23-6.18 (m, 1H), 5.77-5.74 (m, 1H), 4.58 (d, J = 13.2 Hz, 1H), 4.36-4.34 (m, 2H), 4.20 (d, J = 12.8 Hz, 1H), 3.89-3.82 (m, 4H), 3.47 (s, 3H), 3.36-3.34 (m, 1H), 3.02-3.01 (m, 1H), 2.23-2.21 (m, 2H), 1.55-1.50 (m, 2H); MS (ESI): m/z 544 [M+1]+	40	6.23 100 (a)
277		N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(3-morpholinopro poxy)quinazol in-6-yl)acrylamide	1H NMR (400 MHz, free base, Methanol-d4) δ 8.96 (s, 1H), 8.44 (s, 1H), 8.43 (s, 1H), 7.53-7.51 (m, 2H), 7.19 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.66-6.64 (m, 2H), 6.52-6.46 (m, 2H), 5.89-5.86 (m, 1H), 4.29-4.27 (m, 2H), 3.97 (s, 3H), 3.75-3.72 (m, 4H), 2.63-2.54 (m, 6H), 2.15-2.13 (m, 2H); MS (ESI): m/z 530 [M+H]+	12	5.45, 98 (a)
278		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-(3-morpholinopro poxy)quinazol in-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.32 (s, 1H), 8.26 (s, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.67-7.65 (m, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.34 (s, 1H), 6.88-6.81 (m, 1H), 6.69 (d, J = 3.6 Hz, 1H), 6.52-6.51 (m, 1H), 6.26-6.22 (m, 1H), 5.80-5.76 (m, 1H), 4.62-4.61 (m, 1H), 4.36-4.33 (m, 2H), 4.22-4.21 (m, 1H), 3.90-3.80 (m, 9H), 3.12-3.11 (m, 1H), 2.92-2.83 (m, 6H), 2.26-2.23 (m, 4H), 1.76-1.74 (m, 2H); MS (ESI): m/z 616 [M+H]+	14	5.29, 100 (a)
279		(S)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-((tetrahydrof uran-3-yl)oxy)quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.48 (s, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.77-7.74 (m, 1H), 7.55 (s, 1H), 7.49 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.10 (s, 1H), 6.87-6.80 (m, 1H), 6.71 (d, J = 3.6 Hz, 1H), 6.53-6.52 (m, 1H), 6.26-6.21 (m, 1H), 5.80-5.77 (m, 1H), 5.33-5.30 (m, 1H), 4.62-4.61 (m, 1H), 4.31-4.12 (m, 4H), 4.02-3.94 (m, 5H), 3.01-3.00 (m, 1H), 2.52-2.51 (m, 1H), 2.33-2.31 (m, 3H), 1. 57-1. 55 (m, 2H); MS (ESI): m/z 556 [M+H]+	20	6.38 96 (a)
280		(R)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-((tetrahydrof uran-3-yl)oxy)quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ8.24 (s, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.62-7.60 (m, 1H), 7.53-7.52 (m, 1H), 7.25 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.05 (s, 1H), 6.87-6.80 (m, 1H), 6.68-6.67 (m, 1H), 6.51-6.50 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.75 (m, 1H), 5.27-5.26 (m, 1H), 4.60-4.59 (m, 1H), 4.07-4.05 (m, 4H), 3.91-3.88 (m, 5H), 3.34-3.33 (m, 1H), 3.02-3.01 (m, 1H), 2.50-2.49 (m, 1H), 2.25-2.21 (m, 3H), 1.52-1.51 (m, 2H); (ESI): m/z 556 [M+H]+	11	6.27 100 (a)
281		(R)-1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((tetrahydrof uran-3-yl)oxy)quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	1H NMR (400MHz, free base, Methanol-d4) δ 8.23 (s, 1H), 7.89 (s, 1H), 7.54-7.50 (m, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.25 (s, 1H), 7.20 (d, J = 8.8 Hz, 1H), 7.05-7.01 (m, 3H), 6.85-6.78 (m, 1H), 6.24-6.20 (m, 1H), 5.77-5.75 (m, 1H), 5.23-5.22 (m, 1H), 4.59 (d, J = 12.5 Hz, 1H), 4.19-4.01 (m, 4H), 3.94-3.83 (m, 5H), 3.03 (t, J = 12.0 Hz, 1H), 2.44-2.38 (m, 1H), 2.36-2.22 (m, 3H), 1.61-1.48 (m, 3H); MS (ESI): m/z 603 [M+1]+	50	6.78 100 (a)
282		(R)-1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'- biphenyl]-3-yl)amino)-7-((tetrahydrof uran-3-yl)oxy)quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.23 (s, 1H), 7.88 (s, 1H), 7.57-7.53 (m, 1H), 7.47-7.45 (m, 1H), 7.29 (s, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.08-7.03 (m, 3H), 6.87-6.80 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 5.27-5.25 (m, 1H), 4.61-4.59 (m, 1H), 4.11-4.03 (m, 4H), 3.93-3.87 (m, 5H), 3.09-3.01 (m, 1H), 2.51-2.49 (m, 1H), 2.27-2.24 (m, 3H), 1.55-1.52 (m, 2H); MS (ESI): m/z 602 [M+H]+	15	6.92 100 (a)
283		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((1-methylpyrroli din-3-yl)oxy)quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 616 [M+H]+
284		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((1-(2-methoxyethyl) pyrrolidin-3-yl)oxy)quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 660 [M+H]+
285		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((1-(oxetan-3-yl)pyrrolidin -3-yl)oxy)quinaz olin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 658 [M+H]+
286		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((tetrahydrof uran-3-yl)oxy)quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400MHz, TFA salt, Methanol-d4) δ 8.45 (s, 1H), 7.67 (s, 1H), 7.58-7.47 (m, 3H), 7.29 (d, J = 8.8 Hz, 1H), 7.09-7.03 (m, 3H), 6.85-6.78 (m, 1H), 6.23-6.19 (m, 1H), 5.77-5.74 (m, 1H), 5.30-5.27 (m, 1H), 4.62 (d, J = 13.6 Hz, 1H), 4.23-4.03 (m, 4H), 4.02-3.85 (m, 5H), 3.00 (t, J = 12.4 Hz, 1H), 2.46-2.41 (m, 1H), 2.28-2.19 (m, 3H), 1. 60-1. 54 (m, 2H); MS (ESI): m/z 602 [M+1]+	15	6.88 100 (a)

Example 287. Preparation of N-(4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)acrylamide

[0117] 

[Step-1] Preparation of 7-methoxy-6-nitroquinazolin-4 (3H) -one

[0118] In MeOH (0.2 M), 7-fluoro-6-nitroquinazolin-4(3H)-one (1.0 equiv.) and sodium methoxide (2.0 equiv.) were dissolved, and the mixture was stirred at 70 °C for 2 hours. To the mixture, 1N HCl was added to obtain a solid, and the obtained solid was filtered. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 78%, MS (ESI): m/z 222 [M+1]⁺).

[Step-2] Preparation of 4-chloro-7-methoxy-6-nitroquinazoline

[0119] To 7-methoxy-6-nitroquinazolin-4(3H)-one (1.0 equiv.) obtained in Step-1 above, thionyl chloride (30.0 equiv.) and DMF (1 drop) were added under nitrogen. The mixture was stirred at 100 °C for 4 hours and then concentrated. The target compound obtained as a transparent oil was used in the next reaction without further purification (yield: 92%, MS (ESI): m/z 240 [M+1]⁺).

[Step-3] Preparation of N-(5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)-7-methoxy-6-nitroquinazolin-4-amine

[0120] In sec-BuOH (0.1 M), 4-chloro-7-methoxy-6-nitroquinazoline (3.0 equiv.) obtained in Step-2 above and 5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyaniline (1.0 equiv.) were dissolved, and 4M HCl (0.2 equiv.) dissolved in 1,4-dioxane was added and stirred at 80 °C for 2 hours. Ethyl ether was added to the reaction mixture to form a solid, and the formed solid was filtered and washed with ethyl ether. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 39%, MS (ESI): m/z 444 [M+1]⁺).

[Step-4] Preparation of N⁴-(5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)-7-methoxyquinazolin-4,6-diamine

[0121] In ethyl acetate (0.1 M), N-(5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)-7-methoxy-6-nitroquinazolin-4-amine (1.0 equiv.) obtained in Step-3 above and tin(II) chloride dihydrate (5.0 equiv.) were dissolved, and the mixture was stirred at 55 °C for 1 hour. The desired product was confirmed through LC-MS. The mixture was filtered through a celite filter and concentrated to obtain the target compound as a white solid, which was used in the next reaction without further purification (MS (ESI): m/z 414 [M+1]⁺).

[Step-5] Preparation of N-(4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)acrylamide

[0122] In DMF (0.1 M), N⁴-(5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)-7-methoxyquinazolin-4,6-diamine (1.0 equiv.) obtained in Step-4 above and DIPEA (2.5 equiv.) were dissolved, and then acryloyl chloride (1.0 equiv.) was added at 0 °C and stirred at 0 °C for 20 minutes. The reaction mixture was concentrated in vacuo and purified using prep-HPLC to obtain the target compound as a white solid (yield: 15%, MS (ESI) : m/z 468 [M+1]⁺).

Preparation of Compounds of Examples 288 to 296

[0123] Compounds of Examples 288 to 296 according to the present invention were prepared in a similar manner to Example 287 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 7 below.

[Table 7]

Exa mple No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t. (min ) Purity(% ) (method)
287		N-(4-((5-([1,2,4]triaz olo[1,5-a]pyridin-7-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)acrylamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.10 (s, 1H), 8.85 (d, J = 7.2 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.54 (s, 1H), 8.44 (s, 1H), 8.02 (d, J = 1.2 Hz, 1H), 7.74-7.71 (m, 1H), 7.62-7.60 (m, 1H), 7.33-7.30 (m, 2H), 6.76-6.89 (m, 1H), 6.52-6.48 (m, 1H), 5.90-5.87 (m, 1H), 4.13 (s, 3H), 4.06 (s, 3H); MS (ESI): m/z 468 [M+1]+	15	4.42 100 (a)
288		N-(4-((5-(benzofuran-5-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)acrylamide	1H NMR (400MHz, TFA salt, DMSO-d6) δ 9.76 (s, 1H), 9.22 (s, 1H), 8.94 (s, 1H), 8.40 (s, 1H), 8.02 (d, J = 2.4 Hz, 2H), 7.89 (d, J = 1.6 Hz, 1H), 7.67-7.52 (m, 5H), 7.27 (s, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.00-6.99 (m, 1H), 6.80-6.73 (m, 1H), 6.34-6.30 (m, 1H), 5.82-5.78 (m, 1H), 4.02 (s, 3H), 3.85 (s, 3H); MS (ESI): m/z 467 [M+1]+	11	6.83 100 (a)
289		N- (4- ((5-(furan-2-yl)-2-methoxyphenyl ) amino) -7-methoxyquinaz olin-6-yl)acrylamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.28 (s, 1H), 8.66 (s, 1H), 7.97-7.95 (m, 1H), 7.75-7.72 (m, 1H), 7.55-7.54 (m, 1H), 7.31 (s, 1H), 7.24 (d, J = 8.8 Hz, 1H), 6.76-6.69 (m, 2H), 6.54-6.49 (m, 2H), 5.92-5.89 (m, 1H), 4.19 (s, 3H), 3.93 (s, 3H); MS (ESI): m/z 417 [M+1]+	43	6.16 97 (a)
290		N-(7-methoxy-4-((2-methoxy-5-(2-methylfuran-3-yl)phenyl)ami no)quinazolin -6-yl)acrylamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.27 (s, 1H), 8.63 (s, 1H), 7.68 (d J = 2 Hz, 1H), 7.46-7.43 (m, 1H), 7.39 (d, J = 2 Hz, 1H), 7.29 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.73-6.66 (m, 1H), 6.56-6.47 (m, 2H), 5.90-5.87 (m, 1H), 4.17 (s, 3H), 3.91 (s, 3H), 2.44 (s, 3H); MS (ESI): m/z 431 [M+1]+	6	97*
291		N-(3-cyano-7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl ) amino) quinol in-6-yl)acrylamide	1H NMR (400MHz, TFA salt, CDCl3) δ 9.40 (s, 1H), 8.62 (s, 1H), 8.57 (s, 1H), 8.25 (s, 1H), 8.03 (s, 1H), 7.77-7.74 (m, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.07-7.05 (m, 1H), 7.44 (d, J = 2.0 Hz, 1H), 7.07-7.05 (m, 1H), 6.59-6.48 (m, 2H), 6.47-6.38 (m, 1H), 5.95-5.93 (m, 1H), 4.46-4.44 (m, 2H), 3.87 (s, 3H), 1.60 (t, J = 6.8, 7.2 Hz, 3H); MS (ESI): m/z 455 [M+1]+	7	7.27 100 (a)
292		N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(4,4-difluoropiper idin-1-yl)quinazolin -6-yl)acrylamide	1H NMR (400MHz, TFA salt, CDCl-d3) δ 9.16 (s, 1H), 8.87-8.86 (m, 1H), 8.73-8.35 (m, 2H), 7.66 (s, 1H), 7.51-7.45 (m, 1H), 7.28-7.25 (m, 1H), 7.04 (d, J = 8.8 Hz, 1H), 6.99-6.89 (m, 2H), 6.53-6.48 (m, 1H), 6.39-6.32 (m, 1H), 5.92-5.89 (m, 1H), 4.06 (s, 3H), 3.16 (t, J = 5.6 Hz, 4H), 2.29-2.17 (m, 4H); MS (ESI): m/z 552 [M+1]+	56	11.97 100 (b)
293		N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(4-morpholinopip eridin-1-yl)quinazolin -6-yl)acrylamide	MS (ESI): m/z 601 [M+1]+
294		N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(2-oxa-6-azaspiro[3.3] heptan-6-yl)quinazolin -6-yl)acrylamide	MS (ESI): m/z 530 [M+1]+
295		N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(3,3-difluoroazeti din-1-yl)quinazolin -6-yl)acrylamide	1H NMR (400 MHz, TFA salt, DMSO-d6) δ 9.82 (s, 1H), 9.28 (s, 1H), 8.34 (s, 1H), 8.31 (s, 1H), 7.70 (s, 1H), 7.61-7.53 (m, 1H), 7.42-7.30 (m, 2H), 7.23-7.13 (m, 2H), 6.82 (s, 1H), 6.54 (dd, J = 17.2, 10.0 Hz, 1H), 6.31 (d, J = 17.2 Hz, 1H), 5.82 (d, J = 10.4 Hz, 1H), 4.43 (t, J = 12.4 Hz, 4H), 3.83 (s, 3H); MS (ESI): m/z 523 [M]+	17	10.93 99 (b)
296		(E)-N-(4-((2' ,4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-4-methoxybut-2-enamide	MS (ESI): m/z 507 [M]+

Example 297. Preparation of 1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one

[0124] 

[Step-1] Preparation of N-(5-bromo-2-methoxyphenyl)-7-fluoro-6-nitroquinazolin-4-amine

[0125] In isopropyl alcohol (0.2 M), 4-chloro-7-fluoro-6-nitroquinazoline (1.0 equiv.) and 5-bromo-2-methoxyaniline (1.0 equiv.) were dissolved, and stirred at 50 °C for 10 minutes. Ethyl ether was added to produce a solid compound, and the resulting solid was filtered to obtain the target compound as a yellow solid (yield: 72%, MS (ESI): m/z 393 [M+1]⁺).

[Step-2] Preparation of 4-((5-bromo-2-methoxyphenyl)amino)-6-nitroquinazolin-7-ol

[0126] In 1,4-dioxane, N-(5-bromo-2-methoxyphenyl)-7-fluoro-6-nitroquinazolin-4-amine (1.0 equiv.) obtained in Step-1 above was dissolved, then 50% NaOH aqueous solution (12.5 equiv.) was added and stirred at 110 °C for 4 hours. The mixture was acidified by adding 10% sulfuric acid aqueous solution, and organic materials were extracted with EA. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The target compound obtained as a yellow solid was used in the next reaction without further purification (yield: 74%, MS (ESI): m/z 391 [M+1]⁺).

[Step-3] Preparation of N-(5-bromo-2-methoxyphenyl)-7-(difluoromethoxy)-6-nitroquinazolin-4-amine

[0127] In ACN:H₂O (5:1), 4-((5-bromo-2-methoxyphenyl)amino)-6-nitroquinazolin-7-ol (1.0 equiv.) obtained in Step-2 above, 2-chloro-2,2-difluoro-1-phenylethan-1-one (2.0 equiv.) and K₂CO₃ (2.0 equiv.) were dissolved, and the mixture was stirred at 80 °C for 16 hours. Water was added thereto, and organic materials were extracted with EA. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 37%, MS (ESI) : m/z 441 [M+1]⁺).

[Step-4] Preparation of N⁴-(5-bromo-2-methoxyphenyl)-7-(difluoromethoxy)quinazolin-4,6-diamine

[0128] In ethyl acetate (0.1 M), N-(5-bromo-2-methoxyphenyl)-7-(difluoromethoxy)-6-nitroquinazolin-4-amine (1.0 equiv.) obtained in Step-3 above and tin(II) chloride dihydrate (5.0 equiv.) were dissolved, and the mixture was stirred at 60 °C for 2 hours. An aqueous solution of ammonia was added to the reaction mixture and concentrated, then the concentrate was purified using MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 49%, MS (ESI): m/z 411 [M+1]⁺).

[Step-5] Preparation of tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidine-1-carboxylate

[0129] In acetic acid (0.1 M), N⁴-(5-bromo-2-methoxyphenyl)-7-(difluoromethoxy)quinazolin-4,6-diamine (1.0 equiv.) obtained in Step-4 above and tert-butyl 4-oxopiperidine-1-carboxylate (3.0 equiv.) were dissolved, and stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (3.0 equiv.) was added and the mixture was stirred at room temperature for 16 hours. To the mixture, 2M NaOH aqueous solution was added and organic materials were extracted with DCM. The collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a yellow solid was used in the next reaction without further purification (yield: 100%, MS (ESI): m/z 594 [M+1]⁺).

[Step-6] Preparation of N⁴-(5-bromo-2-methoxyphenyl)-7-(difluoromethoxy)-N⁶-(piperidin-4-yl)quinazolin-4,6-diamine

[0130] In DCM, tert-butyl 4-((4-((5-bromo-2-methoxyphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidine-1-carboxylate (1.0 equiv.) obtained in Step-5 above was dissolved, then TFA (50.0 equiv.) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 97%, MS (ESI) : m/z 494 [M+1]⁺).

[Step-7] Preparation of 1-(4-((4-((5-bromo-2-methoxyphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one

[0131] In THF, N⁴-(5-bromo-2-methoxyphenyl)-7-(difluoromethoxy)-N⁶-(piperidin-4-yl)quinazolin-4,6-diamine (1.0 equiv.) obtained in Step-6 above and saturated NaHCO₃ aqueous solution (5.0 equiv.) were dissolved, and then acryloyl chloride (1.0 equiv.) was added at 0 °C and stirred for 10 minutes. The reaction mixture was concentrated to obtain the target compound as a brown solid, which was used in the next reaction without further purification (yield: 100%, MS (ESI): m/z 548 [M+1]⁺).

[Step-8] Preparation of 1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one

[0132] In 1,4-dioxane:water (5:1), 1-(4-((4-((5-bromo-2-methoxyphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one (1.0 equiv.) obtained in Step-7 above, (2,4-difluorophenyl)boronic acid (2.2 equiv.), and K₃PO₄ (2.0 equiv.) were dissolved. The reaction mixture was degassed using nitro gas, and Xphos Pd G2 (0.1 equiv.) was added at 100 °C, followed by stirring at 100 °C for 10 minutes. The mixture was filtered through a celite filter and the filtrate was concentrated. The reaction mixture was purified by prep-HPLC to obtain the target compound as a yellow solid (yield: 7%, MS (ESI): m/z 582 [M+1]⁺).

Preparation of Compounds of Examples 298 to 303

[0133] Compounds of Examples 298 to 303 according to the present invention were prepared in a similar manner to Example 297 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 8 below.

[Table 8]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
297		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(difluorometh oxy)quinazoli n-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.24 (s, 1H), 7.85-7.84 (m, 1H), 7.59-7.47 (m, 3H), 7.44 (d, J = 19.2 Hz, 1H), 7.29-7.23 (m, 1H), 7.11-7.03 (m, 2H), 6.93-6.80 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 4.63-4.59 (m, 1H), 4.23-4.20 (m, 1H), 3.93-3.87 (m, 4H), 3.37-3.36 (m, 1H), 3.05-2.98 (m, 1H), 2.26-2.23 (m, 2H), 1.60-1.55 (m, 2H); MS (ESI): m/z 581 [M+H]+	7	10.97 99 (b)
298		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.24 (s, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.62-7.59 (m, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.22 (s, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.09 (s, 1H), 6.87-6.80 (m, 1H), 6.68 (d, J = 3.6 Hz, 1H), 6.51-6.50 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.75 (m, 1H), 4.22-4.21 (m, 1H), 4.05 (s, 3H), 3.91 (s, 3H), 3.59-3.58 (m, 1H), 3.09-3.07 (m, 1H), 2.25-2.18 (m, 2H), 1.53-1.50 (m, 2H), 1.31-1.29 (m, 2H); MS (ESI): m/z 500 [M+H]+	3	6.14, 98 (a)
299		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.22 (s, 1H), 7.89 (s, 1H), 7.58-7.54 (m, 1H), 7.47-7.44 (m, 1H), 7.25-7.22 (m, 2H), 7.09-7.03 (m, 3H), 6.87-6.80 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 4.60-4.59 (m, 1H), 4.07-4.06 (m, 1H), 4.05 (s, 3H), 3.94 (s, 3H), 3.88-3.87 (m, 1H), 3.37-3.35 (m, 1H), 3.02-3.01 (m, 1H), 2.25-2.22 (m, 2H), 1. 51-1. 50 (m, 2H); MS (ESI): m/z 546 [M+H]+	19	6.79, 100 (a)
300		1-(4-((7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl )amino) quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.47 (s, 1H), 7.84 (s, 1H), 7.76-7.73 (m, 1H), 7.54 (s, 1H), 7.47 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.11 (s, 1H), 6.87-6.80 (m, 1H), 6.71-6.70 (m, 1H), 6.53-6.52 (m, 1H), 6.23-6.21 (m, 1H), 5.80-5.76 (m, 1H), 4.99-4.98 (m, 1H), 4.67-4.66 (m, 1H), 4.40-4.35 (m, 2H), 4.12-4.11 (m, 1H), 3.99-3.97 (m, 4H), 3.01-2.99 (m, 1H), 2.29-2.27 (m, 2H), 1. 61-1. 57 (m, 5H); MS (ESI): m/z 514 [M+H]+	68	10.45 99 (b)
301		1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl] -3-yl)amino)-7-ethoxyquinazo lin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.46 (s, 1H), 7.70 (s, 1H), 7.60-7.54 (m, 2H), 7.48 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.10-7.05 (m, 3H), 6.87-6.80 (m, 1H), 6.26-6.21 (m, 1H), 5.80-5.77 (m, 1H), 4.72-4.71 (m, 1H), 4.38-4.35 (m, 2H), 4.23-4.21 (m, 1H), 3.93-3.90 (m, 4H), 3.36-3.35 (m, 1H), 3.11-3.10 (m, 1H), 2.21-2.19 (m, 2H), 1.60-1.56 (m, 5H); MS (ESI): m/z 560 [M+H]+	53	11.24 100 (b)
302		1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl )amino) -7-(methylamino) quinazolin-6-yl)oxy)piperi din-1-yl)prop-2-en-1-one	MS (ESI): m/z 500 [M+1]+
303		1-(4-((5-chloro-4-((5-(furan-2-yl)-2-methoxyphenyl )amino)quinaz olin-6-yl)amino)pipe ridin-1-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.99 (d, J = 2.1 Hz, 1H), 8.57 (s, 1H), 7.66 (s, 2H), 7.54 (d, J = 1.2 Hz, 1H), 7.51 (dd, J = 8.5, 2.1 Hz, 1H), 7.13 (d, J = 8.6 Hz, 1H), 6.82 (dd, J = 16.8, 10.7 Hz, 1H), 6.67 (d, J = 2.8 Hz, 1H), 6.52 (dd, J = 3.3, 1.8 Hz, 1H), 6.22 (dd, J = 16.8, 2.0 Hz, 1H), 5.77 (dd, J = 10.7, 2.0 Hz , 1H), 4.59 (d, J = 13.0 Hz, 1H), 4.18 (d, J = 13.6 Hz, 1H), 3.92-3.83 (m, 1H), 3.35-3.33 (m, 1H), 2.98 (t, J = 11.9 Hz, 1H), 2.16-2.08 (m, 2H), 1. 65-1. 55 (m, 3H); MS (ESI): m/z 503 [M] +	16	11.10 86 (b)

Example 304. Preparation of (R,E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide

[0134] 

[Step-1] Preparation of N-(5-bromo-2-methoxyphenyl)-7-methoxy-6-nitroquinazolin-4-amine

[0135] In sec-BuOH (0.2 M), 4-chloro-7-methoxy-6-nitroquinazoline (1.0 equiv.) and 5-bromo-2-methoxyaniline (1.0 equiv.) were dissolved, and then 4M HCl (0.2 equiv.) dissolved in 1,4-dioxane was added and stirred at 90 °C for 2 hours. Ethyl ether was added to the reaction mixture, and the resulting solid was filtered and washed with ethyl ether to obtain the target compound as a yellow solid (yield: 99%, MS (ESI) : m/z 406 [M+1]⁺).

[Step-2] Preparation of N⁴-(5-bromo-2-methoxyphenyl)-7-methoxyquinazolin-4,6-diamine

[0136] In ethyl acetate (0.1 M), N-(5-bromo-2-methoxyphenyl)-7-methoxy-6-nitroquinazolin-4-amine (1.0 equiv.) obtained in Step 1 above and tin(II) chloride dihydrate (5.0 equiv.) were dissolved, and the mixture was stirred at 60 °C for 1 hour. The mixture was filtered through a celite filter, and the target compound as a brown solid obtained after concentrating the filtrate was used in the next reaction without further purification (MS (ESI): m/z 376 [M+1]⁺).

[Step-3] Preparation of diethyl (2-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate

[0137] In DMF (0.5 M), 2-(diethoxyphosphoryl)-2-fluoroacetic acid (2.0 equiv.) was dissolved, and then HATU (3.0 equiv.) was added and stirred at 50 °C for 1 hour. To the reaction mixture, N⁴-(5-bromo-2-methoxyphenyl)-7-methoxyquinazolin-4,6-diamine (1.0 equiv.) obtained in Step 2 above and DIPEA (3.0 equiv.) were added and stirred at 50 °C for 1 hour. The solid obtained by adding ice water was filtered and washed with distilled water to obtain the target compound as a yellow solid (yield: 30%, MS (ESI): m/z 572 [M+1]⁺).

[Step-4] Preparation of tert-butyl (R,E)-2-(3-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate

[0138] To diethyl (2-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (1.0 equiv.) obtained in Step-3 above, NaOH (8.0 equiv.) dissolved in ethanol (0.02 M) and distilled water (0.2 M) were added and stirred for 30 minutes. To the reaction mixture, tert-butyl (R)-2-formylpyrrolidine-1-carboxylate (2.0 equiv.) was added at 0 °C and stirred at room temperature for 30 minutes. Water was added to the reaction mixture, and organic materials were extracted with EA. The collected organic layer was concentrated by removing remaining water using Na₂SO₄. The target compound obtained as a yellow solid was used in the next reaction without further purification (yield: 91%, MS (ESI): m/z 616 [M+1]⁺).

[Step-5] Preparation of (R,E)-N-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide

[0139] In DCM (0.1 M), tert-butyl (R,E)-2-(3-((4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate (1.0 equiv.) obtained in Step 4 above was dissolved, and TFA (10.0 equiv.) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 97%, MS (ESI) : m/z 516 [M+1]⁺).

[Step-6] Preparation of (R,E)-N-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide

[0140] In DCE (0.1 M), (R,E)-N-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide (1.0 equiv.) obtained in Step 5 above was dissolved, and 37% formaldehyde (5.0 equiv.) dissolved in distilled water was added and stirred at room temperature for 1 hour. Then, NaBH(OAc)₃ (7.0 equiv.) was added and the mixture was stirred at 80 °C for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 56%, MS (ESI) : m/z 530 [M+1]⁺).

[Step-7] Preparation of (R,E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide

[0141] In 1,4-dioxane (0.1 M) and water (0.5 M), (R,E)-N-(4-((5-Bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide (1.0 equiv.) obtained in Step 6 above, (2,4-difluorophenyl)boronic acid (2.2 equiv.), and K₃PO₄ (2.0 equiv.) were dissolved. The reaction mixture was degassed using nitro gas, and Xphos Pd G2 (0.13 equiv.) was added at 80 °C, followed by stirring at 90 °C for 10 minutes. The reaction mixture was concentrated and purified by prep-HPLC to obtain the target compound as a pale yellow solid (yield: 22%, MS (ESI) : m/z 564 [M+1]⁺).

Preparation of Compounds of Examples 305 to 313

[0142] Compounds of Examples 305 to 313 were prepared in a similar manner to Example 304 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 9 below.

[Table 9]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t.(min ) Purity(% ) (method)
304		(R,E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2-fluoro-3-(1-methylpyrroli din-2-yl)acrylamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.19 (s, 1H), 8.67 (s, 1H), 7.77 (s, 1H), 7.61-7.52 (m, 2H), 7.36 (s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.11-7.06 (m, 2H), 6.42-6.32 (m, 1H), 4.52-4.50 (m, 1H), 4.20 (s, 3H), 3.94 (s, 3H), 3.83-3.82 (m, 1H), 3.51-3.50 (m, 1H), 3.15 (s, 3H), 2.09-2.01 (m, 4H); MS (ESI): m/z 564 [M+H]+	26	8.84 100 (b)
305		(R,E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-3-(1-methylpyrroli din-2-yl)acrylamide	1H NMR (400 MHz, HCl salt, Methanol-d4) δ 9.02 (s, 1H), 8.41 (s, 1H), 8.23 (s, 1H), 7.59-7.49 (m, 1H), 7.40-7.34 (m, 1H), 7.21 (s, 1H), 7.18 (d, J = 8.6 Hz, 1H), 7.07-6.99 (m, 2H), 6.88 (dd, J = 15.2, 8.4 Hz, 1H), 6.53 (d, J = 15.2 Hz, 1H), 4.07 (s, 3H), 3.97 (s, 3H), 3.19-3.11 (m, 1H), 2.92 (q, J = 8.3 Hz, 1H), 2.38-2.29 (m, 4H), 2.18-2.07 (m, 1H), 1. 95-1. 85 (m, 2H), 1.82-1.70 (m, 1H); MS (ESI): m/z 546 [M+1]+	39	8.73 99 (b)
306		(R,E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-3-(1-methylpyrroli din-2-yl) acrylamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.09 (s, 1H), 8.50 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.59-7.56 (m, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.27 (s, 1H), 7.17 (d, J = 8.8 Hz, 1H), 6.96-6.90 (m, 1H), 6.86 (d, J = 15.2 Hz, 1H), 6.67 (d, J = 3.6 Hz, 1H), 6.51-6.50 (m, 1H), 4.11-4.09 (m, 4H), 3.96 (s, 3H), 3.49-3.48 (m, 1H), 2.90 (s, 3H), 2.46-2.44 (m, 1H), 2.24-2.09 (m, 4H); MS (ESI): m/z 500 [M+H]+	51	8.01 99 (b)
307		(R,E)-2-fluoro-N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-3-(1-methylpyrroli din-2-yl)acrylamide	1H NMR (400 MHz, free base, Methanol-d4) δ 8.96 (s, 1H), 8.48 (s, 1H), 8.42 (d, J = 2.0 Hz, 1H), 7.57-7.54 (m, 2H), 7.27 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.68-6.67 (m, 1H), 6.52-6.51 (m, 1H), 6.27-6.16 (m, 1H), 4.12 (s, 3H), 3.97 (s, 3H), 3.36-3.35 (m, 1H), 3.17-3.15 (m, 1H), 2.40-2.39 (m, 4H), 2.17-2.16 (m, 1H), 1.95-1.93 (m, 2H), 1.88-1.87 (m, 1H); MS (ESI): m/z 526 [M+H]+	47	7.99 99 (1H NMR) (b)
308		(R,E)-N-(7-methoxy-4-((2',4',6-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino) quin azolin-6-yl)-3-(1-methylpyrroli din-2-yl)acrylamide	1H NMR (400MHz, HCl salt, Methanol-d4) δ 9.24 (s, 1H), 8.60 (s, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.49-7.43 (m, 1H), 7.30 (s, 1H), 7.13 (s, 1H), 7.10-7.05 (m, 2H), 7.04-6.84 (m, 2H), 4.17-4.10 (m, 4H), 3.92 (s, 3H), 3.80-3.79 (m, 1H), 2.95 (s, 3H), 2.49-2.47 (m, 1H), 2.29-2.07 (m, 3H); MS (ESI): m/z 564 [M+1]+	60	8.91 100 (b)
309		(S,E)-2-fluoro-N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-3-(1-methylpyrroli din-2-yl)acrylamide	1H NMR (400 MHz, HCl salt, Methanol-d4) δ 9.19 (s, 1H), 8.69 (s, 1H), 7.91 (s, 1H), 7.77-7.74 (m, 1H), 7.55 (s, 1H), 7.38 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 6.71 (d, J = 3.2 Hz, 1H), 6.53-6.32 (m, 2H), 4.52-4.50 (m, 1H), 4.12 (s, 3H), 3.92 (s, 3H), 3.84-3.82 (m, 1H), 2.99 (s, 3H), 2.57-2.55 (m, 1H), 2.49-2.40 (m, 4H); MS (ESI): m/z 518 [M+H]+	91	8.07 99 (b)
310		(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2-fluoro-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide	MS (ESI): m/z 663 [M+1]+
311		(Z)-2-cyano-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide	MS (ESI): m/z 670 [M+1]+
312		(E)-N-(4-((2'4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2-fluoro-4,4-dimethylpent-2-enamide	MS (ESI): m/z 537 [M+1]+
313		(R,Z)-N-(4-((2'4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2-fluoro-3-(1-methylpyrroli din-2-yl)acrylamide	MS (ESI): m/z 564 [M+1]+

Example 314. (E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide

[0143] 

[Step-1] Preparation of N-(5-(furan-2-yl)-2-methoxyphenyl)-7-methoxy-6-nitroquinazolin-4-amine

[0144] In isopropyl alcohol (0.1 M), 4-chloro-7-methoxy-6-nitroquinazoline (1.0 equiv.) and 5-(furan-2-yl)-2-methoxyaniline (1.1 equiv.) were dissolved, and stirred at 80 °C for 2 hours. The reaction mixture was cooled to room temperature, then the obtained solid was filtered and washed with ethyl ether. The target compound obtained as a yellow solid was used in the next reaction without further purification (yield: 96%, MS (ESI): m/z 393 [M+1]⁺).

[Step-2] Preparation of N⁴-(5-(furan-2-yl)-2-methoxyphenyl)-7-methoxyquinazolin-4,6-diamine

[0145] In EA (0.1 M), N-(5-(furan-2-yl)-2-methoxyphenyl)-7-methoxy-6-nitroquinazolin-4-amine (1.0 equiv.) obtained in Step-1 above was dissolved, and tin(II) chloride dihydrate (6.0 equiv.) was added and stirred at 60 °C for 3 hours. The reaction mixture was cooled to room temperature, and aqueous ammonia was added until the reaction solution turned white. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 68%, MS (ESI): m/z 363 [M+1]⁺).

[Step-3] Preparation of (E)-4-bromo-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)but-2-enamide

[0146] In DMF (0.2 M), N⁴-(5-(furan-2-yl)-2-methoxyphenyl)-7-methoxyquinazolin-4,6-diamine (1.0 equiv.) obtained in Step-2 above, (E)-4-bromobut-2-enoic acid (2.0 equiv.), DIPEA (4.5 equiv.), and HATU (3.0 equiv.) were dissolved, and the mixture was stirred at 40 °C for 16 hours. Water and brine were added to the mixture, organic materials were extracted with DCM, and the collected organic layer was concentrated by removing remaining water using Na₂SO₄. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 7%, MS (ESI): m/z 510 [M+1]⁺).

[Step-4] Preparation of (E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide

[0147] In DMF (0.1 M), (E)-4-bromo-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)but-2-enamide obtained in Step-3 above was dissolved, then K₂CO₃ (2.3 equiv.), KI (1.8 equiv.), and 1-methylpiperazine (4.0 equiv.) were added and stirred at 40 °C for 1 hour. Water and brine were added to the mixture, organic materials were extracted with DCM, and the collected organic layer was concentrated by removing remaining water using MgSO₄. The reaction mixture was purified by prep-HPLC to obtain the target compound as a white solid (yield: 19%, MS (ESI): m/z 529 [M+1]⁺).

Preparation of Compounds of Examples 315 to 319

[0148] Compounds of Examples 315 to 319 were prepared in a similar manner to Example 314 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 10 below.

[Table 10]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t. (min ) Purity(% ) (method)
314		(E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-4-(4-methylpiperaz in-1-yl)but-2-enamide	1H NMR (400MHz, TFA salt, Methanol-d4) δ 9.02 (s, 1H), 8.46 (s, 1H), 8.41 (d, J = 2.0 Hz, 1H), 7.56-7.52 (m, 2H), 7.23 (s, 1H), 7.15 (d, J = 8.8 Hz, 1H), 6.99-6.94 (m, 1H), 6.67 (d, J = 3.2 Hz, 1H), 6.61 (d, J = 15.6 Hz, 1H), 6.50-6.49 (m, 1H), 4.08 (s, 3H), 3.96 (s, 3H), 3.07-3.05 (m, 4H), 2.69-2.60 (m, 7H); MS (ESI): m/z 529 [M+1]+	19	7.85 96 (b)
315		(E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-4-morpholinobut -2-enamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.32 (s, 1H), 8.66 (s, 1H), 7.79 (s, 1H), 7.62-7.54 (m, 2H), 7.33-7.30 (m, 2H), 7.12-7.01 (m, 3H), 6.89 (d, J = 15.2 Hz, 1H), 4.20-3.95 (m, 12H), 3.51-3.49 (m, 4H); MS (ESI): m/z 562 [M+H]+	29	8.72 100 (b)
316		(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-4-morpholinobut -2-enamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.32 (s, 1H), 8.66 (s, 1H), 7.79 (s, 1H), 7.62-7.54 (m, 2H), 7.33-7.30 (m, 2H), 7.12-7.01 (m, 3H), 6.89 (d, J = 15.2 Hz, 1H), 4.20-3.95 (m, 12H), 3.51-3.49 (m, 4H); MS (ESI): m/z 562 [M+H]+	29	8.72 100 (b)
317		(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-4-(4-methylpiperaz in-1-yl)but-2-enamide	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 9.29 (s, 1H), 8.65 (s, 1H), 7.79 (s, 1H), 7.61-7.56 (m, 2H), 7.33-7.29 (m, 2H), 7.11-7.01 (m, 3H), 6.69 (d, J = 15.2 Hz, 1H), 4.19 (s, 3H), 3.98 (s, 3H), 3.48-3.46 (m, 6H), 2.99-2.96 (m, 7H); MS (ESI): m/z 575 [M+H]+	19	8.64 100 (b)
318		(E)-4-(3-oxa-6-azabicyclo[3. 1.1]heptan-6-yl)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)but-2-enamide	1H NMR (400 MHz, FA salt, Methanol-d4) δ 9.01 (s, 1H), 8.46 (s, 1H), 8.43-8.37 (m, 2H), 7.55-7.50 (m, 2H), 7.21 (s, 1H), 7.13 (d, J = 8.6 Hz, 1H), 7.02-6.93 (m, 1H), 6.69-6.61 (m, 2H), 6.51-6.48 (m, 1H), 4.32 (d, J = 11.6 Hz, 2H), 4.08 (s, 3H), 4.00-3.84 (m, 9H), 3.01-2.84 (m, 1H), 2.10-2.01 (m, 1H); MS (ESI): m/z 528 [M+1]+	8.1 9	7.97 100 (b)
319		(E)-4-(3-oxa-6-azabicyclo[3. 1.1]heptan-6-yl)-N-(4-((2',4'-difluoro-4-methoxy-[1,1')-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)but-2-enamide	1H NMR (400 MHz, FA salt, Methanol-d4) δ 9.06 (s, 1H), 8.44 (s, 1H), 8.26 (s, 3H), 8.22 (s, 1H), 7.57-7.52 (m, 1H), 7.41-7.38 (m, 1H), 7.26-7.25 (d, J = 2.2 Hz, 1H), 7.28-7.19 (dd, J = 8.4 Hz, 1H), 7.06-6.93 (m, 3H), 6.76-6.72 (d, J = 16.32 Hz, 1H), 4.39-4.35 (dd, J = 12.02 Hz, 2H), 4.24-3.91 (m, 12H), 2.98 (s, 1H), 2.20 (s, 1H); MS (ESI): m/z 574 [M+1]+	19	8.75 99 (b)

Example 320. Preparation of (E)-N-(5-chloro-4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

[0149] 

[Step-1] Preparation of 4-(1H-benzo[d][1,2,3]triazol-1-yl)-5-chloroquinazolin-6-amine

[0150] In acetonitrile (0.1 M), 6-amino-5-chloroquinazolin-4(3H)-one (1.0 equiv.) and BOP (1.5 equiv.) were dissolved, then DBU (2.0 equiv.) was added and stirred for 1 hour at room temperature. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 100%, MS (ESI): m/z 296 [M+1]⁺).

[Step-2] Preparation of N⁴-(5-bromo-2-methoxyphenyl)-5-chloroquinazolin-4,6-diamine

[0151] In isopropyl alcohol, 4-(1H-benzo[d][1,2,3]triazol-1-yl)-5-chloroquinazolin-6-amine (1.0 equiv.) obtained in Step-1 above and 5-bromo-2-methoxyaniline (1.2 equiv.) were dissolved, and stirred at 90 °C for 10 minutes, and then p-toluenesulfonic acid monohydrate (0.1 equiv.) was added and stirred at 90 °C for 1 hour. The reaction mixture was cooled to room temperature and water was added to form a solid. The resulting solid was filtered through a filter to obtain the target compound as a yellow solid (yield: 39%, MS (ESI): m/z 379 [M+1]⁺).

[Step-3] Preparation of (E)-N-(4-((5-bromo-2-methoxyphenyl)amino)-5-chloroquinazolin-6-yl)-4-(dimethylamino)but-2-enamide

[0152] In NMP (0.1 M), N⁴-(5-bromo-2-methoxyphenyl)-5-chloroquinazolin-4,6-diamine (1.0 equiv.) obtained in Step-2 above was dissolved, then (E)-4-(dimethylamino)but-2-enoyl chloride (1.0 equiv.) was added under nitrogen and stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 44%, MS (ESI): m/z 490 [M+1]⁺).

[Step-4] Preparation of (E)-N-(5-chloro-4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

[0153] In dioxane: water (5:1, 0.1 M), (E)-N-(4-((5-Bromo-2-methoxyphenyl)amino)-5-chloroquinazolin-6-yl)-4-(dimethylamino)but-2-enamide (1.0 equiv.) obtained in Step-3 above, (2,4-difluorophenyl)boronic acid (2.2 equiv.), and K₃PO₄ (2.0 equiv.) were dissolved. The reaction mixture was degassed using nitro gas, and Xphos Pd G2 (0.13 equiv.) was added at 80 °C, followed by stirring at 90 °C for 10 minutes. The reaction mixture was filtered through a celite filter, concentrated, and purified by prep-HPLC to obtain the target compound as a yellow solid (yield: 8%, MS (ESI): m/z 524 [M+1]⁺).

Preparation of Compound of Example 321

[0154] A compound of Example 321 according to the present invention was prepared in a similar manner to Example 320 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 11 below.

[Table 11]

Exa mpl e No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t. (min ) Purity(% ) (method)
320		(E)-N-(5-chloro-4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino) quin azolin-6-yl)-4-(dimethylamin o)but-2-enamide	1H NMR (400 MHz, FA salt, Methanol-d4) δ 9.01 (s, 1H), 8.65 (s, 1H), 8.20 (d, J = 9.2 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.58-7.53 (m, 1H), 7.35-7.32 (m, 1H), 7.21 (d, J = 8.4 Hz, 1H), 7.09-7.04 (m, 3H), 6.98-6.60 (m, 1H), 4.05 (s, 3H), 3.63 (d, J = 6.8 Hz, 2H), 2.68 (s, 6H); MS (ESI): m/z 524 [M+H]+	8	9.61 98 (b)
321		(E)-N-(5-chloro-4-((5-(furan-2-yl)-2-methoxyphenyl ) amino) quinaz olin-6-yl)-4-(dimethylamin o)but-2-enamide	1H NMR (400 MHz, TFA salt, DMSO-d6) δ 10.40 (s, 1H), 10.31 (s, 1H), 8.93 (s, 1H), 8.76 (s, 1H), 8.15 (d, J = 9.2 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.75 (s, 1H), 7.55-7.53 (m, 1H), 7.25 (d, J = 2.0 Hz, 1H), 6.88-6.81 (m, 2H), 6.71-6.59 (m, 2H), 4.00-3.99 (m, 5H), 2.91 (s, 6H); MS (ESI): m/z 478 [M+H]+	21	8.86 100 (b)

Example 322. Preparation of 1-(2-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one

[0155] 

[Step-1] Preparation of 5-fluoro-4-methoxy-2-nitrobenzonitrile

[0156] In DMF (0.2 M), 1-bromo-5-fluoro-4-methoxy-2-nitrobenzene (1.0 equiv.) and CuCN (1.5 equiv.) were dissolved, and stirred at 180 °C for 2 hours. Ice water was added to the reaction mixture to produce a solid, and the formed solid was filtered to obtain the target compound as a yellow solid (yield: 90%).

[Step-2] Preparation of tert-butyl 2-(5-cyano-2-methoxy-4-nitrophenyl)-2,6-diazaspiro[3.5]nonane-6-carboxylate

[0157] In DMSO (0.1 M), 5-fluoro-4-methoxy-2-nitrobenzonitrile (1 equiv.) obtained in Step-1 above, tert-butyl 2,6-diazaspiro[3.5]nonane-6-carboxylate (1.0 equiv.), and DIPEA (4.0 equiv.) were dissolved, and stirred at 120 °C for 1 hour. Water was added to the reaction mixture to form a solid compound, and the solid compound was filtered through a filter to obtain the target compound as a yellow solid (yield: 51%, MS (ESI): m/z 347 [M+1]⁺).

[Step-3] Preparation of tert-butyl 2-(4-amino-5-cyano-2-methoxyphenyl)-2,6-diazaspiro[3.5]nonane-6-carboxylate

[0158] In MeOH (0.1 M), tert-butyl 2-(5-cyano-2-methoxy-4-nitrophenyl)-2,6-diazaspiro[3.5]nonane-6-carboxylate (1.0 equiv.) obtained in Step-2 above was dissolved, then Pd/C (10% purity, 0.1 equiv.) was added, and the reaction mixture was stirred at room temperature for 1 hour under hydrogen. The stirred mixture was filtered through celite, and the filtrate was concentrated. The target compound obtained as a yellow solid was used in the next reaction without further purification (yield: 98%, MS (ESI): m/z 373 [M+1]⁺).

[Step-4] Preparation of tert-butyl (Z)-2-(5-cyano-4-(((dimethylamino)methylene)amino)-2-methoxyphenyl)-2,6-diazaspiro[3.5]nonane-6-carboxylate

[0159] In toluene (0.1 M), tert-butyl 2-(4-amino-5-cyano-2-methoxyphenyl)-2,6-diazaspiro[3.5]nonane-6-carboxylate (1 equiv.) obtained in Step-3 above and N,N-dimethylformamide dimethylacetal (5.0 equiv.) were dissolved, and the mixture was stirred at 100 °C for 1 hour and then concentrated. The reaction mixture was purified by MPLC (DCM:MeOH) to obtain the target compound as a yellow solid (yield: 81%, MS (ESI): m/z 428 [M+1]⁺).

[Step-5] Preparation of tert-butyl 2-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonane-6-carboxylate

[0160] In acetic acid (0.1 M), tert-butyl (Z)-2-(5-cyano-4-(((dimethylamino)methylene)amino)-2-methoxyphenyl)-2,6-diazaspiro[3.5]nonane-6-carboxylate (1.0 equiv.) obtained in Step-4 above and 5-bromo-2-methoxyaniline (1.1 equiv.) were dissolved, and stirred at 120 °C for 1 hour. After cooling the mixture to room temperature, saturated NaHCO₃ aqueous solution was added to the reaction mixture to a pH of 8, and the organic layer was extracted with DCM. The collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a brown solid was used in the next reaction without further purification (yield: 30%, MS (ESI): m/z 584 [M+1]⁺).

[Step-6] Preparation of N-(5-bromo-2-methoxyphenyl)-7-methoxy-6-(2,6-diazaspiro[3.5]nonan-2-yl)quinazolin-4-amine

[0161] In DCM, tert-butyl 2-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonane-6-carboxylate (1.0 equiv.) obtained in Step-5 above was dissolved and an excess of TFA was added. The reaction mixture was stirred at room temperature for 1 hour. The desired product was confirmed through LC-MS, concentrated, and purified by MPLC (DCM:MeOH) to obtain the target compound as a white solid (yield: 100%, MS (ESI): m/z 484 [M+1]⁺).

[Step-7] Preparation of 1-(2-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one

[0162] In THF (0.1 M), N-(5-bromo-2-methoxyphenyl)-7-methoxy-6-(2,6-diazaspiro[3.5]nonan-2-yl)quinazolin-4-amine (1.0 equiv.) obtained in Step-6 above and saturated NaHCO₃ aqueous solution (5.0 equiv.) were dissolved, and then acryloyl chloride (1.0 equiv.) was added at 0 °C and stirred for 30 minutes. The reaction mixture was concentrated, water was added, and the organic layer was extracted with DCM. The collected organic layer was concentrated by removing remaining water using MgSO₄. The target compound obtained as a white solid was used in the next reaction without further purification (yield: 42%, MS (ESI): m/z 538 [M+1]⁺).

[Step-8] Preparation of 1-(2-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one

[0163] In dioxane:water (5:1, 0.006 M), 1-(2-(4-((5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one (1.0 equiv.) obtained in Step-7 above, (2,4-difluorophenyl)boronic acid (1.1 equiv.), and K₃PO₄ (2.5 equiv.) were dissolved. The reaction mixture was degassed using nitro gas, and Xphos Pd G2 (0.1 equiv.) was added to the mixture at 80 °C, followed by stirring at 100 °C for 1 hour. The mixture was filtered through celite, and the filtrate was concentrated and purified using prep-HPLC to obtain the target compound as a yellow solid (yield: 64%, MS (ESI): m/z 572 [M+1]⁺).

Preparation of Compounds of Examples 323 to 330

[0164] Compounds of Examples 323 to 330 were prepared in a similar manner to Example 322 above. Chemical structures, compound names, ¹H NMR, MS, HPLC data and yields of respective Examples are summarized in Table 12 below.

[Table 12]

Example No.	Structure	Compound Name	1H NMR; MS	Yie ld (%)	HPLC r.t. (min ) Purity(% ) (method)
322		1-(2-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2,6-diazaspiro[3. 5]nonan-6-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.19 (s, 1H), 7.92-7.90 (m, 1H), 7.82 (s, 1H), 7.63-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.31 (s, 1H), 7.16-7.09 (m, 3H), 7.00-6.79 (m, 1H), 6.32-6.19 (m, 1H), 5.80-5.75 (m, 1H), 4.05 (s, 3H), 3.98 (s, 3H), 3.97-3.96 (m, 2H), 3.93-3.87 (m, 4H), 3.85-3.37 (m, 2H), 1.98-1.96 (m, 2H), 1.75-1.68 (m, 2H); MS (ESI): m/z 572 [M+1]+	64	11.35 100 (b)
323		1-(2-(4-((5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-2,6-diazaspiro[3. 5]nonan-6-yl)prop-2-en-1-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.08 (s, 1H), 7.96-7.94 (m, 1H), 7.86-7.85 (m, 1H), 7.50-7.49 (m, 1H), 7.35-7.33 (m, 1H), 7.21 (s, 1H), 7.06 (s, 1H), 6.90-6.80 (m, 1H), 6.73-6.72 (m, 1H), 6.46-6.45 (m, 1H), 6.25-6.08 (m, 1H), 5.78-5.65 (m, 1H), 3.96 (s, 3H), 3.88-3.75 (m, 9H), 3.56-3.55 (m, 2H), 1.88-1.87 (m, 2H), 1. 63-1.50 (m, 2H); MS (ESI): m/z 526 [M+1]+	26	10.71 100 (b)
324		1-(2-(4-((5-(furan-2-yl)- 2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-2,7-diazaspiro[3. 5]nonan-7-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.49 (s, 1H), 7.86 (s, 1H), 7.73 (d, J = 2.4 Hz, 1H), 7.50 (s, 1H), 7.24-7.21 (m, 2H), 7.11 (s, 1H), 6.82-6.80 (m, 1H), 6.70-6.69 (m, 1H), 6.53-6.52 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 4.06 (s, 3H), 4.01 (s, 4H), 3.90 (s, 3H), 3.70-3.69 (m, 4H), 1.94-1.91 (m, 4H); MS (ESI): m/z 526 [M+H]+	51	10.56 100 (b)
325		1-(2-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2,7-diazaspiro[3. 5]nonan-7-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.48 (s, 1H), 7.72-7.71 (m, 1H), 7.60-7.52 (m, 2H), 7.30 (d, J = 8.8 Hz, 1H), 7.22 (s, 1H), 7.11-7.04 (m, 3H), 6.85-6.79 (m, 1H), 6.25-6.20 (m, 1H), 5.79-5.76 (m, 1H), 4.06 (s, 3H), 4.01 (s, 4H), 3.99 (s, 3H), 3.69-3.68 (m, 4H), 1.94-1.91 (m, 4H); MS (ESI): m/z 572 [M+H]+	26	11.15 100 (b)
326		1-(6-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-2,6-diazaspiro[3. 3]heptan-2-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.31 (s, 1H), 8.11 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.53 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.10 (s, 1H), 7.07 (s, 1H), 6.68 (d, J = 3.2 Hz, 1H), 6.51-6.50 (m, 1H), 6.38-6.29 (m, 2H), 5.79 (d, J = 11.2 Hz, 1H), 4.54 (s, 2H), 4.28 (s, 2H), 4.26 (s, 4H), 4.01 (s, 3H), 3.92 (s, 3H); MS (ESI): m/z 498 [M+H]+	34	9.86 100 (b)
327		1-(6-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2,6-diazaspiro [3. 3]heptan-2-yl)prop-2-en-1-one	1H NMR (400 MHz, FA salt, Methanol-d4) δ 8.30 (s, 1H), 7.92 (s, 1H), 7.56-7.54 (m, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.09-7.03 (m, 4H), 6.37-3.29 (m, 2H), 5.79-5.76 (m, 1H), 4.54 (s, 2H), 4.28 (s, 2H), 4.26 (s, 4H), 4.01 (s, 3H), 3.94 (s, 3H); MS (ESI): m/z 498 [M+H]+	34	10.64 100 (b)
328		1-(7-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-2,7-diazaspiro[4. 4]nonan-2-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.39 (s, 1H), 7.74 (s, 1H), 7.65-7.62 (m, 1H), 7.46-7.44 (m, 1H), 7.21 (s, 1H), 7.14 (d, J = 8.8 Hz, 1H), 7.06 (d, J = 1.6 Hz, 1H), 6.60-6.53 (m, 2H), 6.43-6.42 (m, 1H), 6.22-6.21 (m, 1H), 5.72-5.71 (m, 1H), 3.99 (s, 3H), 3.77 (s, 3H), 3.69-3.25 (m, 10H), 2.08-1.94 (m, 2H); MS (ESI): m/z 526 [M+H]+	21	10.41 95 (b)
329		1-(7-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinaz olin-6-yl)-2,7-diazaspiro[4. 4]nonan-2-yl)prop-2-en-1-one	1H NMR (400 MHz, TFA salt, Methanol-d4) δ 8.25 (s, 1H), 7.91 (s, 1H), 7.57-7.55 (m, 1H), 7.46-7.43 (m, 1H), 7.24-7.21 (m, 2H), 7.13 (s, 1H), 7.08-7.03 (m, 2H), 6.67-6.60 (m, 1H), 6.33-6.28 (m, 1H), 5.79-5.74 (m, 1H), 4.01 (s, 3H), 3.93 (s, 3H), 3.80-3.62 (m, 4H), 3.52-3.49 (m, 4H), 2.09-2.04 (m, 4H); MS (ESI): m/z 572 [M+H]+	11	11.13 97 (b)
330		2-acryloyl-7-(4-((5-(furan-2-yl)-2-methoxyphenyl )amino)-7-methoxyquinaz olin-6-yl)-5-oxa-2,7-diazaspiro[3. 4]octan-6-one	1H NMR (400MHz, FA salt, Methanol-d4) δ 8.48 (s, 1H), 8.38 (s, 1H), 8.21-8.20 (m, 1H), 7.61-7.60 (m, 1H), 7.54-7.53 (m, 1H), 7.33 (s, 1H), 7.19-7.17 (m, 1H), 6.69-6.68 (m, 1H), 6.52-6.41 (m, 1H), 6.38-6.34 (m, 2H), 5.84-5.81 (m, 1H), 4.72-4.70 (m, 2H), 4.45-4.44 (m, 2H), 4.37-4.36 (m, 2H), 3.93 (s, 3H), 3.35 (s, 3H); MS (ESI): m/z 528 [M+1]+	6	5.3 98 (a)

(*: wherein "*" marked to the right side of the numerical value in the last column means NMR purity)

<Experimental Example 1> Evaluation of HER2, EGFR enzyme inhibitory activity

[0165] Biochemical kinase assays for HER2 and EGFR were performed by Reaction Biology Corp (San Diego, USA). Compounds were diluted 3-fold from 10 µM under the condition of ATP (10 µM) for HER2 and EGFR enzymes, and IC₅₀ values were determined in 10-dose. Results thereof are shown in Table 13 below.

[Table 13]

Example No.	HER2	EGFR
68	A	A
80	A	-
90	A	-
157	A	-
304	A	A
305	A	A
306	A	A

(A: GI50 ≤ 50 nM, B: 50 < GI50 ≤ 100 nM, C: 100 < GI50 ≤ 500 nM, D: 500 nM < GI50)

<Experimental Example 2> Evaluation of SK-BR-3, BT-474, N-87, and HaCaT cell proliferation inhibitory activity

[0166] To evaluate the cell proliferation inhibitory activity of the compound according to the present invention on HER2 and EGFR kinases, the following method was performed using HER2 overexpressing cell lines (SK-BR-3, BT-474, and N-87) and EGFR expressing cell line (HaCaT).

[0167] McCOY'S 5A supplemented with 10% FBS was used for SK-BR-3 cells, RPMI-1640 medium supplemented with 20% FBS was used for BT-474 cancer cells, and RPMI-1640 medium supplemented with 10% FBS was used for N-87 cancer cells. DMEM supplemented with 10% FBS was used for HaCaT cells.

[0168] For SK-BR-3 cells, 5000 cells were aliquoted into each well of a white clear bottom 96 well plate (Corning) 48 hours before treatment with the compounds of Examples. For BT-474 cells, 5000 cells were aliquoted into each well of a white clear bottom 96 well plate (Corning) 48 hours before treatment with the compounds of Examples. For N-87 cells, 5000 cells were aliquoted into each well of a white clear bottom 96 well plate (Corning) 24 hours before treatment with the compounds of Examples. For HaCaT cells, 3000 cells were aliquoted into each well of a white clear bottom 96 well plate (Corning) 24 hours before treatment with the compounds of Examples. For SK-BR-3 cells and BT-474 cells, the compounds of Examples were diluted in dimethyl sulfoxide (three-fold dilution, a total of 11 concentrations) and injected each in an amount of 1 µl to a final concentration of 0.2 nM to 10 µM. For N-87 cells, the compounds of Examples were diluted in dimethyl sulfoxide (five-fold dilution, a total of 11 concentrations) and injected each in an amount of 0.5 µl to a final concentration of 0.5 pM to 5 µM. For HaCaT cells, the compounds of Examples were diluted in dimethyl sulfoxide (three-fold dilution, a total of 11 concentrations) and injected each in an amount of 0.5 µl to a final concentration of 0.8 nM to 45 µM. For the measurement of living cells, the cells were stored at room temperature for 10 minutes using CellTiter-Glo cell viability reagent (Promega) after a certain period of time (SK-BR-3: 120 hours, BT-474: 120 hours, N-87: 72 hours, and HaCaT: 72 hours) post treatment with the compounds of Examples, and the luminescence intensity thereof was measured using a reader (SynergyNeo, Biotek). Each test was repeated three times.

[0169] The result values were calculated as a cell growth rate (%) compared to those of the control group. A graph was created using the GraphPad Prism version 5.0 program, and GI₅₀ values were calculated. Results thereof are shown in Table 14 below.

[Table 14]

Example No.	GI50, nM
	SK-BR-3	BT-474	N-87	HaCaT
1	-	A	A	C
2	-	A	A	C
3	-	A	A	B
4	-	A	A	C
5	A	-	-	-
6	B	-	-	-
7	A	-	-	-
8	A	-	-	A
9	B	-	-	B
10	A	-	-	A
11	B	-	-	A
12	A	-	-	A
13	A	-	-	A
14	A	-	-	A
15	A	-	-	A
17	A	A	A	B
18	A	-	-	A
19	A	-	-	A
20	A	-	-	A
21	A	A	A	A
22	A	A	A	A
23	B	-	-	A
24	A	A	A	A
25	A	-	-	A
26	A	-	-	A
27	B	-	-	B
28	B	-	-	B
29	A	-	-	A
30	B	-	-	-
31	B	-	-	C
32	B	-	-	-
34	C	-	-	B
35	A	-	-	B
36	B	-	-	B
37	A	-	-	-
39	B	-	-	B
40	B	-	-	A
41	A	-	-	A
42	B	-	-	-
43	A	-	-	-
44	A	-	-	-
45	A	-	-	-
46	B	-	-	-
47	A	-	-	-
51	A	-	-	A
52	A	-	-	A
53	-	A	-	A
54	A	-	-	A
55	A	-	-	A
56	B	-	-	C
57	B	-	-	B
58	B	-	-	-
59	B	-	-	C
60	A	-	-	B
61	B	-	-	C
63	B	-	-	-
64	B	-	-	-
65	A	-	-	-
66	B	-	-	B
67	A	A	A	B
68	A	A	A	A
69	B	-	-	-
70	B	-	-	C
71	B	-	-	C
73	A	-	-	A
75	B	-	-	C
77	B	-	-	B
78	A	-	-	-
79	A	A	A	A
80	A	A	-	A
81	B	-	-	-
82	A	-	-	A
83	B	-	-	B
84	A	-	-	A
85	A	-	-	A
86	-	-	-	B
88	-	A		A
92	-	B		B
95	B	-	-	A
96	B	-	-	A
99	-	A		A
100	-	A		A
104	A	-	-	A
105	A	-	-	A
111	A	-	-	A
112	A	A	A	A
113	A	A	A	A
114	B	-	-	A
115	B	-	-	A
116	B	-	-	A
117	A	-	-	A
118	A	-	-	A
119	B	-	-	A
120	B	-	-	-
121	C	-	-	A
125	B	-	-	B
128	B	-	-	B
129	-	A	A	B
130	B	-	-	B
131	B	-	-	B
132	C	-	-	B
133	B	-	-	B
134	B	-	-	B
135	B	-	-	B
136	A	-	-	A
137	A	-	-	A
138	A	A	A	B
139	A	A	A	B
140	A	A	A	A
141	C	-	-	B
142	A	A	A	B
143	A	A	A	A
144	A	-	-	A
145	A	-	-	A
146	A	-	A	C
147	B	-	-	B
148	A	-	-	A
149	B	-	-	B
151	A	A	A	B
152	-	B	-	B
153	-	B	-	C
154	-	A	A	A
155	-	A	A	A
157	-	A	A	A
158	-	A	A	A
159	-	A	A	B
161	A	A	A	A
162	C			B
163	A	B	A	B
164	B	-	-	A
165	C	-	-	B
166	A	-	-	A
167	-	A	-	A
168	-	A	A	B
169	-	A	A	A
170	-	A	A	A
171	A	A	A	A
172	-	A	-	A
173	-	A	A	A
174	-	A	-	A
176	-	A	A	A
178	-	A		A
179	A	-	-	A
180	B	-	-	C
181	A	A	A	A
182	A	A	A	A
183	-	B	-	B
184	-	C	-	B
185	-	A	-	A
187	-	B	-	A
188	-	B	-	A
189	-	A	A	A
190	-	A	A	A
191	-	A	A	A
192	-	A	A	A
193	-	B	-	A
195	-	A	-	A
196	-	A	-	B
197	-	B	-	C
198	-	B	-	C
199	-	A	-	B
200	-	A	-	A
201	-	A	-	A
202	-	A	-	C
203	-	A	-	B
204	-	A	-	B
205	-	B	-	C
207	-	A	-	B
208	-	B	-	C
209	-	A	-	B
210	-	A	-	B
211	-	A	-	B
213	-	A	-	A
214	-	A	-	C
215	-	A	A	B
216	-	B	-	B
218	-	C	-	B
220	-	B	-	B
221	-	C	-	B
224	-	A	A	A
225	-	B	A	C
226	-	A	A	C
227	B	-	-	C
229	-	A	A	B
234	B	-	-	B
236	B	-	-	C
237	B	-	-	C
238	A	-	-	A
239	-	A	-	A
240	A	-	-	A
241	A	-	-	A
242	B	-	-	A
248	A	-	-	A
249	B	-	-	A
250	A	-	-	A
251	A	-	-	A
253	A	-	-	A
255	A	-	-	A
257	B	-	-	A
258	B	-	-	A
259	A	-	-	A
260	A	A	A	A
262	A	-	-	A
269	A	-	-	A
270	A	A	A	A
271	A	-	-	A
272	A	-	-	A
273	A	-	-	A
274	A	-	-	A
275	A	-	-	A
277	A	-	-	A
278	A	A	A	A
279	A	-	-	A
280	A	-	-	A
281	A	-	A	A
282	A	-	-	A
286	A	A	A	A
287	A	-	-	C
288	B	-	-	C
289	A	-	-	A
290	B	-	-	A
291	C	-	-	A
297	-	A	-	A
298	A	A	A	A
299	A	A	A	A
300	-	A	A	A
301	-	A	A	A
304	-	A	A	A
305	A	A	A	A
306	A	A	A	A
307	A	A	A	A
308	-	A	-	A
309	-	A	-	A
314	-	A	-	A
315	-	A	-	A
316	-	A	-	A
317	-	A	-	A
318	-	A	-	A
319	-	A	-	A
320	-	B	-	B
321	-	C	-	B
324	-	C	-	B
325	-	B	-	B
326	-	C	-	B
330	B	-	-	B

(A: GI50 ≤ 150 nM, B: 150 < GI50 ≤ 1000 nM, C: 1000 nM < GI50)

<Experimental Example 3> Evaluation of transduced Ba/F3 cell proliferation inhibitory activity

[0170] For Ba/F3 cells, RPMI-1640 supplemented with 10% FBS and 5 ng/ml IL-3 (R&D Systems) was used. Transduced Ba/F3 cells were cultured by adding 1 ug/ml puromycin (Invitrogen) to the same medium.

[0171] 3000 to 5000 cells were aliquoted into each well of a white clear bottom 96 well plate (Corning) 24 hours before treatment with the compounds of Examples. The compounds of Examples were diluted in dimethyl sulfoxide (three-fold dilution, a total of 12 concentrations) and injected each in an amount of 1 µl to a final concentration of 0.2 nM to 5 µM. For the measurement of living cells, the cells were stored at room temperature for 10 minutes using CellTiter-Glo luminescentcell-viability reagent (Promega) in 72 hours after treatment with the compounds of Examples, and the luminescence intensity thereof was measured using a reader (SynergyNeo, Biotek). Each test was repeated three times. The result values were calculated as a cell growth rate (%) compared to those of the control group. A graph was created using the GraphPad Prism version 8.3.0 program, and GI₅₀ values were calculated.

[0172] Table 15 below shows the results of evaluating the Ba/F3 cell proliferation inhibitory activity of L869R, L756S, T798I, and T862A expressing HER2 rare or uncommon and drug-resistant mutations and G719A, L861Q, S768I, G719A/S768I, and Del19/T790M expressing EGFR rare or uncommon and drug-resistant mutations.

[Table 15]

Exam ple No.	Ba/F3 (GI50, µM)
	HER2					EGFR
	WT	L869 R	L755 S	T798 I	T862 A	WT	G719 A	L861 Q	S768 I	G719 A/ S768 I	Dell 9/ T790 M
80	A	A	A	A	A	A	A	A	A	A	A
78	-	A	-	A	-	-	-	-	-	-	-
68	A	A	A	C	A	B	A	A	B	A	A
112	-	A	A	-	A
143	-	A	A	-	A	-	-	-	-	-	-
300	A	-	A	C	A	-	-	-	-	-	-
305	A	-	A	A	A	-	-	-	-	-	-
306	-	-	-	-	-	A	-	-	A	-	-
307	-	-	-	-	-	A	-	-	A	-	-

[416] (A: GI50 ≤ 50 nM, B: 50 nM < GI50 ≤ 100 nM, C: 100 nM < GI50 ≤ 500 nM, D: 500 nM < GI50)

Claims

1. A compound represented by the following Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof:

in Chemical Formula 1 above,

X is N or CR_X1;

R₁ is -H, -OR_X2, or -NR_X3R_X4;

R_X1 is -H, -C_1-6alkyl, -C_1-6haloalkyl, -CN, or -halo;

R_X2 is -H, -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -C_1-6alkyl-O(C_1-6alkyl)-C_1-6aminoalkyl, -(CH₂)n-cycloalkyl, or -(CH₂)n-heterocycloalkyl {wherein at least one H of the -(CH₂)n-cycloalkyl or -(CH₂)n-heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, -halo, or heterocycloalkyl};

n is 0, 1, 2, 3, or 4;

R_X3 and R_X4 are each independently -H or -C_1-6alkyl, or R_X3 and R_X4 are linked to each other to form

or

ring together with an N atom, and the W₁ and W₂ are each independently CH₂, NH, O, or S {wherein at least one H of the

heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C₁-₆alkyl), -NO₂, -OH, -halo, or heterocycloalkyl};

a to d are each independently 1, 2, or 3;

R₂ is -H, -C_1-6alkyl, -C_1-6haloalkyl, -CN, or -halo;

L is -NH-,

or

{wherein the ring B is a single ring or multiple rings containing an N atom in the ring, and at least one H of the ring B may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -CN, -NH₂, - NH-C_1-6alkyl, -N(C_1-6alkyl)(C₁-₆alkyl), -NO₂, -OH, =O, or - halo};

R₃ is -CZ₁=Z₂Z₃, -C_1-6alkyl, -C_1-6haloalkyl, or cycloalkyl;

Z₁ is -H, -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6hydroxyalkyl, -C_1-6haloalkyl, -CN, or -halo;

Z₂ and Z₃ are each independently -H, -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -halo, cycloalkyl, heterocycloalkyl, -C_1-6alkylcycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein at least one H of the cycloalkyl, heterocycloalkyl, -C_1-6alkylcycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl, -C_1-6hydroxyalkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, =O, or heterocycloalkyl};

Y₁ to Y₃ are each independently N or CR_Y;

R_Y is -H, -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6hydroxyalkyl, -C_1-6haloalkyl, -CN, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NO₂, -OH, or -halo;

R₄ is -C_1-6alkyl, -C_1-6alkyl-O-C_1-6alkyl, -C_1-6haloalkyl, cycloalkyl, heterocycloalkyl, -C_1-6alkyl-cycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein at least one H of the cycloalkyl, heterocycloalkyl, -C_1-6alkyl-cycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl};

ring A is aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl {wherein at least one H of the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring may be substituted with -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6hydroxyalkyl, -C_1-6haloalkyl, -C_1-6alkenyl, -CN, -C(=O)-R_A1, -NO₂, -NR_A2R_A3, - OR_A4, -S-C_1-6alkyl, -halo, or heterocycloalkyl [here, at least one H of the heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -halo, or heterocycloalkyl, and substituents on the aryl or heteroaryl ring may be linked to each other to form a 5-6 membered cycloalkyl or a 5-6 membered heterocycloalkyl};

R_A1 is -H, -C_1-6alkyl, -NH₂, -NH-C_1-6alkyl, -N(C_1-6alkyl)(C_1-6alkyl), -NH-(CH₂)m-aryl, -OH, or -O-C_1-6alkyl {wherein at least one H of the -NH-(CH₂)m-aryl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, or -halo};

m is 0, 1, 2, 3, or 4;

R_A2 and R_A3 are each independently -H, -C_1-6alkyl, -C(=O)-C_1-6alkyl, -C(=O)-C_1-6alkenyl, -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or -C(=O)-aryl {wherein at least one H of the -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or -C(=O)-aryl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, -halo, or aryl}; and

R_A4 is -H, -C_1-6alkyl, or -C_1-6haloalkyl.

2.  The compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein

X is N or CR_X1;

R₁ is -H, -OR_X2, or -NR_X3R_X4;

R_X1 is -H or -CN;

R_X2 is -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -C_1-6alkyl-O(C_1-6alkyl)-C_1-6aminoalkyl, or - (CH₂)n-heterocycloalkyl {wherein at least one H of the - (CH₂)n-heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6alkyl-O(C_1-6alkyl), or heterocycloalkyl};

n is 0, 1, 2, 3, or 4;

R_X3 and R_X4 are each independently -H or -C_1-6alkyl, or R_X3 and R_X4 are linked to each other to form

or

ring together with an N atom, and W₁ and W₂ are each independently CH₂, NH, or O {wherein at least one H of the

ring may be substituted with - halo, or heterocycloalkyl};

a to d are each independently 1 or 2;

R₂ is -H or -halo;

{wherein the ring B is a single ring or multiple rings containing an N atom in the ring, and at least one H of the ring B may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, or -halo};

R₃ is -CZ₁=Z₂Z₃, -C_1-6haloalkyl, or cycloalkyl;

Z₁ is -H, -C_1-6aminoalkyl, -CN, or -halo;

Z₂ and Z₃ are each independently -H, -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6alkyl-O(C_1-6alkyl), -halo, -heterocycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein at least one H of the -heterocycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl or -heterocycloalkyl};

Y₁ to Y₃ are each independently N or CR_Y;

R_Y is -H, -C_1-6alkyl, or -halo;

R₄ is -C_1-6alkyl, -C_1-6alkyl-O-C_1-6alkyl, -C_1-6haloalkyl, cycloalkyl, or heterocycloalkyl {wherein at least one H of the cycloalkyl or heterocycloalkyl may be substituted with -C_1-6alkyl } ;

ring A is aryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl {wherein at least one H of the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -C_1-6alkenyl, -CN, -C(=O)-R_A1, -NO₂, -NR_A2R_A3, - OR_A4, -S-C_1-6alkyl, -halo, or heterocycloalkyl [here, at least one H of the heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -halo, or heterocycloalkyl , and substituents on the aryl or heteroaryl ring may be linked with each other to form a 5-6 membered cycloalkyl or a 5-6 membered heterocycloalkyl};

R_A1 is -H, -NH-(CH₂)m-aryl, -OH, or -O-C_1-6alkyl {wherein at least one H of the -NH-(CH₂)m-aryl ring may be substituted with -halo};

m is 0, 1, 2, 3, or 4;

R_A2 and R_A3 are each independently -H, -C_1-6alkyl, -C(=O)-C_1-6alkyl, -C(=O)-C_1-6alkenyl, -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or -C(=O)-aryl {wherein at least one H of the -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or -C(=O)-aryl ring may be substituted with =O, -halo, or aryl}; and

R_A4 is -H, -C_1-6alkyl, or -C_1-6haloalkyl.

3. The compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein

X is N or CR_X1;

R₁ is -H, -OR_X2, or -NR_X3R_X4;

R_X1 is -H or -CN;

R_X2 is -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6haloalkyl, -C_1-6alkyl-O(C_1-6alkyl), -C_1-6alkyl-O(C_1-6alkyl)-C_1-6aminoalkyl, or -(CH₂)n-heterocycloalkyl {wherein the -(CH₂)n-heterocycloalkyl ring is 4-6 membered, and at least one H of the -(CH₂)n-heterocycloalkyl ring may be substituted with - C_1-6alkyl, -C_1-6alkyl-O(C_1-6alkyl), or 4-6 membered heterocycloalkyl};

n is 0, 1, 2, or 3;

R_X3 and R_X4 are each independently -H or -C_1-6alkyl, or R_X3 and R_X4 are linked to each other to form

or

together with an N atom, and W₁ and W₂ are each independently CH₂ or O {wherein at least one H of the

or

ring may be substituted with -halo, or 4-6 membered heterocycloalkyl};

a to d are each independently 1 or 2; and

R₂ is -H or -halo.

4. The compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein

L is -NH-,



{wherein at least one H of the



ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, or -halo};

V₁ and V₂ are linked together by a single bond, C₁alkyl, C₂alkyl, or C₃alkyl to form a bridged double ring or nothing (null); and

e to h are each independently 1, 2, or 3.

5. The compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein

R₃ is -CZ₁=Z₂Z₃, -C_1-6haloalkyl, or cycloalkyl {wherein the cycloalkyl ring is a single ring or multiple rings};

Z₁ is -H, -C_1-6aminoalkyl, -CN, or -halo;

Z₂ and Z₃ are each independently -H, -C_1-6alkyl, -C_1-6aminoalkyl, -C_1-6alkyl-O(C_1-6alkyl), -halo, -heterocycloalkyl, or -C_1-6alkyl-heterocycloalkyl {wherein the heterocycloalkyl or -C_1-6alkyl-heterocycloalkyl ring is 4-6 membered, and at least one H of the heterocycloalkyl, -C_1-6alkyl-cycloalkyl, or -C_1-6alkyl-heterocycloalkyl may be substituted with -C_1-6alkyl, or 4-6 membered heterocycloalkyl}.

6. The compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein

Y₁ to Y₃ are each independently N or CR_Y;

R_Y is -H, -C_1-6alkyl, or -halo; and

R₄ is -C_1-6alkyl, -C_1-6alkyl-O-C_1-6alkyl, -C_1-6haloalkyl, 3-7 membered cycloalkyl, or 4-6 membered heterocycloalkyl {wherein at least one H of the 3-7 membered cycloalkyl or 4-6 membered heterocycloalkyl may be substituted with -C_1-6alkyl}.

7. The compound represented by Chemical Formula 1, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein

ring A is phenyl, 5-10 membered heteroaryl, 4-6 membered heterocycloalkyl, or 4-6 membered heterocycloalkenyl {wherein at least one H of the phenyl, 5-10 membered heteroaryl, 4-6 membered heterocycloalkyl, or 4-6 membered heterocycloalkenyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -C_1-6alkenyl, -CN, -C(=O)-R_A1, -NO₂, -NR_A2R_A3, - OR_A4, -S-C_1-6alkyl, -halo, or 4-6 membered heterocycloalkyl [here, at least one H of the 4-6 membered heterocycloalkyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, -halo, or heterocycloalkyl], and substituents on the phenyl or 5-10 membered heteroaryl ring may be linked to each other to form a 5-6 membered cycloalkyl or a 5-6 membered heterocycloalkyl};

R_A1 is -H, -NH-(CH₂)m-phenyl, -OH, or -O-C_1-6alkyl {wherein at least one H of the -NH-(CH₂)m-phenyl ring may be substituted with -halo};

m is 0, 1, or 2;

R_A2 and R_A3 are each independently -H, -C_1-6alkyl, -C(=O)-C_1-6alkyl, -C(=O)-C_1-6alkenyl, -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or -C(=O)-phenyl {wherein at least one H of the -C(=O)-cycloalkyl, -C(=O)-heterocycloalkyl, or - C(=O)-phenyl ring may be substituted with -C_1-6alkyl, -C_1-6haloalkyl, =O, -halo, or phenyl}; and

R_A4 is -H, -C_1-6alkyl, or -C_1-6haloalkyl.

8. The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein
the compound represented by Chemical Formula 1 above is selected from the group consisting of the following compounds:

1	N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)acetamide
2	N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropancarboxamide
3	N-(3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2,4-difluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropancarboxamide
4	N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-fluoro-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropancarboxamide
5	1-(3-((7-methoxy-4-((4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
6	1-(3-((7-methoxy-4-((2-methoxy-5-(pyridin-3-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
7	1-(3-((4-((4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
8	1-(3-((4-((3'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
9	1-(3-((7-methoxy-4-((4-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
10	1-(3-((4-((2',5'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
11	1-(3-((4-((3',5'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
12	3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile
13	1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
14	3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-fluoro-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile
15	1-(3-((4-((4'-chloro-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
16	3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-3-fluoro-4'-methoxy-[1,1'-biphenyl]-4-carbonitrile
17	1-(3-((4-((2'-fluoro-4-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
18	1-(3-((4-((2'-chloro-3'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
19	1-(3-((4-((2',3'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
20	1-(3-((4-((3'-chloro-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
21	3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2-fluoro-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile
22	1-(3-((4-((5-(6-fluoropyridin-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
23	1-(3-((4-((3'-fluoro-4-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
24	1-(3-((4-((2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
25	1-(3-((4-((4'-fluoro-4-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
26	3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-4-carbonitrile
27	1-(3-((4-((5-(6-chloro-5-fluoropyridin-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
28	1-(3-((4-((4'-chloro-3'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
29	1-(3-((4-((3',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
30	1-(3-((4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
31	1-(3-((4-((5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
32	1-(3-((7-methoxy-4-((2-methoxy-5-(pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
33	1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
34	1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-indol-6-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
35	1-(3-((4-((5-(imidazo[1,2-a]pyridin-8-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
36	1-(3-((4-((5-(benzo[d]thiazol-7-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
37	1-(3-((4-((5-(benzofuran-5-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
38	1-(3-((4-((5-(benzofuran-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
39	1-(3-((7-methoxy-4-((2-methoxy-5-(pyrazolo[1,5-a]pyrimidin-3-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
40	1-(3-((4-((5-(benzofuran-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
41	1-(3-((4-((5-(benzo[b]thiophen-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
42	1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
43	1-(3-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
44	1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
45	1-(3-((4-((5-(furan-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
46	1-(3-((7-methoxy-4-((2-methoxy-5-(thiazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
47	1-(3-((7-methoxy-4-((2-methoxy-5-(thiophen-3-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
48	1-(3-((7-methoxy-4-((2-methoxy-5-(2-methylthiazol-5-yl))amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
49	1-(3-((7-methoxy-4-((2-methoxy-5-(5-methylthiophen-3-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
50	1-(3-((7-methoxy-4-((2-methoxy-5-(5-methylfuran-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
51	1-(3-((7-methoxy-4-((2-methoxy-5-(2-methylfuran-3-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
52	1-(3-((7-methoxy-4-((2-methoxy-4-methyl-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
53	1-(4,4-difluoro-3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)piperidin-1-yl)prop-2-en-1-one
54	1-(3-((4-((2-ethoxy-5-(thiophen-2-yl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
55	1-(3-((4-((2-ethoxy-5-(furan-2-yl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
56	1-(3-((4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-ethoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
57	1-(3-((4-((5-(benzofuran-5-yl)-2-ethoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
58	1-(3-((7-methoxy-4-((4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
59	1-(3-((7-methoxy-4-((2-methoxy-5-(pyridin-3-yl)phenyl)amino)quinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
60	1-(3-((4-((4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
61	1-(3-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one

62	1-(3-((7-methoxy-4-((2-methoxy-5-(thiazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
63	1-(3-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
64	1-(3-((4-((5-(furan-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
65	1-(4-((7-methoxy-4-((4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
66	1-(4-((7-methoxy-4-((2-methoxy-5-(pyridin-3-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
67	1-(4-((4-((4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
68	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
69	1-(4-((4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
70	1-(4-((4-((5-(imidazo[1,2-a]pyridin-8-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
71	1-(4-((4-((5-(benzofuran-5-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
72	1-(4-((4-((5-(benzofuran-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
73	1-(4-((4-((5-(benzofuran-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
74	1-(4-((4-((5-(2-hydroxytetrahydro-2H-pyran-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
75	1-(4-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
76	1-(4-((7-methoxy-4-((2-methoxy-5-(1-methyl-1H-pyrazol-3-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
77	1-(4-((7-methoxy-4-((2-methoxy-5-(thiazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
78	1-(4-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
79	1-(4-((7-methoxy-4-((2-methoxy-5-(thiophen-3-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
80	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
81	1-(4-((4-((5-(furan-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
82	1-(4-((7-methoxy-4-((2-methoxy-5-(3-methylthiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
83	1-(4-((7-methoxy-4-((2-methoxy-5-(4-methylthiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
84	1-(4-((7-methoxy-4-((2-methoxy-5-(2-methylfuran-3-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
85	1-(4-((4-((5-(isoxazol-4-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
86	1-(4-((7-methoxy-4-((2-methoxy-5-(5-methylfuran-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
87	1-(4-((4-((5-(5-ethylfuran-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
88	1-(4-((4-((5-(5-fluorofuran-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
89	1-(4-((7-methoxy-4-((2-methoxy-5-(3-methylfuran-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
90	1-(4-((7-methoxy-4-((2-methoxy-5-(4-methylfuran-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
91	1-(4-((4-((5-(3,5-dimethylfuran-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
92	5-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)furan-2-carbonitrile
93	1-(4-((7-methoxy-4-((2-methoxy-5-(tetrahydrofuran-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
94	1-(4-((7-methoxy-4-((2-methoxy-5-(tetrahydro-2H-pyran-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
95	1-(4-((7-methoxy-4-((2-methoxy-4-methyl-5-(thiophen-2-yl))amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
96	1-(4-((4-((5-(furan-2-yl)-2-methoxy-4-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
97	1-(4-((4-((3-(furan-2-yl)-6-methoxy-2,4-dimethylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
98	1-(4-((4-((2-fluoro-3-(furan-2-yl)-6-methoxy-4-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
99	1-(3,3-difluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)piperidin-1-yl)prop-2-en-1-one
100	1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-5-yl)oxy)-4,4-difluoropiperidin-1-yl)prop-2-en-1-one
101	1-(4-((4-((3-fluoro-5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
102	1-(4-((4-((4-fluoro-5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
103	1-(4-((4-((2-fluoro-3-(furan-2-yl)-6-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
104	1-(4-((4-((5-(furan-2-yl)-2-methoxypyridin-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
105	1-(4-((4-((2-(furan-2-yl)-5-methoxypyridin-4-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
106	1-(4-((4-((2-(furan-2-yl)-5-methoxypyrimidin-4-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
107	1-(4-((4-((6-(furan-2-yl)-3-methoxypyridin-2-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
108	1-(4-((4-((6-(furan-2-yl)-3-methoxypyrazin-2-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
109	1-(4-((4-((6-(furan-2-yl)-3-methoxypyridazin-4-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
110	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-methylpiperidin-1-yl)prop-2-en-1-one
111	1-(3,3-difluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
112	1-(3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
113	1-(4,4-difluoro-3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
114	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-(trifluoromethyl)piperidin-1-yl)prop-2-en-1-one
115	1-(5-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)prop-2-en-1-one
116	1-(4-((4-((5-(furan-2-yl)-2-(trifluoromethoxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
117	1-(4-((4-((2-ethoxy-5-(thiophen-2-yl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
118	1-(4-((4-((2-ethoxy-5-(furan-2-yl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
119	(E)-4-(dimethylamino)-1-(4-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)but-2-en-1-one
120	(E)-4-(dimethylamino)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)but-2-en-1-one
121	2-((dimethylamino)methyl)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
122	(E)-3-fluoro-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
123	2-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-carbonyl) acrylonitrile
124	(E)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-3-(1-methylpyrrolidin-2-yl)prop-2-en-1-one
125	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
126	6-((1-acryloylpiperidin-4-yl)oxy)-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinolin-3-carbonitrile
127	1-(4-((4-((2-(furan-2-yl)-5-methoxypyrimidin-4-yl)amino)-7-methoxyquinolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
128	1-(3-((4-((5-([1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
129	1-(4-((4-((3'-(3,3-difluoroazetidin-1-yl)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
130	1-(4-((7-methoxy-4-((2-methoxy-5-(oxazol-5-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
131	1-(4-((4-((2'-fluoro-4-methoxy-4'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
132	(S)-1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one
133	1-(4-((4-((5-(6-fluoropyridin-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
134	3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-2-fluoro-4'-methoxy-[1,1'-biphenyl]-3-carbonitrile
135	1-(4-((4-((3'-chloro-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
136	1-(4-((4-((2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
137	1-(4-((4-((2',3'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
138	1-(4-((4-((2'-fluoro-4-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
139	1-(4-((7-methoxy-4-((4-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
140	1-(3-fluoro-4-((4-((4-fluoro-5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
141	1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-4,4-difluoropiperidin-1-yl)prop-2-en-1-one
142	1-(4-((4-((4'-fluoro-4-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
143	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one
144	1-(3-fluoro-4-((7-methoxy-4-((2-methoxy-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
145	1-(4-((4-((5-(2,5-difluoropyridin-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
146	1-(4-((4-((3'-amino-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
147	1-(4-((4-((5-(2,6-difluoropyridin-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
148	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-methylpiperidin-1-yl)prop-2-en-1-one
149	1-(4-((7-methoxy-4-((2-methoxy-5-(pyridin-4-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
150	1-(4-((4-((5-(5-fluoropyridin-3-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
151	1-(4-((4-((3'-(dimethylamino)-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
152	1-((3S,4S)-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one
153	1-(4-((4-((5-(benzo[d][1,3]dioxol-5-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
154	1-((3R,4S)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
155	1-(4-((4-((3'-(dimethylamino)-2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
156	1-(4-((4-((2,4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
157	1-(4-((7-methoxy-4-((2',4',6-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino) quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
158	1-(4-((4-((3'-amino-2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
159	1-(4-((4-((3'-(azetidin-1-yl)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
160	1-(4-((4-((5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
161	1-(4-((4-((5'-amino-4'-fluoro-4-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
162	1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
163	1-(4-((4-((3'-amino-2'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
164	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-(trifluoromethyl)piperidin-1-yl)prop-2-en-1-one
165	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-(trifluoromethyl)piperidin-1-yl)prop-2-en-1-one
166	1-(3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-8-azabicyclo[3.2.1]octan-8-yl)prop-2-en-1-one
167	1-((1R,3r,5S)-3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-8-azabicyclo[3.2.1]octan-8-yl)prop-2-en-1-one
168	1-(4-((4-((4'-fluoro-3'-hydroxy-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
169	1-((3R,4S)-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-methylpiperidin-1-yl)prop-2-en-1-one
170	1-(4-((4-((5'-amino-2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
171	1-(trans-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one
172	1-((1R,3s,5S)-3-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-8-azabicyclo[3.2.1]octan-8-yl)prop-2-en-1-one
173	1-((3R,4R)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
174	1-((3S,4S)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
175	5-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)furan-2-carboxylic acid
176	1-(4-((4-((5-(2,3-dihydrothieno[3,4-b][1,4]dioxin-5-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
177	1-(4-((4-((5-(2-hydroxytetrahydrofuran-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-l-one
178	1-((3S,4R)-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-l-one
179	1-(trans-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-l-one
180	1-(4-((4-((3'-amino-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
181	1-(cis-3-fluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-l-one
182	1-(cis-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one
183	5-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)furan-2-carbonitrile
184	2-fluoro-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-l-one
185	1-(4-((4-((2-fluoro-3-(furan-2-yl)-6-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
186	1-(4-((7-methoxy-4-((2,2',4'-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino) quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
187	2-chloro-1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-2-fluoroethan-1-one
188	2-chloro-2-fluoro-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)ethan-1-one
189	1-((3S,4R)-4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one
190	1-(4-((7-methoxy-4-((2',4',6'-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino) quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
191	1-(4-((4-((2'-chloro-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
192	1-(4-((4-((2'-fluoro-4-methoxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
193	1-(4-((4-((5-(benzo[b]thiophen-6-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
194	1-(4-((4-((5-(benzo[d]thiazol-6-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
195	1-(3,3-difluoro-4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)piperidin-1-yl)prop-2-en-1-one
196	1-(4-((4-((3'-(difluoromethyl)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
197	1-(4-((7-methoxy-4-((4-methoxy-3'-nitro-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
198	1-(4-((7-methoxy-4-((2',3',4',5',6'-pentafluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino))quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
199	1-(3-((4-((3'-(dimethylamino)-4-methoxy-[1,1'-biphenyl]-3-yl) amino)-7-methoxyquinazolin-6-yl)oxy) azetidin-1-yl)prop-2-en-1-one
200	1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino) quinazolin-5-yl)oxy)-4,4-difluoropiperidin-1-yl)prop-2-en-1-one
201	1-(3-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-5-yl)oxy)-4,4-difluoropiperidin-1-yl)prop-2-en-1-one
202	1-(4-((4-((2',4'-difluoro-4-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
203	1-(4-((7-methoxy-4-((2',3',4'-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
204	methyl3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-carboxylate
205	1-(4-((7-methoxy-4-((4-methoxy-3'-(methylthio)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
206	1-(4-((7-methoxy-4-((2-methoxy-5-(quinoxalin-6-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
207	1-(4-((4-((2',4'-difluoro-4-methoxy-3'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
208	N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)acrylamide
209	3'-((6-((1-acryloylpiperidin-4-yl)amino)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-carbaldehyde
210	1-(4-((4-((2',4'-difluoro-3',4-dimethoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
211	1-(4-((7-methoxy-4-((4-methoxy-3'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
212	1-(4-((4-((2',4'-difluoro-4-methoxy-5'-methyl-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
213	1-(4-((4-((2',4'-difluoro-4,5'-dimethoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
214	1-(4-((4-((4'-fluoro-4-methoxy-3'-(2,2,2-trifluoroethoxy)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
215	1-(4-((7-methoxy-4-((4-methoxy-3'-vinyl-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
216	1-(4-((4-((5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
217	1-(3-((4-((5-(5-chloro-1-((3S,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
218	1-(6-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one
219	1-(6-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one
220	1-(2-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-6-azaspiro[3.4]octan-6-yl)prop-2-en-1-one
221	1-(6-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azaspiro[3.4]octan-2-yl)prop-2-en-1-one
222	1-(6-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azaspiro[3.4]octan-2-yl)prop-2-en-1-one
223	bicyclo[1.1.0]butan-1-yl(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)methanone
224	N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl) acetamide
225	1-(4-((4-((3'-(azetidin-1-yl)-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
226	N-(3'-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-fluoro-4'-methoxy-[1,1'-biphenyl]-3-yl) acetamide
227	N-(3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl) amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)cyclopropancarboxamide
228	1-(4-((7-methoxy-4-((2-methoxy-5-(1,2,5-trimethyl-1H-pyrrol-3-yl)phenyl) amino) quinazolin-6-yl)oxy) piperidin-1-yl)prop-2-en-1-one
229	1-(4-((4-((3'-(dimethylamino)-4'-fluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
230	1-(4-((4-((5'-bromo-2',3',4'-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
231	4-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)-N-(3-fluorophenethyl)thiophen-2-carboxamide
232	4-(3-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)-N-benzylthiophen-2-carboxamide
233	N-(6-(3-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)benzo[d]thiazol-2-yl)cyclopropancarboxamide
234	N-(7-(3-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)isothiazolo[4,3-b]pyridin-3-yl)cyclopropancarboxamide
235	N-(5-(3-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4-methoxyphenyl)pyridin-3-yl)-3-fluorobenzamide
236	(R)-N-(3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)-2-oxo-4-phenyloxazolidin-3-carboxamide
237	(S)-N-(3'-((6-((1-acryloylazetidin-3-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-4'-methoxy-[1,1'-biphenyl]-3-yl)-2-oxo-4-phenyloxazolidin-3-carboxamide
238	1-(4-((7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl) amino) quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
239	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-ethoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
240	1-(3-((7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
241	1-(3-((4-((5-(furan-2-yl)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2en-1-one
242	1-(3-((4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-((1-methylpyrrolidin-3-yl)oxy))phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
243	1-(3-((4-((5-(furan-2-yl)-2-((tetrahydrofuran-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
244	1-(3-((4-((2-cyclopropoxy-5-(furan-2-yl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
245	1-(3-((4-((5-(furan-2-yl)-2-((1-methylazetidin-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
246	1-(3-((4-((5-(furan-2-yl)-2-(oxetan-3-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
247	1-(3-((4-((5-(furan-2-yl)-2-((1-methylpiperidin-4-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
248	1-(3-((7-methoxy-4-((2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
249	1-(3-((4-((5-(furan-2-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one
250	1-(4-((7-methoxy-4-((2-((1-methylpyrrolidin-3-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
251	1-(4-((4-((5-(furan-2-yl)-2-((1-methylpyrrolidin-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
252	1-(4-((4-((5-(furan-2-yl)-2-((tetrahydrofuran-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
253	1-(4-((4-((2-cyclopropoxy-5-(furan-2-yl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
254	1-(4-((4-((5-(furan-2-yl)-2-((1-methylazetidin-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
255	1-(4-((4-((5-(furan-2-yl)-2-(oxetan-3-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
256	1-(4-((4-((5-(furan-2-yl)-2-((1-methylpiperidin-4-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
257	1-(4-((7-methoxy-4-((2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(thiophen-2-yl)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
258	1-(4-((4-((5-(furan-2-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
259	1-(4-((4-((5-(furan-2-yl)-2-(2-methoxyethoxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
260	1-(4-((4-((4-cyclopropoxy-2',4'-difluoro-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
261	1-(4-((4-((2',4'-difluoro-4-((1-methylpyrrolidin-3-yl)oxy)-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
262	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
263	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
264	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-morpholinoethoxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
265	1-(4-((7-(2-(dimethylamino)ethoxy)-4-((5-(furan-2-yl)-2-methoxyphenyl) amino) quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
266	1-(4-((7-(2-(2-(dimethylamino)ethoxy)ethoxy)-4-((5-(furan-2-yl)-2-methoxyphenyl) amino) quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
267	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(3-methoxypropoxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
268	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(4-methoxybutoxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
269	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
270	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
271	N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-morpholinoethoxy) quinazolin-6-yl) acrylamide
272	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-morpholinoethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
273	N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(3-methoxypropoxy) quinazolin-6-yl) acrylamide
274	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(3-methoxypropoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
275	N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-methoxyethoxy) quinazolin-6-yl) acrylamide
276	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
277	N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(3-morpholinopropoxy) quinazolin-6-yl) acrylamide
278	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
279	(S)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
280	(R)-1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
281	(R)-1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
282	(R)-1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
283	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((1-methylpyrrolidin-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
284	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((1-(2-methoxyethyl) pyrrolidin-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
285	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((1-(oxetan-3-yl)pyrrolidin-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
286	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
287	N-(4-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methoxyphenyl) amino)-7-methoxyquinazolin-6-yl)acrylamide
288	N-(4-((5-(benzofuran-5-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)acrylamide
289	N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)acrylamide
290	N-(7-methoxy-4-((2-methoxy-5-(2-methylfuran-3-yl)phenyl)amino)quinazolin-6-yl)acrylamide
291	N-(3-cyano-7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)quinolin-6-yl)acrylamide
292	N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(4,4-difluoropiperidin-1-yl)quinazolin-6-yl)acrylamide
293	N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)acrylamide
294	N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinazolin-6-yl)acrylamide
295	N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(3,3-difluoroazetidin-1-yl)quinazolin-6-yl)acrylamide
296	(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-4-methoxybut-2-enamide
297	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-(difluoromethoxy)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
298	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
299	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino)-7-methoxyquinazolin-6-yl) amino)piperidin-1-yl)prop-2-en-1-one
300	1-(4-((7-ethoxy-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
301	1-(4-((4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl) amino)-7-ethoxyquinazolin-6-yl) amino)piperidin-1-yl)prop-2-en-1-one
302	1-(4-((4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-(methylamino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
303	1-(4-((5-chloro-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)quinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one
304	(R,E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide
305	(R,E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide
306	(R,E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl) acrylamide
307	(R,E)-2-fluoro-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide
308	(R,E)-N-(7-methoxy-4-((2',4',6-trifluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide
309	(S,E)-2-fluoro-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide
310	(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide
311	(Z)-2-cyano-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide
312	(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4,4-dimethylpent-2-enamide
313	(R,Z)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide
314	(E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide
315	(E)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-4-morpholinobut-2-enamide
316	(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-4-morpholinobut-2-enamide
317	(E)-N-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide
318	(E)-4-(3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)-N-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)but-2-enamide
319	(E)-4-(3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)-N-(4-((2',4'-difluoro-4-methoxy-[1,1')-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)but-2-enamide
320	(E)-N-(5-chloro-4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide
321	(E)-N-(5-chloro-4-((5-(furan-2-yl)-2-methoxyphenyl)amino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide
322	1-(2-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one
323	1-(2-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one
324	1-(2-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,7-diazaspiro[3.5]nonan-7-yl)prop-2-en-1-one
325	1-(2-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2,7-diazaspiro[3.5]nonan-7-yl)prop-2-en-1-one
326	1-(6-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.3]heptan-2-yl)prop-2-en-1-one
327	1-(6-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2,6-diazaspiro[3.3]heptan-2-yl)prop-2-en-1-one
328	1-(7-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2,7-diazaspiro[4.4]nonan-2-yl)prop-2-en-1-one
329	1-(7-(4-((2',4'-difluoro-4-methoxy-[1,1'-biphenyl]-3-yl)amino)-7-methoxyquinazolin-6-yl)-2,7-diazaspiro[4.4]nonan-2-yl)prop-2-en-1-one
330	2-acryloyl-7-(4-((5-(furan-2-yl)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-5-oxa-2,7-diazaspiro[3.4]octan-6-one

9. A pharmaceutical composition for preventing or treating cancer, comprising the compound according to any one of claims 1 to 8, the optical isomer thereof, or the pharmaceutically acceptable salt thereof as an active ingredient.

10.  The pharmaceutical composition of claim 9, wherein
the pharmaceutical composition inhibits HER2 and/or EGFR.

11. The pharmaceutical composition of claim 10, wherein
the pharmaceutical composition inhibits at least one selected from the group consisting of HER2 L869R, HER2 L755S, HER2 T798I, HER2 T862A, EGFR G719A, EGFR L861Q, EGFR S768I, EGFR G719A/S768I, and EGFR Del19/T790M.

12. The pharmaceutical composition of claim 9, wherein
the cancer is one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell tumor, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, sinonasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small bowel cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, renal cancer, heart cancer, duodenal cancer, malignant soft tissue tumor, malignant bone tumor, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid tumor, gastrointestinal stromal tumor, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid tumor, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleura cancer, hematological cancer, and thymic carcinoma.

13. Use of the compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 for use in preparation of a medicament to treat or prevent cancer.

14. A method for treating or preventing cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 8.